

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 3 NOV 26 MARPAT enhanced with FSORT command  
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 5 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 6 DEC 01 ChemPort single article sales feature unavailable  
NEWS 7 DEC 12 GBFULL now offers single source for full-text  
coverage of complete UK patent families  
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS  
NEWS 9 JAN 06 The retention policy for unread STNmail messages  
will change in 2009 for STN-Columbus and STN-Tokyo  
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent  
Classification Data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 11:50:50 ON 28 JAN 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 11:50:56 ON 28 JAN 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JAN 2009 HIGHEST RN 1096770-81-8  
DICTIONARY FILE UPDATES: 27 JAN 2009 HIGHEST RN 1096770-81-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          0.48      0.70
```

FILE 'REGISTRY' ENTERED AT 11:51:02 ON 28 JAN 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JAN 2009 HIGHEST RN 1096770-81-8  
DICTIONARY FILE UPDATES: 27 JAN 2009 HIGHEST RN 1096770-81-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\10583814.str
```



```

chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
1-2 1-6 1-10 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 10-11

```

G1:O,S,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 11:51:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 153176 TO ITERATE

100.0% PROCESSED 153176 ITERATIONS

1078 ANSWERS

SEARCH TIME: 00.00.07

L2 1078 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.58

FILE 'CAPLUS' ENTERED AT 11:51:54 ON 28 JAN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Jan 2009 VOL 150 ISS 5

FILE LAST UPDATED: 27 Jan 2009 (20090127/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l2 full
L3          106 L2
```

```
=> d ibib abs hitstr tot
```



AB Purine derivs., such as I [R2 = arylamino; R6 = heteroaryl, heterocyclyl, etc.; R8 = H, alkyl, halogen, etc.], were prepared for therapeutic use in pharmaceutical compns. for the treatment of diseases characterized by excessive or abnormal cell proliferation and for treatment or prevention


of cancer, infection, inflammation and autoimmune disorders. Thus, purine derivative II was prepared by a series of synthetic steps starting from 2,6-dichloropurine, 3,4,5-trifluoro-1-nitrobenzene, morpholine and 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. The prepared purine derivs. were evaluated for inhibition of proliferation of PC-3 prostate carcinoma cells and for effect on PDK1 kinase activity.

IT 1054315-95-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 9H-purine derivs. for therapeutic use in treatment of proliferative diseases)

RN 1054315-95-5 CAPLUS

CN 1,4-Benzenediamine, N1-(1-ethyl-4-piperidinyl)-2-fluoro-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




IT 1054315-91-1P 1054315-92-2P 1054315-93-3P  
1054315-94-4P 1054315-96-6P 1054315-97-7P  
1054315-98-8P 1054315-99-9P 1054316-02-7P  
1054316-03-8P 1054316-04-9P 1054316-05-0P  
1054316-06-1P 1054316-07-2P 1054316-08-3P  
1054316-09-4P 1054316-28-7P 1054316-29-8P  
1054316-30-1P 1054316-31-2P 1054316-32-3P  
1054316-33-4P 1054316-36-7P 1054316-37-8P  
1054316-38-9P 1054316-39-0P 1054316-40-3P  
1054316-42-5P 1054316-45-8P 1054316-46-9P  
1054316-48-1P 1054316-49-2P 1054316-50-5P  
1054316-51-6P 1054316-52-7P 1054316-53-8P  
1054316-60-7P 1054316-63-0P 1054316-66-3P  
1054316-67-4P 1054316-68-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 9H-purine derivs. for therapeutic use in treatment of proliferative diseases)

RN 1054315-91-1 CAPLUS


CN 9H-Purin-2-amine, N-[3,5-difluoro-4-(4-morpholinyl)phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1054315-92-2 CAPLUS

CN 9H-Purin-2-amine, N-[3-fluoro-4-[(3S)-tetrahydro-3-furanyloxy]phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1054315-93-3 CAPLUS


CN 9H-Purin-2-amine, N-[3-fluoro-4-[(3R)-tetrahydro-3-furanyloxy]phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1054315-94-4 CAPLUS

CN 9H-Purin-2-amine, N-[3-fluoro-4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054315-96-6 CAPLUS

CN 1,4-Benzenediamine, 2-fluoro-N1-(1-methyl-4-piperidinyl)-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




RN 1054315-97-7 CAPLUS

CN 1,4-Benzenediamine, 2-fluoro-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]-N1-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 1054315-98-8 CAPLUS


CN 9H-Purin-2-amine, N-[4-(4-morpholinyl)phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1054315-99-9 CAPLUS


CN D-Mannitol, 1,4:3,6-dianhydro-2-O-[4-[[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1054316-02-7 CAPLUS

CN 1,4-Benzenediamine, 2-fluoro-N1-methyl-N1-(1-methyl-4-piperidinyl)-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




RN 1054316-03-8 CAPLUS


CN 9H-Purin-2-amine, N-[4-(2,6-difluoro-4-morpholinyl)phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-04-9 CAPLUS  
 CN 1,4-Benzenediamine, N1-(1-cyclopropyl-4-piperidinyl)-2-fluoro-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)



RN 1054316-05-0 CAPLUS  
 CN 1,4-Benzenediamine, 2,6-difluoro-N1-methyl-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




RN 1054316-06-1 CAPLUS  
 CN 1,4-Benzenediamine, 2-methyl-N1-(1-methyl-4-piperidinyl)-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




RN 1054316-07-2 CAPLUS

CN 1,4-Benzenediamine, 2-methoxy-N1-(1-methyl-4-piperidinyl)-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




RN 1054316-08-3 CAPLUS

CN 1,4-Benzenediamine, 2-bromo-N1-(1-cyclopropyl-4-piperidinyl)-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)



RN 1054316-09-4 CAPLUS


CN 1,4-Benzenediamine, 2-chloro-N1-(1-methyl-4-piperidinyl)-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)



RN 1054316-28-7 CAPLUS


CN 9H-Purin-2-amine, 8-methyl-N-[4-(4-morpholinyl)phenyl]-6-(3,4,6,7-

tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-29-8 CAPLUS

CN 9H-Purin-2-amine, 8-methyl-N-[4-(4-methyl-1-piperazinyl)phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1054316-30-1 CAPLUS


CN 9H-Purin-2-amine, 8-ethyl-N-[4-(4-morpholinyl)phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1054316-31-2 CAPLUS


CN 9H-Purin-2-amine, 8-ethyl-N-[4-(4-methyl-1-piperazinyl)phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)






RN 1054316-32-3 CAPLUS

CN 1,4-Benzenediamine, N4-[8-ethyl-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]-2-fluoro-N1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1054316-33-4 CAPLUS

CN 1,4-Benzenediamine, 2-fluoro-N1-(1-methyl-4-piperidinyl)-N4-[8-methyl-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




RN 1054316-36-7 CAPLUS

CN 9H-Purin-2-amine, N-[4-(4-(morpholinylmethyl)phenyl)-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-] (CA INDEX NAME)




RN 1054316-37-8 CAPLUS

CN 9H-Purin-2-amine, N-[4-[(dimethylamino)methyl]phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-38-9 CAPLUS

CN 9H-Purin-2-amine, N-[3-[(dimethylamino)methyl]phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-39-0 CAPLUS

CN 9H-Purin-2-amine, N-[3-(4-morpholinylmethyl)phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-40-3 CAPLUS

CN 9H-Purin-2-amine, N-[4-chloro-3-[(dimethylamino)methyl]phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-42-5 CAPLUS

CN 9H-Purin-2-amine, N-[4-chloro-3-(4-morpholinylmethyl)phenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-45-8 CAPLUS

CN 9H-Purin-2-amine, N-[4-(4-morpholinyl)phenyl]-6-(3,4,6,7-tetrahydro-2-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-46-9 CAPLUS

CN 9H-Purin-2-amine, 6-(2-ethyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 1054316-48-1 CAPLUS

CN 1,4-Benzenediamine, 2-[(dimethylamino)methyl]-N1,N1-dimethyl-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




RN 1054316-49-2 CAPLUS

CN 9H-Purin-2-amine, N-[3-[(dimethylamino)methyl]-4-methoxyphenyl]-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-50-5 CAPLUS

CN 9H-Purin-2-amine, N-[4-(4-morpholinyl)phenyl]-6-(3,4,6,7-tetrahydro-3-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-51-6 CAPLUS

CN 9H-Purin-2-amine, N-[4-(4-methyl-1-piperazinyl)phenyl]-6-(3,4,6,7-tetrahydro-3-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-52-7 CAPLUS


CN 9H-Purin-2-amine, N-[4-(4-morpholinyl)phenyl]-6-(1,4,6,7-tetrahydro-1-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-53-8 CAPLUS  
 CN 9H-Purin-2-amine, N-[4-(4-methyl-1-piperazinyl)phenyl]-6-(1,4,6,7-tetrahydro-1-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1054316-60-7 CAPLUS  
 CN 1,4-Benzenediamine, 2-fluoro-N1-(1-methyl-4-piperidinyl)-N4-[6-(1,4,6,7-tetrahydro-1-methyl-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)




RN 1054316-63-0 CAPLUS  
 CN 1,4-Benzenediamine, N1-(1-ethyl-4-piperidinyl)-N1-methyl-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]- (CA INDEX NAME)



RN 1054316-66-3 CAPLUS

CN 1,4-Benzenediamine, 2-fluoro-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]-N1-[(3S)-1-(2,2,2-trifluoroethyl)-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1054316-67-4 CAPLUS

CN 1,4-Benzenediamine, 2-fluoro-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]-N1-[(3R)-1-(2,2,2-trifluoroethyl)-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1054316-68-5 CAPLUS

CN 1,4-Benzenediamine, 2,6-difluoro-N4-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-9H-purin-2-yl]-N1-[(3S)-1-(2,2,2-trifluoroethyl)-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 1054316-76-5 1054316-77-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 9H-purine derivs. for therapeutic use in treatment of  
 proliferative diseases)  
 RN 1054316-76-5 CAPLUS  
 CN 9H-Purine, 2-chloro-8-methyl-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-  
 c]pyridin-5-yl)- (CA INDEX NAME)




RN 1054316-77-6 CAPLUS  
 CN 9H-Purine, 2-chloro-8-ethyl-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-  
 5-yl)- (CA INDEX NAME)



IT 1054316-80-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 9H-purine derivs. for therapeutic use in treatment of  
 proliferative diseases)  
 RN 1054316-80-1 CAPLUS  
 CN 9H-Purine, 2-chloro-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-



(CA INDEX NAME)





REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:1102730 CAPLUS  
 DOCUMENT NUMBER: 149:355702  
 TITLE: Preparation of indole and benzothiophene compounds as  
 modulators of the histamine H3 receptor  
 INVENTOR(S): Allison, Brett D.; Grice, Cheryl A.; Mcclure, Kelly  
 J.; Santillan, Alejandro, Jr.  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.  
 SOURCE: PCT Int. Appl., 109pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008109333	A1	20080912	WO 2008-US55280	20080228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW, RW: AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2007-892330P	P 20070301
OTHER SOURCE(S):			MARPAT 149:355702	
GI				



AB The title compds. I [X = NRa and Y = CH2; or X = S and Y = CH2 or C(O); Ra = H, Me, SO2Me; R1 = H and R2 = (CH2)pyridyl (wherein pyridyl is unsubstituted or substituted with Me); or NR1R2 = (un)substituted

piperazino, homopiperazino, piperidino, etc.; NR3R4 = (un)substituted piperazino, homopiperazino, pyrrolidino, etc.; with the provisos] which are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases, were prepared and claimed. E.g., a multi-step synthesis of II, starting from Me 3-formylindole-6-carboxylate and morpholine, was given. Exemplified compds. I were tested for binding to the cloned human H3 receptors. For example, II showed Ki of 2 nM in this assay. Pharmaceutical compns. comprising the compound I alone or in combination with the other therapeutic agents are disclosed.


IT 1055999-95-5P 1056000-02-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indole and benzothiophene compds. for treating histamine H3 receptor-mediated diseases)


RN 1055999-95-5 CAPLUS

CN Methanone, [3-(4-morpholinylmethyl)-1H-indol-6-yl](3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1056000-02-2 CAPLUS

CN Methanone, [3-(1-piperidinylmethyl)-1H-indol-6-yl](3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




REFERENCE COUNT:

3


THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:1012623 CAPLUS  
 DOCUMENT NUMBER: 149:307833  
 TITLE: Preparation of tetrahydro-pyrazolo-pyridine thioether  
 modulators of cathepsin S  
 INVENTOR(S): Ameriks, Michael K.; Arienti, Kristen L.; Edwards,  
 James P.; Grice, Cheryl A.; Jones, Todd K.; Lee-Dutra,  
 Alice; Liu, Jing; Mani, Neelakandha S.; Neff, Danielle  
 K.; Wickboldt, Alvah T.; Wiener, John J. M.  
 PATENT ASSIGNEE(S): Sunesis Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 492pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008100621	A2	20080821	WO 2008-US2111	20080215
WO 2008100621	A3	20081211		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRIORITY APPLN. INFO.:			US 2007-889976P	P 20070215
			US 2008-31551	A 20080214
OTHER SOURCE(S):	MARPAT 149:307833			
GI				



I




II

AB The title compds. I [NR1R2 = (un)substituted monocyclic heterocycloalkyl; R3 = H, OH, alkyl, alkoxy; R4 = H, alkyl, CO(alkyl), etc.; R5 = halo or CF3; R6 = H or F; each R7 = H or both together form a carbonyl; R8 = H or alkyl; R9 = R10, COR11, SO2R11, etc. (wherein R10, R11 = (un)substituted alkyl, monocyclic cycloalkyl, bicyclic cycloalkyl, etc.); or NR8R9 = (un)substituted monocyclic heterocycloalkyl], useful as cathepsin S modulators, were prepared E.g., a multi-step synthesis of II, starting from 4-piperidone monohydrate hydrochloride, was given. Exemplified compds. I were tested against recombinant human cathepsin S. For example, II showed IC50 of 0.34  $\mu$ M in this test. Compds. I may be used in pharmaceutical compns. and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.


IT 1049099-34-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin S)

RN 1049099-34-4 CAPLUS


CN 1H-Pyrazolo[4,3-c]pyridine-1-ethanol,  
 4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[3-[[2-(4-morpholinyl)ethyl]thio]-4-(trifluoromethyl)phenyl]- $\alpha$ -[3-(4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl]- (CA INDEX NAME)



L3 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:668227 CAPLUS  
 DOCUMENT NUMBER: 149:200868  
 TITLE: Synthesis and structure based optimization of novel Akt inhibitors  
 AUTHOR(S): Lipka, Blaise; Pan, Gonghua; Corbett, Matthew; Li, Chao; Kauffman, Goss S.; Pandit, Jayvardhan; Robinson, Shaughnessy; Wei, Liuqing; Kozina, Ekaterina; Marr, Eric S.; Borzillo, Gary; Knauth, Elisabeth; Barbacci-Tobin, Elsa G.; Vincent, Patrick; Troutman, Merin; Baker, Deborah; Rajamohan, Francis; Kakar, Shefali; Clark, Tracey; Morris, Joel  
 CORPORATE SOURCE: PGRD Groton, Pfizer, Inc., Groton, CT, 06340, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(11), 3359-3363  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 149:200868  
 GI




AB Based on a high throughput screening hit, pyrrolopyrimidine inhibitors of the Akt kinase are explored. X-ray co-crystal structures of two lead series results in the understanding of key binding interactions, the design of new lead series, and enhanced potency. The syntheses of these series and their biol. activities are described. Spiroindoline I is found to have an Akt1 kinase IC50 of  $2.4 \pm 0.6$  nM, Akt cell potency of  $50 \pm 19$  nM, and provides 68% inhibition of tumor growth in a mouse xenograft model (50 mg/kg, qd, po).  
 IT 1041703-81-4P 1041703-83-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of pyrrolopyrimidine derivs. via substitution of chloropyrrolopyrimidine with amines as key step, and their Akt1 kinase inhibitor)  
 RN 1041703-81-4 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



RN 1041703-83-6 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-  
4,5,6,7-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT:

25

THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:668179 CAPLUS

DOCUMENT NUMBER: 149:191026

TITLE: 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors

AUTHOR(S): Eckhardt, Matthias; Haeu, Norbert; Himmelsbach, Frank; Langkopf, Elke; Nar, Herbert; Mark, Michael; Tadayyon, Moh; Thomas, Leo; Guth, Brian; Lotz, Ralf  
CORPORATE SOURCE: Department of Chemical Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, 88400, Germany  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(11), 3158-3162

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Systematic variations of the xanthine scaffold in close analogs of development compound BI 1356 led to the class of 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones which provided, after substituent screening, a series of highly potent DPP-4 inhibitors.


IT 1042165-93-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones are potent DPP-4 inhibitors)

RN 1042165-93-4 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyln-1-yl)-3,5-dihydro-5-[(3-methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)



IT 866933-32-6P 1042166-07-3P 1042166-09-5P


1042166-10-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones are potent DPP-4 inhibitors)


RN 866933-32-6 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-bromo-3-(2-butyln-1-yl)-3,5-dihydro-5-[(3-methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)




RN 1042166-07-3 CAPLUS

CN Carbamic acid, N-[1-[3-(2-butyn-1-yl)-4,5-dihydro-7-methyl-5-[(3-methyl-1-isoquinolinyl)methyl]-4-oxo-3H-imidazo[4,5-c]pyridin-2-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1042166-09-5 CAPLUS

CN Carbamic acid, N-[1-[3-(2-butyn-1-yl)-4,5-dihydro-5-[(3-methyl-1-isoquinolinyl)methyl]-4-oxo-3H-imidazo[4,5-c]pyridin-2-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1042166-10-8 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-bromo-3-(2-butyn-1-yl)-3,5-dihydro-7-methyl-5-[(3-methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT:

15


THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2008:583385 CAPLUS  
 DOCUMENT NUMBER: 148:562180  
 TITLE: Preparation of peptide and peptidomimetic Michael systems as transglutaminase inhibitors  
 INVENTOR(S): Oertel, Kai  
 PATENT ASSIGNEE(S): Zedira G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 183pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008055488	A1	20080515	WO 2007-DE2014	20071108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102006052755	A1	20080515	DE 2006-102006052755	20061108
PRIORITY APPLN. INFO.:			DE 2006-102006052755A	20061108
			US 2006-874246P	P 20061212
OTHER SOURCE(S): MARPAT 148:562180				
AB XX1NCHMCOY, XX1NCHQECMCOY, XX1NCHMCONX2CHQ1COY M = CR1R2CR3R4(CO)mCZ3:CZ1Z2; [E = CH2, CF2, CH2CH2, CH2CF2, CH:CH, COCH2, CO2, P(O)(OH)O, etc.; m = 0, 1; Z1, Z2, Z3 = H, alkylcarbonyl, heteroarylcarbonyl, cyano, CO2H, CONH2, SO2NH2, SO3H, etc.; Z1Z2 = CO2COCH2, CO2CH2CH2; Z2Z3 = CO2CH2, COCH2CH2, CONHCO, etc.; Y = OH, amino, alkoxy, aryloxy, alkyl, haloalkyl, heteroaryl, aryl, peptide residue, etc.; Q, Q1 = amino acid side chain; QX1 = propylene; Q1X2 = propylene; X = peptide residue; X1, X2 = H, alkyl; R1-R4 = H, OH, OMe, OEt, OPr, OPh, SCN, N3, SH, CHO, Ac, CO2H, COCN, CO2Me, SO2Me, SO2Et, amino, NHCONHET, CH2CF3, CF3, CF2Cl, CH2CH2OH, etc.], were prepared Thus, title compound N $\alpha$ -benzyloxycarbonyl-[(E)-(L)-6-aminohept-2-enedicarboxylic acid]-1-ethanoyl-L-valinyl-L-prolinyl-L-leucine Me ester (solution phase preparation given) inhibited transglutaminase TG2 with IC50 = 30 nM.				
IT 1026104-96-0P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of peptide and peptidomimetic Michael systems as transglutaminase inhibitors)				
RN 1026104-96-0 CAPLUS				
CN L-Tyrosine, (6S)-5-[(4E)-1-[[[3S]-1-[3-(acetyl amino)-1-oxopropyl]-3-piperidinyl]carbonyl]-6-(1-methylethoxy)-6-oxo-4-hexen-1-yl]-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carbonyl-3-[(aminocarbonyl)amino]-L-alanyl-L-leucyl-L-prolyl-O-(4-hydroxyphenyl)- (CA INDEX NAME)				

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-A



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:551551 CAPLUS

DOCUMENT NUMBER: 148:538302

TITLE: 2-Aminothiazole-4-carboxylic amides as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Shipp, Gerald W., Jr.; Cheng, Cliff C.; Huang, Xiaohua; Fischmann, Thierry O.; Duca, Jose S.; Richards, Matthew; Zeng, Hongbo; Sun, Binyuan; Reddy, Panduranga A.; Zhao, Lianyun; Tang, Shuyi; Wong, Tzu T.; Tadikonda, Praveen K.; Torres, Luis E.; Siddiqui, M. Arshad; Dwyer, Michael P.; Keertikar, Kartik M.; Guzi, Timothy J.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 274pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008054749	A1	20080508	WO 2007-US22928	20071029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-855421P P 20061031

OTHER SOURCE(S): MARPAT 148:538302

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to anilinopiperazine derivs. of formula I, comps. comprising the anilinopiperazine derivs., and methods for using the anilinopiperazine derivs. for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. Comps. of formula I wherein dashed bond is single and double bond; R1 is a (un)substituted nitrogen-containing heteroaryl, (un)substituted nitrogen-containing heterocyclyl and (un)substituted nitrogen-containing heterocyclyl wherein R1 is joined to the thiazole moiety via nitrogen; A is (CHR11)0-2; B is (CR10R10a)0-1; R2, R3, R3a, R10, R101, and R11 are independently H, (halo)alkyl, hydroxyalkyl, (alkylene)0-1-CONH2 and derivs., etc.; Ar is (un)substituted (hetero)arylene joined via two adjacent carbons; W is NH2 and derivs., S, O, (un)substituted cycloalkyl, and (un)substituted heterocyclyl; Y is H, halo, alkyl and CN; Z is (un)substituted methylene, and N; and their pharmaceutically acceptable

salts, solvated ester, prodrugs and stereoisomers thereof, are claimed.  
 Example compound II was prepared by a general procedure (procedure given).  
 All the invention compds. were evaluated for their kinase inhibitory  
 activity (some data given).


IT 1023295-40-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of piperazinylphenyl aminothiazolecarboxamides  
 derivs. as protein kinase inhibitors useful in treatment and prevention  
 of protein kinase-related diseases)

RN 1023295-40-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-(1-piperazinyl)phenyl]-2-(3,4,6,7-tetrahydro-  
 5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




IT 1026670-54-1P

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP  
 (Preparation); RACT (Reactant or reagent)

(prophetic intermediate; preparation of piperazinylphenyl  
 aminothiazolecarboxamides derivs. as protein kinase inhibitors useful  
 in treatment and prevention of protein kinase-related diseases)

RN 1026670-54-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[2-(3,4,6,7-tetrahydro-5H-imidazo[4,5-  
 c]pyridin-5-yl)-4-thiazolyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl  
 ester (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:207066 CAPLUS

DOCUMENT NUMBER: 148:449346

TITLE: A novel series of parenteral cephalosporins exhibiting potent activities against both *Pseudomonas aeruginosa* and other Gram-negative pathogens. Part 2: Synthesis and structure-activity relationships

AUTHOR(S): Yamawaki, Kenji; Nomura, Takashi; Yasukata, Tatsuro; Tanimoto, Norihiko; Uotani, Koichi; Miwa, Hideaki; Yamano, Yoshinori; Takeda, Kei; Nishitani, Yasuhiro

CORPORATE SOURCE: Discovery Research Laboratories, Shionogi and Co., Ltd., Fukushima-ku, Osaka, 553-0002, Japan

SOURCE: Bioorganic & Medicinal Chemistry (2008), 16(4), 1632-1647

CODEN: BMECEP; ISSN: 0968-0896


PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:449346

GI



AB A novel series of 7 $\beta$ -[2-(2-amino-5-chloro-thiazol-4-yl)-2(Z)-((S)-1-carboxyethoxyimino)acetamido]cephalosporins bearing various pyridinium groups at the C-3' position were synthesized and their in vitro antibacterial activities against Gram-neg. pathogens including *Pseudomonas aeruginosa* and several Gram-pos. pathogens were evaluated. Among the cephalosporins prepared, we found that a cephalosporin bearing the 2-amino-1-(3-methylamino-propyl)-1H-imidazo[4,5-b]pyridinium group at the C-3' position (I) showed potent and well-balanced antibacterial activities against *P. aeruginosa* and other Gram-neg. pathogens including the strains which produce class C  $\beta$ -lactamase and extended spectrum  $\beta$ -lactamase (ESBL). Compound I also showed efficacious in vivo activity and high stability against AmpC  $\beta$ -lactamase. These findings indicate that 2-aminoimidazopyridinium having an aminoalkyl group at the 1-position as a C-3' side chain is suitable for cephalosporins bearing an aminochlorothiazolyl moiety and a carboxyethoxyimino moiety on the C-7 side chain.

IT 604000-52-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antibacterial activity of pyridinium cephalosporins)


RN 604000-52-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 2-amino-5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-[2-(methylamino)ethyl]-, inner salt (CA INDEX NAME)



Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

NHMe

REFERENCE COUNT:


21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:43947 CAPLUS  
 DOCUMENT NUMBER: 148:128298  
 TITLE: Novel pyridazine-containing imidazopyridazine compound  
 and uses thereof  
 INVENTOR(S): Bondy, Steven S.; Dahl, Terrence C.; Oare, David A.;  
 Oliyai, Reza; Tse, Winston C.; Zia, Vahid  
 PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA; K.U. Leuven Research &  
 Development; Puerstinger, Gerhard  
 SOURCE: PCT Int. Appl., 53pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008005519	A2	20080110	WO 2007-US15553	20070706
WO 2008005519	A3	20080424		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, CA US 20080199427 A1 20080821 US 2007-825598 20070706 PRIORITY APPLN. INFO.: US 2006-819289P P 20060707 US 2006-832403P P 20060721 US 2006-832769P P 20060724				

OTHER SOURCE(S): MARPAT 148:128298  
 AB 5-[[[6-[2,4-Bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-  
 fluorophenyl)-5H-imidazo[4,5-c]pyridine (I) and its salts and solvates are  
 provided for the treatment or prophylaxis of hepatitis C virus infections.  
 Methods of making and formulating this compound are provided. The synthesis  
 of I is given. A formulation containing I, oleic acid, BHT, BHA, and EtOH was  
 prepared  
 IT 1000787-75-6P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)  
 (pyridazine-containing imidazopyridazine compound and uses thereof)  
 RN 1000787-75-6 CAPLUS  
 CN 5H-imidazo[4,5-c]pyridine, 5-[[[6-[2,4-bis(trifluoromethyl)phenyl]-3-  
 pyridazinyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)





IT 1000787-76-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(pyridazine-containing imidazopyridazine compound and uses thereof)  
RN 1000787-76-7 CAPLUS  
CN 5H-Imidazo[4,5-c]pyridine, 5-[ (6-chloro-3-pyridazinyl)methyl]-2-(2-  
fluorophenyl)- (CA INDEX NAME)



L3 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:43697 CAPLUS  
 DOCUMENT NUMBER: 148:121730  
 TITLE: Preparation of pyrimidines and related compounds for the treatment of cell proliferative diseases  
 INVENTOR(S): Engelhardt, Harald; Bader, Gerd; Boehmelt, Guido; Brueckner, Ralph; Gerstberger, Thomas; Impagnatiello, Maria; Kuhn, Daniel; Schaaf, Otmar; Stadtmueller, Heinz; Waizenegger, Irene; Zoephel, Andreas  
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany  
 SOURCE: PCT Int. Appl., 67pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008003766	A2	20080110	WO 2007-EP56853	20070705
WO 2008003766	A3	20080228		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, CA			

PRIORITY APPLN. INFO.: EP 2006-116748 A 20060706  
 OTHER SOURCE(S): MARPAT 148:121730  
 GI




AB Title compds. I [X = CH or N; R1 = heterocycloalkyl (optionally substituted with alkyl, cycloalkyl, aryl, etc.); R2 = aryl, heterocycloalkyl or heteroaryl; R3 = halo, -CN, alkyl, etc.] or tautomers, racemates, enantiomers, diastereomers, or mixts. thereof, or pharmacol. acceptable acid salts thereof were prepared. Thus, a multi-step synthesis of compound II, starting from 1-(benzyloxycarbonyl)piperazine, was given. Compds. I herein were tested for PDK1 kinase inhibition and antiproliferative activity. Pharmaceutical composition comprising compds. I is disclosed.

IT 1001000-52-7P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrimidines and related compds. for treatment of diseases characterized by excessive or abnormal cell proliferation)

RN 1001000-52-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-, methyl ester (CA INDEX NAME)



IT 1001000-39-0P 1001000-40-3P 1001000-41-4P  
 1001000-42-5P 1001000-43-6P 1001000-44-7P  
 1001000-45-8P 1001000-46-9P 1001000-47-0P  
 1001000-48-1P 1001000-49-2P 1001000-50-5P  
 1001000-51-6P 1001000-53-8P 1001000-54-9P  
 1001000-55-0P 1001000-57-2P 1001000-59-4P  
 1001000-61-8P 1001000-63-0P 1001000-65-2P  
 1001000-67-4P 1001000-69-6P 1001000-71-0P  
 1001000-73-2P 1001000-74-3P 1001000-75-4P  
 1001000-76-5P 1001000-78-7P 1001000-80-1P  
 1001000-82-3P 1001000-83-4P 1001000-84-5P  
 1001000-85-6P 1001000-86-7P 1001000-88-9P  
 1001000-90-3P 1001000-92-5P 1001000-94-7P  
 1001000-96-9P 1001000-98-1P 1001001-00-8P  
 1001001-02-0P 1001001-04-2P 1001001-05-3P  
 1001001-07-5P 1001001-09-7P 1001001-11-1P  
 1001001-13-3P 1001001-15-5P 1001001-17-7P  
 1001001-19-9P 1001001-21-3P 1001001-23-5P  
 1001001-25-7P 1001001-27-9P 1001001-29-1P  
 1001001-31-5P 1001001-33-7P 1001001-35-9P  
 1001001-38-2P 1001001-40-6P 1001001-42-8P  
 1001001-43-9P 1001001-45-1P 1001001-47-3P  
 1001001-49-5P 1001001-51-9P 1001001-53-1P  
 1001001-55-3P 1001001-57-5P 1001001-59-7P  
 1001001-61-1P 1001001-63-3P 1001001-65-5P  
 1001001-67-7P 1001001-69-9P 1001001-71-3P  
 1001001-73-5P 1001001-75-7P 1001001-78-0P  
 1001001-80-4P 1001001-82-6P 1001001-84-8P


1001001-86-0P 1001001-88-2P 1001001-90-6P  
 1001001-92-8P 1001001-94-0P 1001001-96-2P  
 1001001-98-4P 1001002-00-1P 1001002-02-3P  
 1001002-03-4P 1001002-04-5P 1001002-05-6P  
 1001002-06-7P 1001002-07-8P 1001002-08-9P  
 1001002-09-0P 1001002-10-3P 1001002-11-4P  
 1001002-12-5P 1001002-13-6P 1001002-14-7P  
 1001002-15-8P 1001002-16-9P 1001002-17-0P  
 1001002-18-1P 1001002-19-2P 1001002-20-5P  
 1001002-21-6P 1001002-22-7P 1001002-23-8P  
 1001002-24-9P 1001002-25-0P 1001002-26-1P  
 1001002-27-2P 1001002-28-3P 1001002-29-4P  
 1001002-30-7P 1001002-31-8P 1001002-32-9P  
 1001002-33-0P 1001002-34-1P 1001002-35-2P  
 1001002-36-3P 1001002-41-0P 1001002-42-1P  
 1001002-43-2P 1001002-44-3P 1001002-45-4P  
 1001002-46-5P 1001002-47-6P 1001002-48-7P  
 1001002-49-8P 1001002-50-1P 1001002-51-2P  
 1001002-52-3P 1001002-53-4P 1001002-54-5P  
 1001002-55-6P 1001002-56-7P 1001002-57-8P  
 1001002-58-9P 1001002-59-0P 1001002-60-3P  
 1001002-61-4P 1001002-63-6P 1001002-64-7P  
 1001002-71-6P 1001002-72-7P 1001002-73-8P  
 1001002-74-9P 1001002-75-0P 1001002-76-1P  
 1001002-78-3P 1001002-79-4P 1001002-80-7P  
 1001002-81-8P 1001002-82-9P 1001002-83-0P  
 1001002-84-1P 1001002-85-2P 1001002-87-4P  
 1001002-88-5P 1001002-90-9P 1001002-92-1P  
 1001002-93-2P 1001002-94-3P 1001002-95-4P  
 1001002-96-5P 1001002-97-6P 1001002-98-7P  
 1001002-99-8P 1001003-00-4P 1001003-01-5P  
 1001003-02-6P 1001003-03-7P 1001003-04-8P  
 1001003-05-9P 1001003-06-0P 1001003-07-1P  
 1001003-08-2P 1001003-09-3P 1001003-10-6P  
 1001003-11-7P 1001003-12-8P 1001003-13-9P  
 1001003-14-0P 1001003-15-1P 1001003-16-2P  
 1001003-17-3P 1001003-18-4P 1001003-19-5P  
 1001003-20-8P 1001003-21-9P 1001003-22-0P  
 1001003-23-1P 1001003-24-2P 1001003-25-3P  
 1001003-26-4P 1001003-27-5P 1001003-28-6P  
 1001003-29-7P 1001003-30-0P 1001003-31-1P  
 1001003-32-2P 1001003-33-3P 1001003-34-4P  
 1001003-35-5P 1001003-36-6P 1001003-37-7P  
 1001003-38-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrimidines and related compds. for treatment of diseases  
 characterized by excessive or abnormal cell proliferation)


RN 1001000-39-0 CAPLUS

CN 2-Pyrimidinamine, 5-methoxy-N-[4-(1-piperazinyl)phenyl]-4-(3,4,6,7-  
 tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-40-3 CAPLUS

CN Methanone, [4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-4-morpholinyl- (CA INDEX NAME)




RN 1001000-41-4 CAPLUS

CN 4-Piperidinol, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001000-42-5 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[4-(4-pyridinyl)-1-piperazinyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-43-6 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-44-7 CAPLUS

CN Ethanone, 2-[4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-1-(4-morpholinyl)- (CA INDEX NAME)




RN 1001000-45-8 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-(cyclohexylmethylamino)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-46-9 CAPLUS

CN 1-Piperazineacetamide, 4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1001000-47-0 CAPLUS


CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001000-48-1 CAPLUS


CN 2,5-Pyrimidinediamine, N2-[4-(4-(ethylsulfonyl)-1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)






RN 1001000-49-2 CAPLUS

CN Ethanone, 1-[4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1001000-50-5 CAPLUS

CN Methanone, (4-amino-3,5-dichlorophenyl)[1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-4-piperidinyl]- (CA INDEX NAME)




RN 1001000-51-6 CAPLUS

CN Methanone, [1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-4-piperidinyl]-(4-fluorophenyl)- (CA INDEX NAME)



RN 1001000-53-8 CAPLUS


CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001000-54-9 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001000-55-0 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001000-57-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001000-59-4 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001000-61-8 CAPLUS


CN 2,5-Pyrimidinediamine, N2-[3-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001000-63-0 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-(4,4-difluoro-1-piperidinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-65-2 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[(1-phenyl-4-piperidinyl)amino]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-67-4 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[(4,4-difluorocyclohexyl)amino]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-69-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1001000-71-0 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-73-2 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[methyl(phenylmethyl)amino]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001000-74-3 CAPLUS


CN 2,5-Pyrimidinediamine, N2-[3-chloro-4-(1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001000-75-4 CAPLUS


CN 2,5-Pyrimidinediamine, N2-[3-chloro-4-(1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)

NAME)




RN 1001000-76-5 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[3-fluoro-4-(1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-78-7 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(methylpropylamino)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-80-1 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[4-(1-methyl-4-piperidiny)l-piperazinyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-82-3 CAPLUS


CN 2,5-Pyrimidinediamine, N2-[4-(1H-imidazol-1-yl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-83-4 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-(hexahydro-1H-azepin-1-yl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-84-5 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[3-fluoro-4-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001000-85-6 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[3-fluoro-4-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-86-7 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[methyl(1-methyl-4-piperidinyl)amino]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-88-9 CAPLUS

CN 3-Piperidinol, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001000-90-3 CAPLUS

CN 2,5-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001000-92-5 CAPLUS


CN 2,5-Pyrimidinediamine, N2-[4-[4-(3,5-dichloro-4-pyridinyl)-1-piperazinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-94-7 CAPLUS

CN 2-Piperazinone, 4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RN 1001000-96-9 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-(3,3-difluoro-1-piperidinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001000-98-1 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-00-8 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1001001-02-0 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[3-(4-ethyl-1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-04-2 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-05-3 CAPLUS


CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-07-5 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(3-pyridinyloxy)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-09-7 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[3-methoxy-4-(4-methyl-1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-11-1 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[4-(methylimino)-1(4H)-pyridinyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-13-3 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl]- (CA INDEX NAME)




RN 1001001-15-5 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(1-oxido-4-thiomorpholinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-17-7 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001001-19-9 CAPLUS  
 CN 2-Pyrimidinamine, 5-methoxy-N-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-21-3 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[4-[methyl(tetrahydro-2H-pyran-4-yl)amino]-1-piperidinyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001001-23-5 CAPLUS


CN 2,5-Pyrimidinediamine, N2-[4-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-1-piperidinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1001001-25-7 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[4-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 1001001-27-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]ethylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1001001-29-1 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[ethyl(1-methyl-4-piperidiny)amino]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-31-5 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-33-7 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[4-(cyclopropylmethyl)-1-piperazinyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-35-9 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[methyl(tetrahydro-2H-pyran-4-yl)amino]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-38-2 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[(dimethylamino)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-40-6 CAPLUS

CN 2(1H)-Pyridinone, 3-[4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-1-methyl- (CA INDEX NAME)




RN 1001001-42-8 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[2-(2-thienyl)-1H-benzimidazol-6-yl]- (CA INDEX NAME)




RN 1001001-43-9 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(1H-pyrazol-1-yl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-45-1 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[2-(methylthio)-6-benzothiazolyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-47-3 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-(2-methyl-5-benzothiazolyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-49-5 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-3-fluoro-N-propyl- (CA INDEX NAME)




RN 1001001-51-9 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[2-(trifluoromethyl)-1H-benzimidazol-6-yl]- (CA INDEX NAME)




RN 1001001-53-1 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-(2-methyl-5-benzoxazolyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)







RN 1001001-55-3 CAPLUS  
 CN 2-(3H)-Benzoxazolone, 6-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1001001-57-5 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-(2-methyl-6-benzoxazolyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-59-7 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-(1-methyl-1H-indol-5-yl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001001-61-1 CAPLUS  
 CN Methanesulfonamide, N-[3-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001001-63-3 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[3-(dimethylamino)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-65-5 CAPLUS

CN Ethanone, 1-[6-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-2,3-dihydro-1H-indol-1-yl]- (CA INDEX NAME)




RN 1001001-67-7 CAPLUS

CN Acetamide, N-[3-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001001-69-9 CAPLUS

CN 2H-Indol-2-one, 6-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-1,3-dihydro- (CA INDEX NAME)



RN 1001001-71-3 CAPLUS


CN 1H-Isoindol-1-one, 6-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-2,3-dihydro-2-propyl- (CA INDEX NAME)




RN 1001001-73-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-


5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-2,2-dimethyl- (CA INDEX NAME)




RN 1001001-75-7 CAPLUS  
CN 2H-1,4-Benzoxazin-3(4H)-one, 7-[(5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1001001-78-0 CAPLUS  
CN 2,5-Pyrimidinediamine, N2-(2-ethyl-1H-benzimidazol-6-yl)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-80-4 CAPLUS  
CN 2,5-Pyrimidinediamine, N2-[4-(dimethylamino)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-82-6 CAPLUS  
CN 2,5-Pyrimidinediamine, N2-[4-[(ethylmethylamino)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-84-8 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-(1H-imidazol-1-ylmethyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-86-0 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-[(2,5-dihydro-1H-pyrrol-1-yl)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001001-88-2 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-[(butylmethylamino)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-90-6 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-[(3,5-dimethyl-1-piperidinyl)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-92-8 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[(4-methoxy-1-piperidinyl)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-94-0 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[4-[(4-(trifluoromethyl)-1-piperidinyl)methyl]phenyl]- (CA INDEX NAME)




RN 1001001-96-2 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[(cyclopentylmethylamino)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001001-98-4 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[4-[(cyclohexylmethylamino)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-00-1 CAPLUS

CN Acetamide, N-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001002-02-3 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(1-piperidinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-03-4 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(phenylamino)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-04-5 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-[2-(1-piperidinyl)ethyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-05-6 CAPLUS

CN Ethanone, 2-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-1-(1-piperidinyloxy]ethanone (CA INDEX NAME)




RN 1001002-06-7 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-(1-methyl-1H-indazol-5-yl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-07-8 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-1,3-dihydro- (CA INDEX NAME)




RN 1001002-08-9 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[2-(2-furanyl)-1H-benzimidazol-6-yl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-09-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1001002-10-3 CAPLUS

CN 1H-Benzimidazole-2,6-diamine, N6-[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 1001002-11-4 CAPLUS

CN 2,5-Pyrimidinediamine, N2-(4-amino-3-bromo-5-chlorophenyl)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-12-5 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)







RN 1001002-13-6 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[4-(4-ethyl-1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-14-7 CAPLUS  
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001002-15-8 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-(4-fluorophenyl)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-16-9 CAPLUS  
 CN 2H-Indol-2-one, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-1,3-dihydro- (CA INDEX NAME)




RN 1001002-17-0 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[2,3-dihydro-1-(methylsulfonyl)-1H-indol-5-yl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-18-1 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-19-2 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-(1-methyl-1H-benzimidazol-5-yl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001002-20-5 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-(1,2-dimethyl-1H-benzimidazol-5-yl)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-21-6 CAPLUS  
 CN 2H-Benzimidazol-2-one, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-1,3-dihydro-1-methyl- (CA INDEX NAME)




RN 1001002-22-7 CAPLUS

CN 1H-Benzimidazole-1-ethanol, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1001002-23-8 CAPLUS

CN 1H-Benzimidazole-1-ethanol, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 1001002-24-9 CAPLUS

CN 1H-Benzimidazole-1-ethanol, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-2-ethyl- (CA INDEX NAME)




RN 1001002-25-0 CAPLUS


CN 1H-Benzimidazole-2,5-diamine, N5-[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]-1-methyl-N2-phenyl- (CA INDEX NAME)




RN 1001002-26-1 CAPLUS  
 CN 2H-Benzimidazol-2-one, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-1,3-dihydro-1-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1001002-27-2 CAPLUS  
 CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-2-fluoro- (CA INDEX NAME)




RN 1001002-28-3 CAPLUS  
 CN Benzamide, N-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001002-29-4 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-(2-ethyl-1-methyl-1H-benzimidazol-5-yl)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-30-7 CAPLUS  
 CN 1 (2H)-Naphthalenone, 6-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-3,4-dihydro- (CA INDEX NAME)




RN 1001002-31-8 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-(2,3-dimethyl-6-quinoxaliny)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-32-9 CAPLUS  
 CN 3-Quinolinecarboxylic acid, 6-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-1,2-dihydro-2-oxo-, methyl ester (CA INDEX NAME)




RN 1001002-33-0 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-34-1 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(4-morpholinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-35-2 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-3-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-36-3 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-4-(1,4,6,7-tetrahydro-1-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-41-0 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-(2,3-dihydro-2-methyl-1H-isoindol-5-yl)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-42-1 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-((3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[4-(trifluoromethyl)sulfonyl]phenyl)- (CA INDEX NAME)




RN 1001002-43-2 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-(4-methoxyphenyl)-N5,N5-dimethyl-4-((3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-44-3 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-((3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1001002-45-4 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(methylsulfonyl)phenyl]-4-((3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-46-5 CAPLUS  
 CN 1(3H)-Isobenzofuranone, 6-[[5-(dimethylamino)-4-((3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl)amino]- (CA INDEX NAME)




RN 1001002-47-6 CAPLUS  
 CN 1-(3H)-Isobenzofuranone, 5-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1001002-48-7 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-[3-[(dimethylamino)methyl]phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-49-8 CAPLUS  
 CN Methanesulfonamide, N-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001002-50-1 CAPLUS  
 CN 2-Piperidinone, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)







RN 1001002-51-2 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[3-(methylsulfonyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-52-3 CAPLUS  
 CN 2,5-Pyrimidinediamine, N2-(3-methoxyphenyl)-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-53-4 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1001002-54-5 CAPLUS  
 CN Ethanone, 1-[3-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001002-55-6 CAPLUS  
 CN Ethanone, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001002-56-7 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-4-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-57-8 CAPLUS

CN 2,5-Pyrimidinediamine, 4-(4-ethyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N5,N5-dimethyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 1001002-58-9 CAPLUS

CN 2,5-Pyrimidinediamine, N2-[3-chloro-4-(4-methyl-1-piperazinyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-59-0 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-7-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-60-3 CAPLUS

CN 2,5-Pyrimidinediamine, N5-ethyl-N5-methyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-61-4 CAPLUS

CN 1H-Benzimidazol-6-amine, 2-ethyl-N-[5-methoxy-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 1001002-63-6 CAPLUS

CN 2-Pyrimidinamine, N-[4-(4-ethyl-1-piperazinyl)phenyl]-5-methoxy-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-64-7 CAPLUS

CN 2-Pyrimidinamine, 5-methoxy-N-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-71-6 CAPLUS

CN 2-Pyrimidinamine, 4-(4-ethyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-methoxy-N-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 1001002-72-7 CAPLUS


CN 2-Pyrimidinamine, 5-methoxy-N-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-4-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001002-73-8 CAPLUS


CN 2-Pyrimidinamine, 5-methoxy-N-[4-(4-methyl-1-piperazinyl)phenyl]-4-[(6S)-3,4,6,7-tetrahydro-6-methyl-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1001002-74-9 CAPLUS


CN 2-Pyrimidinamine, 5-methoxy-N-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-7-methyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001002-75-0 CAPLUS


CN 2-Pyrimidinamine, 5-methoxy-N-[4-(4-methyl-1-piperazinyl)phenyl]-4-[(6R)-3,4,6,7-tetrahydro-6-methyl-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001002-76-1 CAPLUS

CN 2-Pyrimidinamine, 5-cyclopropyl-N-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-78-3 CAPLUS

CN 2-Pyrimidinamine, 5-(1-methylethyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-79-4 CAPLUS

CN 2,5-Pyrimidinediamine, N5-methyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N5-(phenylmethyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-80-7 CAPLUS

CN 2,5-Pyrimidinediamine, N5-methyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-81-8 CAPLUS

CN Ethanone, 1-[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-pyrimidinyl]- (CA INDEX NAME)




RN 1001002-82-9 CAPLUS

CN 1-Propanone, 1-[2-[[4-(4-morpholinyl)phenyl]amino]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-pyrimidinyl]- (CA INDEX NAME)




RN 1001002-83-0 CAPLUS


CN 2-Pyrimidinamine, 5-ethyl-N-[4-(1-piperidinylmethyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001002-84-1 CAPLUS  
 CN Ethanone, 1-[2-[[4-(1-piperidinylmethyl)phenyl]amino]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-pyrimidinyl]- (CA INDEX NAME)



RN 1001002-85-2 CAPLUS  
 CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 1001002-87-4 CAPLUS  
 CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 1001002-88-5 CAPLUS  
 CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)






RN 1001002-90-9 CAPLUS

CN Benzamide, N-[2-(dimethylamino)-2-oxoethyl]-4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1001002-92-1 CAPLUS

CN Benzamide, N-(cyclopropylmethyl)-4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1001002-93-2 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-(2-fluoroethyl)- (CA INDEX NAME)




RN 1001002-94-3 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 1001002-95-4 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1001002-96-5 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 1001002-97-6 CAPLUS

CN Benzamide, N-butyl-4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1001002-98-7 CAPLUS

CN Benzamide, N-[3-(dimethylamino)phenyl]-4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1001002-99-8 CAPLUS

CN Benzamide, N-1H-benzimidazol-6-yl-4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1001003-00-4 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-(1-methyl-1H-benzimidazol-5-yl)- (CA INDEX NAME)




RN 1001003-01-5 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 1001003-02-6 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)



RN 1001003-03-7 CAPLUS


CN Benamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-methyl-N-phenyl- (CA INDEX NAME)



RN 1001003-04-8 CAPLUS

CN Benamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-[trans-4-(4-morpholinyl)cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 1001003-05-9 CAPLUS


CN Benamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-[trans-3-(4-morpholinyl)cyclobutyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 1001003-06-0 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl][4-(4-pyridinyl)-1-piperazinyl]-  
(CA INDEX NAME)




RN 1001003-07-1 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl] (4-phenyl-1-piperazinyl)-  
(CA INDEX NAME)




RN 1001003-08-2 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl] [4-(phenylmethyl)-1-piperazinyl]-  
(CA INDEX NAME)




RN 1001003-09-3 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1001003-10-6 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl][4-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1001003-11-7 CAPLUS

CN Methanone, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl][4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1001003-12-8 CAPLUS

CN Ethanone, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1001003-13-9 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl][4-(2-pyrazinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1001003-14-0 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001003-15-1 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl][4-(2-(4-pyridinyl)ethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1001003-16-2 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl][4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1001003-17-3 CAPLUS

CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl] (5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)- (CA INDEX NAME)




RN 1001003-18-4 CAPLUS

CN 1-Piperazineacetamide, 4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]benzoyl]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1001003-19-5 CAPLUS


CN Methanone, [4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1001003-20-8 CAPLUS


CN Ethanone, 2-[4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl]-1-(4-morpholinyl)- (CA INDEX NAME)






RN 1001003-21-9 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidiny1)[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001003-22-0 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-(1-methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1001003-23-1 CAPLUS

CN Benzamide, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-methyl-N-(1-methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1001003-24-2 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidiny1)[1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-4-piperidiny1]- (CA INDEX NAME)




RN 1001003-25-3 CAPLUS

CN Methanone, (3,3-difluoro-1-piperidiny1)[1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-4-piperidinyl]- (CA INDEX NAME)



RN 1001003-26-4 CAPLUS


CN Methanone, [1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-4-piperidinyl]-4-morpholinyl- (CA INDEX NAME)



RN 1001003-27-5 CAPLUS


CN Methanone, [1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]-4-piperidinyl][(2R,6S)-2,6-dimethyl-4-morpholinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1001003-28-6 CAPLUS

CN 1-Piperazineacetonitrile, 4-[3-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1001003-29-7 CAPLUS

CN 1-Piperidineacetonitrile, 4-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]ethylamino]- (CA INDEX NAME)




RN 1001003-30-0 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1001003-31-1 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-N2-[4-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 1001003-32-2 CAPLUS


CN 2,5-Pyrimidinediamine, N2-[4-(3-furanyl)phenyl]-N5,N5-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001003-33-3 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(4-pyridinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001003-34-4 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(3-pyridinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001003-35-5 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(5-pyrimidinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001003-36-6 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(2-pyridinyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 1001003-37-7 CAPLUS  
 CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(1H-pyrrol-3-yl)phenyl]-4-

(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001003-38-8 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(1H-pyrrol-2-yl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




IT 1001003-49-1P

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidines and related compds. for treatment of diseases characterized by excessive or abnormal cell proliferation)

RN 1001003-49-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




IT 1001003-47-9 1001003-48-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidines and related compds. for treatment of diseases characterized by excessive or abnormal cell proliferation)

RN 1001003-47-9 CAPLUS


CN Benzoic acid, 4-[[5-(dimethylamino)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1001003-48-0 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[3-(1-piperazinyl)phenyl]-4-

(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




IT 514842-74-1P 514842-79-6P 1001006-84-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidines and related compds. for treatment of diseases characterized by excessive or abnormal cell proliferation)


RN 514842-74-1 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 5-(2-chloro-5-methoxy-4-pyrimidinyl)-4,5,6,7-tetrahydro- (CA INDEX NAME)




RN 514842-79-6 CAPLUS

CN 5-Pyrimidinamine, 2-chloro-N,N-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 1001006-84-3 CAPLUS



CN 1-Piperazinecarboxylic acid, 4-[4-[[5-methoxy-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]aminophenyl]-, phenylmethyl ester (CA INDEX NAME)





L3 ANSWER 11 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:1475931 CAPLUS  
 DOCUMENT NUMBER: 148:100628  
 TITLE: Substituted 3-amino-pyrrolidine-4-lactam derivatives,  
 processes for preparing them, pharmaceutical  
 compositions containing them, and their use as DPP-IV  
 (dipeptidyl peptidase IV) inhibitors  
 INVENTOR(S): Benbow, John William; Piotrowski, David Walter; Hui,  
 Yu  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 83pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007148185	A2	20071227	WO 2007-IB1588	20070611
WO 2007148185	A3	20080313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, CA US 20070299076 A1 20071227 US 2007-764445 20070618 PRIORITY APPLN. INFO.: US 2006-805371P P 20060621 US 2006-871482P P 20061222 OTHER SOURCE(S): MARPAT 148:100628 GI				






AB The invention relates to substituted 3-amino-pyrrolidine-4-lactam derivs. I, processes for preparing them, pharmaceutical preps. comprising them, and their pharmaceutical use. I are inhibitors of dipeptidyl peptidase IV (DPP-IV), useful in the treatment of, e.g., diabetes type 2. In compds. I, A is (CH<sub>2</sub>)<sub>n</sub>, wherein n is 1 or 2; R<sub>1</sub> and R<sub>2</sub> are independently H or F; R<sub>3</sub> is (un)substituted heteroaryl, etc.; including pharmaceutically acceptable salts thereof. For instance, the invention compound II was prepared and showed dipeptidyl peptidase inhibition IC<sub>50</sub> value of 24.1 nM.

IT 1000301-76-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted 3-amino-pyrrolidine-4-lactam derivs. as DPP-IV inhibitors)

RN 1000301-76-7 CAPLUS

CN [1,3'-Bipyrrolidin]-2-one, 4'-amino-1'-[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-4-pyrimidinyl]-, hydrochloride (1:2), (3'S,4'S)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

L3 ANSWER 12 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1309234 CAPLUS

DOCUMENT NUMBER: 147:541902

TITLE: Preparation of triazolopyrazine derivatives for treating hyperproliferative disorders

INVENTOR(S): Cheng, Hengmiao; Cui, Jingrong Jean; Hoffman, Jacqui Elizabeth; Jia, Lei; Johnson, Mary Catherine; Kania, Robert Steven; Le, Phuong Thi Quy; Nambu, Mitchell David; Fairish, Mason Alan; Shen, Hong; Tran-Dube, Michelle Bich

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 113pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070265272	A1	20071115	US 2007-745921	20070508
NL 20000613	C2	20071120	NL 2007-2000613	20070426
AU 2007251283	A1	20071122	AU 2007-251283	20070430
WO 2007132308	A1	20071122	WO 2007-IB1142	20070430
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

KR 2009006187 A 20090114

KR 2008-727474 20081110

PRIORITY APPLN. INFO.:

US 2006-799966P P 20060511

US 2007-893231P P 20070306

WO 2007-IB1142 W 20070430

OTHER SOURCE(S): MARPAT 147:541902

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [R1, R2 = H, Br, Cl, F, etc.; R3 = (un)substituted Ph (with the proviso); R4 = H, F, alkyl, aryl; n = 0-4], useful for treating c-Met related disorders such as cancer, were prepared Thus, reacting II with tert-But-3-(methylsulfonyloxy)azetidine-1-carboxylate in the presence of NaH followed by treatment of the resulting intermediate with 4N HCl afforded 34% III. Exemplified compds. I were tested in HGFR continuous-coupled spectrophotometric assay (data given). The invention also relates to pharmaceutical compns. containing the compds. I and to methods of treating hyperproliferative disorders in a mammal by administering the compds. I.


IT 956905-84-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazolopyrazine derivs. for treating hyperproliferative disorders)

RN 956905-84-3 CAPLUS

CN Quinoline, 6-[[6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]- (CA INDEX NAME)



L3 ANSWER 13 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1177863 CAPLUS

DOCUMENT NUMBER: 147:469247

TITLE: Preparation of quinolones derivatives useful as inducible nitric oxide synthase inhibitors  
 INVENTOR(S): Roppe, Jeffrey R.; Bonnefous, Celine; Smith, Nicholas D.; Lindstrom, Andrew K.; Noble, Stewart A.; Hassig, Christian A.; Payne, Joseph E.; Zhuang, Hui; Chen, Xiaohong; Duron, Sergio G.

PATENT ASSIGNEE(S): Kalypsys, Inc., USA

SOURCE: PCT Int. Appl., 238pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117778	A2	20071018	WO 2007-US62769	20070223
WO 2007117778	A3	20080207		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007235132	A1	20071018	AU 2007-235132	20070223
CA 2643011	A1	20071018	CA 2007-2643011	20070223
US 20080139558	A1	20080612	US 2007-678572	20070223
EP 1986747	A2	20081105	EP 2007-757450	20070223
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2008DN07205	A	20081003	IN 2008-DN7205	20080822
KR 2008108478	A	20081215	KR 2008-723220	20080923
PRIORITY APPLN. INFO.:			US 2006-776561P	P 20060224
			US 2006-848696P	P 20061002
			WO 2007-US62769	W 20070223

OTHER SOURCE(S): MARPAT 147:469247

GI



I



II

AB The invention relates to novel quinolones of formula I [R1 = (un)substituted acyl, alkyl, alkylene, aminoalkyl, amidoalkyl, alkynyl, aryl, arylalkyl, arylalkoxy, etc.; R2 = (un)substituted acyl, alkoxy, alkoxyalkyl, alkyl, alkylene, alkylamino, alkynyl, alkylimino, etc.; R2 may combine with R1 to form (un)substituted heterocycloalkyl; R3 = H, NH2, (un)substituted aryl, haloalkyl, (hetero)arylalkyl, (hetero)(cyclo)alkyl; A, B, C and D independently = (un)substituted acyl, alkoxy, alkyl, alkylene, alkylamino, alkynyl, etc.; any two or more A, B, C and D may combine to form aryl, cycloalkyl, heteroaryl or heterocycloalkyl], and their pharmaceutically acceptable salts, esters or prodrugs, are prepared and disclosed as inducible nitric oxide synthase (iNOS) inhibitors. Thus, e.g. II was prepared by acylation of aniline with Et 3-oxobutanoate followed by bromination and cyclization to generate intermediate 4-(bromomethyl)quinolin-2(1H)-one, which underwent substitution with aniline and acylation with furan-2-carbonyl chloride to provide II. The inhibitory activity of all exemplary compds. was evaluated in DAN assay and II was found to have EC50 value of  $\leq 5 \mu\text{M}$ . I should prove useful for inhibiting or modulating nitric oxide synthase and/or lowering nitric oxide levels of iNOS and for the treatment of an iNOS-mediated disease in a patient in need thereof.


IT 953069-41-5P, 7,8-Difluoro-4-[(2-isopropyl-5H-imidazo[4,5-c]pyridin-5-yl)methyl]quinolin-2(1H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolones derivs. useful as inducible nitric oxide synthase inhibitors)

RN 953069-41-5 CAPLUS

CN 2(1H)-Quinolinone, 7,8-difluoro-4-[[2-(1-methylethyl)-5H-imidazo[4,5-c]pyridin-5-yl)methyl]- (CA INDEX NAME)





L3 ANSWER 14 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1061608 CAPLUS

DOCUMENT NUMBER: 147:386017

TITLE: Preparation of piperazinyloxoalkyl tetrahydroisoquinolines and related analogues as histamine H3 receptor modulators

INVENTOR(S): Gao, Yang; Han, Bingsong; Xu, Yuelian; Caldwell, Timothy M.; Xie, Linghong

PATENT ASSIGNEE(S): Neurogen Corp., USA

SOURCE: PCT Int. Appl., 277pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007106349	A2	20070920	WO 2007-US5762	20070308
WO 2007106349	A3	20071129		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007225273	A1	20070920	AU 2007-225273	20070308
US 20070232591	A1	20071004	US 2007-716354	20070308
EP 1998620	A2	20081210	EP 2007-752458	20070308
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2008DN07349	A	20080926	IN 2008-DN7349	20080828
KR 2008109841	A	20081217	KR 2008-724892	20081010
PRIORITY APPLN. INFO.:			US 2006-781516P	P 20060310
			WO 2007-US5762	W 20070308
OTHER SOURCE(S):	MARPAT 147:386017			
GI				



I



II

AB The title compds. I [n, p = 0-3; m, o = 1-3; X = CH or N (if p = 0 then X = CH); R1 = alkyl, alkenyl, cycloalkylalkyl, etc.; or R1 and R3 are taken together to form (un)substituted fused 5-7 membered cycloalkyl or heterocycloalkyl; R2 = alkyl, cycloalkylalkyl, phenylalkyl, etc.; or two R2 are taken together with a ring atom to which they attached to form (un)substituted spiro cycloalkyl or a spiro 4-7 membered heterocycloalkyl; R3 = alkyl, haloalkyl; or two R3 groups are taken together to form (un)substituted fused 5-7 membered cycloalkyl or heterocycloalkyl; A = (un)substituted Ph or 5-6 membered heteroaryl] which may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals, were prepared E.g., a multi-step synthesis of II, starting from 1-cyclobutylpiperazine, was given. Compds. I were tested in chimeric human H3 receptor GTP binding assay (data given for representative compds. I). Compds. I may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compns. and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).


IT 1057338-49-4 1057338-50-7

RL: PRPH (Prophetic)

(Preparation of piperazinyloxoalkyl tetrahydroisoquinolines and related analogues as histamine H3 receptor modulators)

RN 1057338-49-4 CAPLUS

CN Ethanone, 2-[2-(4-acetylphenyl)-3,4,6,7-tetrahydro-3-methyl-5H-imidazo[4,5-c]pyridin-5-yl]-1-(4-cyclobutyl-1-piperazinyl)- (CA INDEX NAME)




RN 1057338-50-7 CAPLUS

CN Benzonitrile, 4-[5-[2-(4-cyclobutyl-1-piperazinyl)-2-oxoethyl]-4,5,6,7-



tetrahydro-1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-

(CA INDEX NAME)



L3 ANSWER 15 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:963940 CAPLUS

DOCUMENT NUMBER: 147:301192

TITLE: Preparation of substituted quinazolines as phosphodiesterase (PDE10) inhibitors for treating neurological and psychiatric disorders  
 INVENTOR(S): Allen, Martin Patrick; Chappie, Thomas Allen; Humphrey, John Michael; Liras, Spiros  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 37pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007096743	A1	20070830	WO 2007-IB411	20070209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2641670 A1 20070830 CA 2007-2641670 20070209 EP 1996587 A1 20081203 EP 2007-705627 20070209 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR US 20090023756 A1 20090122 US 2008-279869 20080819 PRIORITY APPLN. INFO.: US 2006-776112P P 20060223 WO 2007-IB411 W 20070209				

OTHER SOURCE(S): MARPAT 147:301192


GI



AB The invention pertains to substituted quinazoline compds. of structures I


and II (wherein the rings containing W1, X1 and Y1, and W, X, Y and Z, or tautomers thereof, are aromatic or heteroarom.; R2, R5 and R6 are H, halo, CN, COOH, etc.) that serve as effective phosphodiesterase (PDE) inhibitors; no biol. data given in patent. The invention also relates to compds. which are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compds.; pharmaceutical compns. comprising such compds.; and the use of such compds. in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom. Example compound 2-(6,7-dimethoxyquinazolin-4-yl)-2,3,4,9-tetrahydro-1H-b-carboline was prepared by reacting 4-chloro-6,7-dimethoxyquinazoline with 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole.

IT 947264-87-1P, 6,7-Dimethoxy-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)quinazoline  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted quinazolines as phosphodiesterase (PDE10) inhibitors for treating neurol. and psychiatric disorders)  
 RN 947264-87-1 CAPLUS  
 CN Quinazoline, 6,7-dimethoxy-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 16 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:923536 CAPLUS  
 DOCUMENT NUMBER: 147:448691  
 TITLE: Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines:  
 Further optimization of anti-hepatitis C virus  
 activity  
 AUTHOR(S): Puerstinger, Gerhard; Paeshuyse, Jan; Heinrich,  
 Susanne; Mohr, Joachim; Schraffl, Nicole; De Clercq,  
 Erik; Neyts, Johan  
 CORPORATE SOURCE: Institut fuer Pharmazie, Abteilung Pharmazeutische  
 Chemie, Universitaet Innsbruck, Innsbruck, A-6020,  
 Austria  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007),  
 17(18), 5111-5114  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 147:448691  
 GI



- AB Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines represent a novel  
 class of compds. with activity against pestiviruses and the hepatitis C  
 virus (HCV). Several series of analogs with modifications of the  
 substituents in positions 2 and 5 were prepared. These efforts resulted in  
 the discovery of several compds. with potent antiviral activity of which  
 2-(2,3-difluorophenyl)-5-(4-(trifluoromethyl)benzyl)-5H-imidazo[4,5-  
 c]pyridine (I) was most potent against HCV (EC50 of 0.10  $\mu$ M and a  
 selectivity index of 1080).  
 IT 952291-00-8P 952291-01-9P  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
 activity); SPN (Synthetic preparation); BIOL (Biological study); PREP  
 (Preparation)  
 (preparation, anti-hepatitis C virus, anti-bovine viral diarrhea virus  
 activity, cytotoxicity, and SAR of imidazopyridine derivs.)  
 RN 952291-00-8 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-(2-pyridinylmethyl)- (CA  
 INDEX NAME)



RN 952291-01-9 CAPLUS  
CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-(3-pyridinylmethyl)- (CA  
INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:774419 CAPLUS

DOCUMENT NUMBER: 147:132872

TITLE: QSAR studies of 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines as potent angiotensin II receptor antagonists by MLR and NLR analysis

AUTHOR(S): Narasimhan, Balasubramanian; Dhake, Avinash; Mourya, Vishnukant

CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, 125001, India

SOURCE: ARKIVOC (Gainesville, FL, United States) (2007), (1), 189-204

CODEN: AGFUAR

URL: [http://content.arkat-usa.org/ARKIVOC/JOURNAL\\_CONTENT/manuscripts/2007/07-2291BP%20as%20published%20mainmanuscript.pdf](http://content.arkat-usa.org/ARKIVOC/JOURNAL_CONTENT/manuscripts/2007/07-2291BP%20as%20published%20mainmanuscript.pdf)

PUBLISHER: Arkat USA Inc.

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

AB A quant. structure activity relationship (QSAR) was employed to find out the correlation between the structural properties and angiotensin II receptor antagonistic activity of 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines collected from the literature. The multiple linear regression (MLR) and non-linear regression (NLR) analyses have been carried out to derive best QSAR models. The developed models were cross-validated by the 'leave one out' technique as well as by the calcn. of statistical parameters. The present investigation indicated the importance of the quantum chemical descriptor, energy of LUMO, LUMO and the lipophilic parameter, log P, in contribution to the studied biol. activity. The results of NLR showed that neglecting log P, based on its low correlation by MLR, as followed by most of the QSAR studies, can lead to fortuitous results and one must perform non-linear regression before coming to a decision on the contribution of the lipophilic parameter, log P.

IT 177263-98-8 177264-18-5 193753-32-1


193753-33-2

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(QSAR studies of 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines as potent angiotensin II receptor antagonists by MLR and NLR anal.)


RN 177263-98-8 CAPLUS

CN Carbamic acid, N-[[4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)




RN 177264-18-5 CAPLUS


CN Carbamic acid, N-[[4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 193753-32-1 CAPLUS  
 CN Benzenepropanamide, N-[[4'-[[4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)



RN 193753-33-2 CAPLUS  
 CN Carbamic acid, N-[[4'-[[4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT





AB The invention provides compds. of formula I and related compds., capable of modulating tyrosine kinases, compns. comprising the compds. and methods of their use. Compds. of formula I wherein R1 is (un)substituted heterocyclyl, (un)substituted alkyl, (un)substituted sulfonyl, acyl, etc.; R2 is H, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkylalkyl, (un)substituted (hetero)aryl(alkyl), heterocycloalkyl, etc.; Q1, Q2, Q3 and Q4 are independently. C1-5 alkyl; and their stereoisomers, tautomers, salts, hydrates and prodrugs thereof, are claimed. Example compound II was prepared by amidation of 2-[2-hydroxy-5-(2-methoxypyridin-3-yl)phenyl]benzimidazole-5-carboxylic acid with 1-methoxy-2-propylamine. All the invention compds. were evaluated for their tyrosine kinase modulatory activity (some data given).


IT 936931-89-4P 936934-85-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heterocyclic compds. as tyrosine kinase modulators and their use in the treatment of diseases)


RN 936931-89-4 CAPLUS

CN Methanone, [2-[2-hydroxy-5-(2-methoxy-3-pyridinyl)phenyl]-1H-benzimidazol-6-yl][3,4,6,7-tetrahydro-4-(2-pyridinyl)-5H-imidazo[4,5-c]pyridin-5-yl]-(CA INDEX NAME)



RN 936934-85-9 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-6-carboxylic acid, 4,5,6,7-tetrahydro-5-[[2-[2-hydroxy-5-(2-methoxy-3-pyridinyl)phenyl]-1H-benzimidazol-6-yl]carbonyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT:


5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:351573 CAPLUS  
 DOCUMENT NUMBER: 146:379974  
 TITLE: Preparation of aryl substituted imidazo[4,5-c]pyridine derivatives as C3A receptor antagonists  
 INVENTOR(S): Butler, Todd William  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 74pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007034277	A1	20070329	WO 2006-IB2557	20060917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-718539P P 20050919  
 OTHER SOURCE(S): MARPAT 146:379974  
 GI




AB Title compds. represented by the formula I [wherein X = a single bond or (un)substituted alkylene; R1 = independently H, halo, carbonylalkyl, etc.; R2 = H, halo, amino, etc.; R3 = H, hydroxy, (oxy)alkyl, etc.; R4 = H, (un)substituted alkyl, alkenyl; or R3R4 = cyclyl; and pharmaceutically acceptable salts thereof] were prepared as Complement protein C3A antagonists. For example, cyclization of 3',4'-dimethylbiphenyl-4-carboxylic acid with 3,4-diaminopyridine gave 2-((3',4'-dimethylbiphenyl-4-yl)-3H-imidazo[4,5-c]pyridine. I showed biol. activity in C3A receptor binding assay. Thus, I and their pharmaceutical compns. are useful as C3A receptor antagonists for the treatment of a variety of medical conditions associated with the Complement cascade.

IT 930767-75-2P, 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[[1-(4-tolylsulfonyl)-1H-imidazol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine  
 930767-76-3P, 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[[1-(4-tolylsulfonyl)-1H-imidazol-4-yl)methyl]-5H-imidazo[4,5-c]pyridine  
 930767-84-3P, 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)ethanone  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of aryl substituted imidazo[4,5-c]pyridine derivs. as C3A receptor antagonists)


RN 930767-75-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[[1-[(4-methylphenyl)sulfonyl]-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 930767-76-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[[1-[(4-methylphenyl)sulfonyl]-1H-imidazol-4-yl)methyl]- (CA INDEX NAME)



RN 930767-84-3 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)- (CA INDEX NAME)



IT 930767-72-9P, 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(pyridin-3-yl)methyl]-5H-imidazo[4,5-c]pyridine 930767-73-0P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(pyridin-4-yl)methyl]-5H-imidazo[4,5-c]pyridine 930767-74-1P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(pyridin-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930767-77-4P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(5-methyl-[1,3,4]oxadiazol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930767-78-5P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(thiazol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930767-79-6P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[2-(1H-imidazol-4-yl)ethyl]-5H-imidazo[4,5-c]pyridine 930767-81-0P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1-methylimidazol-5-yl)methyl]-5H-imidazo[4,5-c]pyridine 930767-82-1P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1-methyl-1H-imidazol-4-yl)methyl]-5H-imidazo[4,5-c]pyridine 930767-83-2P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(2-methyl-1H-imidazol-4-yl)ethanone 930767-86-5P,  
 1-(2-Amino-4-methylthiazol-5-yl)-2-[2-(3',4'-dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]ethanone 930767-87-6P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[2-(1H-pyrazol-3-yl)ethyl]-5H-imidazo[4,5-c]pyridine 930767-89-8P,  
 2-[2-(4'-Methoxybiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)ethanone dihydrochloride 930767-91-2P,  
 2-[2-(4'-Fluorobiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)ethanone hydrochloride 930767-93-4P,  
 2-[2-(3'-Methylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)ethanone 930767-95-6P,  
 2-[2-(3'-Chlorobiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)ethanone hydrochloride 930767-97-8P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-pyrazol-3-yl)methyl]-5H-imidazo[4,5-c]pyridine hydrochloride 930767-98-9P,  
 2-(3'-Chlorobiphenyl-4-yl)-5-[(1H-pyrazol-3-yl)methyl]-5H-imidazo[4,5-c]pyridine hydrochloride 930767-99-0P,  
 2-(3'-Methylbiphenyl-4-yl)-5-[(1H-pyrazol-3-yl)methyl]-5H-imidazo[4,5-c]pyridine hydrochloride 930768-02-8P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-tetrazol-5-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-03-9P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-tetrazol-5-yl)methyl]-5H-imidazo[4,5-c]pyridine dihydrochloride 930768-09-5P,  
 5-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl)methyl]-1,2-dihydropyrazol-3-one 930768-10-8P 930768-11-9P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-imidazol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-12-0P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-imidazol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine trihydrochloride 930768-13-1P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-imidazol-4-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-14-2P,  
 5-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl)methyl]-2,4-dihydro-[1,2,4]triazol-3-one 930768-16-4P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-[1,2,4]triazol-3-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-18-6P,  
 5-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl)methyl]-3H-

[1,3,4]oxadiazol-2-one 930768-20-0P,  
 [5-[(2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl)methyl][1,3,4]oxadiazol-2-yl]amine 930768-21-1P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(2-methyl-1H-imidazol-4-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-23-3P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-pyrazol-4-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-25-5P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-[2-methyl-1-[2-(2-methyl-1H-imidazol-4-yl)-2-oxoethyl]-1H-imidazol-4-yl]ethanone 930768-28-8P, 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-[2-methyl-1-[2-(2-methyl-1H-imidazol-4-yl)-2-oxoethyl]-1H-imidazol-4-yl]ethanone hydrochloride 930768-29-9P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(2-methyl-1H-imidazol-4-yl)ethanol 930768-30-2P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(2-methyl-1H-imidazol-4-yl)ethanol hydrochloride 930768-31-3P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)ethanol 930768-32-4P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(pyrazin-2-yl)ethanol 930768-40-4P,  
 2-[2-[4-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)phenyl]imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)ethanone maleate 930768-47-1P, 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(2-methyl-2H-pyrazol-3-yl)ethanone 930768-48-2P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1,3,4]oxadiazol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-49-3P,  
 [5-[(2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl)methyl][1,3,4]oxadiazol-2-yl]dimethylamine 930768-50-6P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(oxazol-5-yl)ethanone 930768-51-7P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-[(1,3,4]oxadiazol-2-yl)ethanone 930768-52-8P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(oxazol-2-yl)ethanone 930768-53-9P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(4-methyloxazol-2-yl)ethanone 930768-54-0P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(5-methyloxazol-2-yl)ethanone 930768-55-1P,  
 2-(3-Fluoro-3',4'-Dimethylbiphenyl-4-yl)-5-[(4-methylthiazol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-57-3P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[3-(1H-imidazol-4-yl)propyl]-5H-imidazo[4,5-c]pyridine 930768-58-4P,  
 2-[2-(4-Methoxybiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(2-methyl-1H-imidazol-4-yl)ethanone 930768-65-3P,  
 1-[2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]ethyl]pyrrolidin-2-one 930768-66-4P,  
 1-[2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]ethyl]-1,3-dihydroimidazol-2-one 930768-67-5P,  
 1-[2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]ethyl]imidazolidin-2-one 930768-68-6P,  
 1-[2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]ethyl]-3-methylimidazolidin-2-one 930768-69-7P,  
 1-[2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]ethyl]-3-methyl-1,3-dihydroimidazol-2-one 930768-70-0P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(2-methyl-2H-tetrazol-5-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-71-1P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(1,2-dimethyl-1H-imidazol-4-yl)ethanone 930768-72-2P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(2-methyl-2H-pyrazol-3-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-73-3P,  
 1-[5-[(2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl)methyl]pyrazol-1-yl]ethanone 930768-74-4P,


1-(1-Acetyl-2-methyl-1H-imidazol-4-yl)-2-[2-(3',4'-dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]ethanone 930768-75-5P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(pyrimidin-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-76-6P,  
 6-[[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl)methyl]pyridin-2-ol 930768-77-7P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(pyridazin-3-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-78-8P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(pyrimidin-5-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-79-9P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(pyrazin-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-80-2P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(pyrimidin-4-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-81-3P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(pyridin-4-yl)ethanone 930768-82-4P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(pyridin-3-yl)ethanone 930768-83-5P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(pyridin-2-yl)ethanone 930768-84-6P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(pyrimidin-4-yl)ethanone 930768-85-7P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(pyridazin-3-yl)ethanone 930768-86-8P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(pyrimidin-2-yl)ethanone 930768-87-9P,  
 5-[(Benzo[d]isoxazol-3-yl)methyl]-2-(3',4'-dimethylbiphenyl-4-yl)-5H-imidazo[4,5-c]pyridine 930768-88-0P,  
 5-[(Benzoxazol-2-yl)methyl]-2-(3',4'-dimethylbiphenyl-4-yl)-5H-imidazo[4,5-c]pyridine 930768-89-1P,  
 5-[(1H-Benzimidazol-2-yl)methyl]-2-(3',4'-dimethylbiphenyl-4-yl)-5H-imidazo[4,5-c]pyridine 930768-90-4P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1-methyl-1H-benzimidazol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-91-5P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-indol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-92-6P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1-methyl-1H-indol-2-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-93-7P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1H-indol-3-yl)methyl]-5H-imidazo[4,5-c]pyridine 930768-94-8P,  
 2-(3',4'-Dimethylbiphenyl-4-yl)-5-[(1-methyl-1H-indol-3-yl)methyl]-5H-imidazo[4,5-c]pyridine 930769-01-0P 930769-02-1P  
 930769-03-2P 930769-04-3P 930769-05-4P  
 930769-06-5P 930769-07-6P 930769-08-7P  
 930769-09-8P 930769-10-1P 930769-11-2P  
 930769-12-3P 930769-13-4P 930769-14-5P  
 930769-15-6P 930769-16-7P 930769-22-5P  
 930769-23-6P 930769-24-7P 930769-25-8P  
 930769-26-9P 930769-27-0P 930769-28-1P  
 930769-29-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl substituted imidazo[4,5-c]pyridine derivs. as C3A receptor antagonists)


RN 930767-72-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 930767-73-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 930767-74-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 930767-77-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]- (CA INDEX NAME)




RN 930767-78-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 930767-79-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)




RN 930767-81-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)




RN 930767-82-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1-methyl-1H-imidazol-4-yl)methyl]- (CA INDEX NAME)



RN 930767-83-2 CAPLUS


CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(2-methyl-1H-imidazol-5-yl)- (CA INDEX NAME)



RN 930767-86-5 CAPLUS




CN Ethanone, 1-(2-amino-4-methyl-5-thiazolyl)-2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 930767-87-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[2-(1H-pyrazol-3-yl)ethyl]- (CA INDEX NAME)



RN 930767-89-8 CAPLUS


CN Ethanone, 2-[2-(4'-methoxy[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 930767-91-2 CAPLUS


CN Ethanone, 2-[2-(4'-fluoro[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 930767-93-4 CAPLUS

CN Ethanone, 2-[2-(3'-methyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 930767-95-6 CAPLUS


CN Ethanone, 2-[2-(3'-chloro[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 930767-97-8 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-pyrazol-3-ylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 930767-98-9 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(3'-chloro[1,1'-biphenyl]-4-yl)-5-(1H-pyrazol-3-ylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 930767-99-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3'-methyl[1,1'-biphenyl]-4-yl)-5-(1H-pyrazol-3-ylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 930768-02-8 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 930768-03-9 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(2H-tetrazol-5-ylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 930768-09-5 CAPLUS  
 CN 3H-Pyrazol-3-one, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-1,2-dihydro- (CA INDEX NAME)




RN 930768-10-8 CAPLUS  
 CN 3H-Pyrazol-3-one, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-1,2-dihydro-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930768-09-5

CMF C24 H21 N5 O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 930768-11-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-imidazol-2-ylmethyl)- (CA INDEX NAME)



RN 930768-12-0 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-imidazol-2-ylmethyl)-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 930768-13-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-imidazol-2-ylmethyl)- (CA INDEX NAME)




RN 930768-14-2 CAPLUS

CN 1,2,4-Triazolidin-3-one, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]- (CA INDEX NAME)




RN 930768-16-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-1,2,4-triazol-5-ylmethyl)- (CA INDEX NAME)




RN 930768-18-6 CAPLUS

CN 1,3,4-Oxadiazol-2(3H)-one, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]- (CA INDEX NAME)




RN 930768-20-0 CAPLUS

CN 1,3,4-Oxadiazol-2-amine, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]- (CA INDEX NAME)




RN 930768-21-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(2-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)




RN 930768-23-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-pyrazol-4-ylmethyl)- (CA INDEX NAME)




RN 930768-25-5 CAPLUS

CN Ethanone, 2-[4-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-2-methyl-1H-imidazol-1-yl]-1-(2-methyl-1H-imidazol-5-yl)- (CA INDEX NAME)



RN 930768-28-8 CAPLUS


CN Ethanone, 2-[4-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-2-methyl-1H-imidazol-1-yl]-1-(2-methyl-1H-imidazol-5-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 930768-29-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-ethanol,  
2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-α-(2-methyl-1H-imidazol-5-yl)-  
(CA INDEX NAME)



RN 930768-30-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-ethanol,  
2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-α-(2-methyl-1H-imidazol-5-yl)-  
, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 930768-31-3 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine-5-ethanol,

2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)- $\alpha$ -1H-pyrazol-3-yl- (CA INDEX NAME)



RN 930768-32-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-ethanol,  
2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)- $\alpha$ -2-pyrazinyl- (CA INDEX NAME)




RN 930768-40-4 CAPLUS

CN Ethanone, 2-[2-[4-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930768-39-1

CMF C22 H16 F3 N7 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.






RN 930768-47-1 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 930768-48-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1,3,4-oxadiazol-2-ylmethyl)- (CA INDEX NAME)




RN 930768-49-3 CAPLUS

CN 1,3,4-Oxadiazol-2-amine, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 930768-50-6 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(5-oxazolyl)- (CA INDEX NAME)




RN 930768-51-7 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)




RN 930768-52-8 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(2-oxazolyl)- (CA INDEX NAME)




RN 930768-53-9 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(4-methyl-2-oxazolyl)- (CA INDEX NAME)




RN 930768-54-0 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(5-methyl-2-oxazolyl)- (CA INDEX NAME)




RN 930768-55-1 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 2-(3-fluoro-3',4'-dimethyl[1,1'-biphenyl]-4-yl)-1-[(4-methyl-2-thiazolyl)methyl]- (CA INDEX NAME)




RN 930768-57-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[3-(1H-imidazol-5-yl)propyl]- (CA INDEX NAME)




RN 930768-58-4 CAPLUS

CN Ethanone, 2-[2-(4'-methoxy[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(2-methyl-1H-imidazol-5-yl)- (CA INDEX NAME)




RN 930768-65-3 CAPLUS

CN 2-Pyrrolidinone, 1-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]ethyl]- (CA INDEX NAME)




RN 930768-66-4 CAPLUS

CN 2H-Imidazol-2-one, 1-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]ethyl]-1,3-dihydro- (CA INDEX NAME)




RN 930768-67-5 CAPLUS


CN 2-Imidazolidinone, 1-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]ethyl]- (CA INDEX NAME)




RN 930768-68-6 CAPLUS  
 CN 2-Imidazolidinone, 1-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]ethyl]-3-methyl- (CA INDEX NAME)




RN 930768-69-7 CAPLUS  
 CN 2H-Imidazol-2-one, 1-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]ethyl]-1,3-dihydro-3-methyl- (CA INDEX NAME)




RN 930768-70-0 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(2-methyl-2H-tetrazol-5-yl)methyl]- (CA INDEX NAME)



RN 930768-71-1 CAPLUS  
 CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1,2-dimethyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 930768-72-2 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1-methyl-1H-pyrazol-5-yl)methyl]- (CA INDEX NAME)




RN 930768-73-3 CAPLUS

CN Ethanone, 1-[5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 930768-74-4 CAPLUS

CN Ethanone, 1-(1-acetyl-2-methyl-1H-imidazol-4-yl)-2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 930768-75-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)




RN 930768-76-6 CAPLUS

CN 2(1H)-Pyridinone, 6-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]- (CA INDEX NAME)




RN 930768-77-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(3-pyridazinylmethyl)- (CA INDEX NAME)




RN 930768-78-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(5-pyrimidinylmethyl)- (CA INDEX NAME)



RN 930768-79-9 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(2-pyrazinylmethyl)- (CA INDEX NAME)



RN 930768-80-2 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(4-

pyrimidinylmethyl)- (CA INDEX NAME)




RN 930768-81-3 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(4-pyridinyl)- (CA INDEX NAME)




RN 930768-82-4 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(3-pyridinyl)- (CA INDEX NAME)




RN 930768-83-5 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(2-pyridinyl)- (CA INDEX NAME)




RN 930768-84-6 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(4-pyrimidinyl)- (CA INDEX NAME)




RN 930768-85-7 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(3-pyridazinyl)- (CA INDEX NAME)




RN 930768-86-8 CAPLUS

CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(2-pyrimidinyl)- (CA INDEX NAME)



RN 930768-87-9 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-(1,2-benzisoxazol-3-ylmethyl)-2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)



RN 930768-88-0 CAPLUS




CN 5H-Imidazo[4,5-c]pyridine, 5-(2-benzoxazolylmethyl)-2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)




RN 930768-89-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-(1H-benzimidazol-2-ylmethyl)-2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)




RN 930768-90-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1-methyl-1H-benzimidazol-2-yl)methyl]- (CA INDEX NAME)




RN 930768-91-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-indol-2-ylmethyl)- (CA INDEX NAME)




RN 930768-92-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1-methyl-1H-indol-2-yl)methyl]- (CA INDEX NAME)




RN 930768-93-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-indol-3-ylmethyl)- (CA INDEX NAME)



RN 930768-94-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1-methyl-1H-indol-3-yl)methyl]- (CA INDEX NAME)




RN 930769-01-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(3-pyridinylmethyl)-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 930767-72-9


CMF C26 H22 N4



CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 930769-02-1 CAPLUS  
CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(4-pyridinylmethyl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 930767-73-0  
CMF C26 H22 N4



CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 930769-03-2 CAPLUS  
CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(2-pyridinylmethyl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930767-74-1  
CMF C26 H22 N4




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 930769-04-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[[1-[(4-methylphenyl)sulfonyl]-1H-imidazol-2-yl)methyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930767-75-2

CMF C31 H27 N5 O2 S




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 930769-05-4 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[[1-[(4-methylphenyl)sulfonyl]-1H-imidazol-4-yl]methyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 930767-76-3  
 CMF C31 H27 N5 O2 S




CM 2  
 CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.



RN 930769-06-5 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 930767-77-4  
 CMF C24 H21 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 930769-07-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(2-thiazolylmethyl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930767-78-5

CMF C24 H20 N4 S




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 930769-08-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[2-(1H-imidazol-5-yl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 930769-09-8 CAPLUS  
CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 930769-10-1 CAPLUS  
CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(1-methyl-1H-imidazol-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 930769-11-2 CAPLUS  
CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(2-methyl-1H-imidazol-5-yl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 930769-12-3 CAPLUS  
 CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 930769-13-4 CAPLUS  
 CN Ethanone, 1-(2-amino-4-methyl-5-thiazolyl)-2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 930769-14-5 CAPLUS  
 CN 5H-imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[2-(1H-pyrazol-3-yl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)






● 2 HCl

RN 930769-15-6 CAPLUS  
 CN Ethanone, 2-[2-(4'-methoxy[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 930769-16-7 CAPLUS  
 CN Ethanone, 2-[2-(4'-fluoro[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 930769-22-5 CAPLUS  
 CN 1,2,4-Triazolidin-3-one, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 930768-14-2  
 CMF C23 H22 N6 O



CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 930769-23-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-1,2,4-triazol-5-ylmethyl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930768-16-4

CMF C23 H20 N6




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 930769-24-7 CAPLUS

CN 1,3,4-Oxadiazol-2(3H)-one, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 930769-25-8 CAPLUS

CN 1,3,4-Oxadiazol-2-amine, 5-[[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930768-20-0

CMF C23 H20 N6 O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 930769-26-9 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-[(2-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 930769-27-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5-(1H-pyrazol-4-ylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

CN 5H-Imidazo[4,5-c]pyridine-5-ethanol,  
2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)- $\alpha$ -1H-pyrazol-3-yl-,  
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930768-31-3

CMF C25 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 930769-29-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-ethanol,  
2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)- $\alpha$ -2-pyrazinyl-,  
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 930768-32-4

CMF C26 H23 N5 O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT 930768-26-6P, 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-[2-methyl-1-(4-tolylsulfonyl)-1H-imidazol-4-yl]ethanone  
 930768-27-7P 930768-33-5P,  
 2-[2-(3',4'-Dimethylbiphenyl-4-yl)imidazo[4,5-c]pyridin-5-yl]-1-(pyrazin-2-yl)ethanone  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of aryl substituted imidazo[4,5-c]pyridine derivs. as C3A receptor antagonists)  
 RN 930768-26-6 CAPLUS  
 CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-[2-methyl-1-(4-methylphenyl)sulfonyl]-1H-imidazol-4-yl]- (CA INDEX NAME)



RN 930768-27-7 CAPLUS  
 CN Ethanone, 2-[4-[2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-2-methyl-1H-imidazol-1-yl]-1-(2-methyl-1-(4-methylphenyl)sulfonyl)-1H-imidazol-4-yl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 930768-33-5 CAPLUS  
 CN Ethanone, 2-[2-(3',4'-dimethyl[1,1'-biphenyl]-4-yl)-5H-imidazo[4,5-c]pyridin-5-yl]-1-(2-pyrazinyl)- (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:129784 CAPLUS  
 DOCUMENT NUMBER: 146:379763  
 TITLE: Novel carbazole derivatives as NPY Y1 antagonists  
 AUTHOR(S): Leslie, Colin P.; Di Fabio, Romano; Bonetti, Francesca; Borriello, Manuela; Braggio, Simone; Dal Forno, Giovanna; Donati, Daniele; Falchi, Alessandro; Ghirlanda, Damiano; Giovannini, Riccardo; Pavone, Francesca; Pecunioso, Angelo; Pentassuglia, Giorgio; Pizzi, Domenica A.; Rumboldt, Giovanna; Stasi, Luigi  
 CORPORATE SOURCE: GlaxoSmithKline Medicines Research Centre, Verona, 37135, Italy  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(4), 1043-1046  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 146:379763  
 GI



AB The synthesis of a series of carbazole derivs., e.g., I, and their SAR at the NPY Y1 receptor is described. Modulation of physicochem. properties by appropriate decoration led to the identification of a high-affinity NPY Y1 antagonist that shows high brain penetration and modest oral bioavailability.  
 IT 931414-43-6P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (calculated pKa value; preparation, NPY Y1 receptor antagonistic activity, and  
 SAR of chlorophenoxy carbazole derivs.)  
 RN 931414-43-6 CAPLUS  
 CN Methanone, [1-(4-chlorophenoxy)-9-[(3R,4S)-3-fluoro-4-piperidinyl]methyl]-9H-carbazol-3-yl] (3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:


16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




L3 ANSWER 21 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:117372 CAPLUS  
 DOCUMENT NUMBER: 146:202022  
 TITLE: Drug-resistant mutation in nonstructural proteins of hepatitis C virus  
 INVENTOR(S): Boddeker, Nina; Neyts, Johan; Shih, I-Hung; Vliegen, Inge; Zhong, Weidong  
 PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA; K.U. Leuven Research & Development; Puerstinger, Gerhard  
 SOURCE: PCT Int. Appl., 27pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014174	A2	20070201	WO 2006-US28727	20060724
WO 2007014174	A3	20070913		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20070128625	A1	20070607	US 2006-491756	20060724
PRIORITY APPLN. INFO.:			US 2005-702534P	P 20050725
AB	Provided are hepatitis C virus mutations in nonstructural proteins, which are associated with drug resistance, especially imidazopyridine compds. The mutations are (1) Q581E, A391V, M582L, and C432S within NS3 region, (2) V24A within NS4A region, (3) L4P, Q93R, and L78T within NS4B region, (4) M416T, E441G, and V362A within NS5A region, and (5) C316Y, C445F, Y448H, and Y452H within NS5N region. The mutations V24A, E441G, C316Y, C445F, Y448H, and Y452H were found to be sufficient resistance when introduced into wildtype replicons. The combination of two mutations was found to be resistance at a higher drug level than either single mutation. In addition, the present invention provides methods for screening for therapeutic compds. capable of inhibiting HCV as well as methods for inhibiting HCV, e. g., by targeting specific binding sites associated with HCV drug resistance.			
IT	858935-18-9 858935-19-0 858935-21-4			
RL:	THU (Therapeutic use); BIOL (Biological study); USES (Uses) (resistant to; drug-resistant mutation in nonstructural proteins of hepatitis C virus)			
RN	858935-18-9 CAPLUS			
CN	5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)			




RN 858935-19-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)



RN 858935-21-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-[4-fluoro-2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)



L3 ANSWER 22 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1356990 CAPLUS

DOCUMENT NUMBER: 146:100696

TITLE: Preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus (RSV)

INVENTOR(S): Bonfanti, Jean-Francois; Muller, Philippe; Fortin, Jerome Michel Claude; Doublet, Frederic Marc Maurice  
Tibotec Pharmaceuticals Ltd, Ire.

PATENT ASSIGNEE(S): PCT Int. Appl., 52pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006136561	A1	20061228	WO 2006-EP63365	20060620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006260969	A1	20061228	AU 2006-260969	20060620
CA 2612263	A1	20061228	CA 2006-2612263	20060620
EP 1896473	A1	20080312	EP 2006-763808	20060620
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008546738	T	20081225	JP 2008-517487	20060620
IN 2007DN09456	A	20080620	IN 2007-DN9456	20071207
MX 200716537	A	20080306	MX 2007-16537	20071218
CN 101203517	A	20080618	CN 2006-80021972	20071219
PRIORITY APPLN. INFO.:			EP 2005-76438	A 20050620
			WO 2006-EP63365	W 20060620
OTHER SOURCE(S):		CASREACT 146:100696; MARPAT 146:100696		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [R = II or III; Q = H or alkyl optionally substituted with a heterocycle or Q = alkyl substituted with both a radical -OR4 and a heterocycle; Alk = alkanediyl; X = O or S; al:a2a3:a4 = N:CHCH:CH, CH:NCH:CH, CH:CHN:CH or CH:CHCH:N; R1 = Ar or a heterocycle; R2 = H, (un)substituted alkyl, cycloalkyl; R3 = H, alkyl, cyano, aminocarbonyl, polyhaloalkyl, alkenyl or alkynyl; R4 = H or alkyl; Ar = (un)substituted Ph; and their salts], useful as inhibitors of RSV replication, were prepared E.g., a multi-step synthesis of IV, starting from V, was given. Exemplified compds. I were screened in vitro for their activity against respiratory syncytial virus (pEC50 values were provided). Pharmaceutical

comps. containing comps. I and processes for preparing comps. I were disclosed.


IT 918151-93-6P 918151-94-7P 918151-95-8P  
918151-96-9P 918151-97-0P 918151-99-2P  
918152-00-8P 918152-01-9P 918152-02-0P  
918152-05-3P 918152-06-4P 918152-07-5P  
918152-08-6P 918152-09-7P 918152-10-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus)


RN 918151-93-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[2-amino-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-6-yl]methyl]-1-cyclopropyl-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)




RN 918151-94-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




RN 918151-95-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




RN 918151-96-9 CAPLUS  
 CN 2H-Imidazo[4,5-c]pyridinium, 1,3-dihydro-1-(2-hydroxyethyl)-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)



RN 918151-97-0 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(2-(phenylmethoxy)ethyl)-, inner salt (CA INDEX NAME)


PAGE 1-A



—CH<sub>2</sub>—Ph


RN 918151-99-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[2-amino-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-6-yl]methyl]-1-[2-(4-fluorophenyl)ethyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)




RN 918152-00-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(3-phenylpropyl)-, inner salt (CA INDEX NAME)



RN 918152-01-9 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(2-phenylethyl)-, inner salt, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 918152-02-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[2-amino-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-6-yl]methyl]-2,3-dihydro-2-oxo-1-propyl-, inner salt (CA INDEX NAME)




RN 918152-05-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




RN 918152-06-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)



RN 918152-07-5 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(2-phenylethyl)-, inner salt (CA INDEX NAME)



RN 918152-08-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-[2-(4-fluorophenyl)ethyl]-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)

PAGE 1-A









RN 918152-09-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[2-amino-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-6-yl]methyl]-2,3-dihydro-2-oxo-1-(3-phenylpropyl)-, inner salt (CA INDEX NAME)



RN 918152-10-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




IT 918152-13-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus)

RN 918152-13-3 CAPLUS

CN 2H-Imidazo[4,5-c]pyridinium, 5-[[2-amino-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-6-yl]methyl]-1-cyclopropyl-1,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)




REFERENCE COUNT:

3


THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1285816 CAPLUS  
 DOCUMENT NUMBER: 146:45547  
 TITLE: Preparation of aryl bicyclo and spiro compounds as  
 therapeutic modulators of CCR-5 activity  
 INVENTOR(S): Boman, Erik; Dahl, Russell; Delaet, Nancy G. J.;  
 Ernst, Justin; Lum, Christopher; Sebo, Lubomir; Urban,  
 Jan  
 PATENT ASSIGNEE(S): Kemia, Inc., USA  
 SOURCE: PCT Int. Appl., 235pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006130426	A2	20061207	WO 2006-US20255	20060525
WO 2006130426	A3	20070621		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRIORITY APPLN. INFO.:			US 2005-685147P	P 20050527
			US 2006-785090P	P 20060322
OTHER SOURCE(S):	MARPAT 146:45547			
GI				



I



II



III

AB The present invention relates to low mol. weight compds., including compds. of Formulas I and II, and pharmaceutical compns. thereof, useful as modulators of CCR-5 activity (no biol. activity given). For I and II, A = a substituted spiro, bicyclo, or piperazinyl ring; R1 = (un)substituted alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl or heterocyclylalkyl group; R2= halo or (un)substituted C1-C4 alkyl; R3, R3a, R4, R4a, R7, and R7a = H, halo, or (un)substituted C1-6 alkyl or C1-4 alkoxy group; and n = 0-5. The invention further relates to the use of such compds. and compns. in treating disorders mediated by CCR-5 such as viral infections and inflammatory diseases. Preparation methods for I and II are disclosed. For example, III is prepared by reacting 8-boc-3,8-diaza-3-(4-methylpyrid-3-yl)bicyclo[3.2.1]octane (preparation given) and (S)-tert-Bu 3-oxo-1-phenylpropylcarbamate to give an amine intermediate which is subsequently reacted with cyclopentyl carbonyl chloride.

IT 916458-03-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aryl bicyclo and spiro compds. as therapeutic modulators of CCR-5 activity)


RN 916458-03-2 CAPLUS

CN Urea, N'-(4-methylphenyl)-N-phenyl-N-[3-[(3-endo)-3-[4,5,6,7-tetrahydro-2-methyl-5-(1-pyrrolidinylcarbonyl)-1H-imidazo[4,5-c]pyridin-1-yl]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (CA INDEX NAME)


Relative stereochemistry.



L3 ANSWER 24 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1171607 CAPLUS  
 DOCUMENT NUMBER: 147:157340  
 TITLE: QSAR modeling of AT1 receptor antagonists using ANN  
 AUTHOR(S): Su, Qing; Zhou, Lu  
 CORPORATE SOURCE: Department of Pharmaceutical Engineering, College of  
 Chemical Engineering, Sichuan University, Chengdu,  
 Sichuan, 610065, Peop. Rep. China  
 SOURCE: Journal of Molecular Modeling (2006), 12(6), 869-875  
 CODEN: JMMOFK; ISSN: 0948-5023  
 URL: <http://www.springerlink.com/content/yjp5446686056147/fulltext.pdf>  
 PUBLISHER: Springer GmbH  
 DOCUMENT TYPE: Journal; (online computer file)  
 LANGUAGE: English  
 AB Multiple linear regression (MLR) and artificial neural networks (ANN) have  
 been used for structure-activity relationship anal. for a set of 113 AT1  
 receptor antagonists. The ANN model showed better performance with a  
 6-6-1 architecture than MLR. The results obtained from this study  
 indicate that three descriptors, hydration energy (EH), n-octanol/water  
 partition (LOGP), and energy of the LUMO (LUMO), play an important role on  
 the activity of AT1 receptor antagonists with biphenyltetrazole  
 structures. This information is pertinent to the further design of new  
 AT1 receptor antagonists.  
 IT 156222-13-8 156222-17-2  
 RL: BSU (Biological study, unclassified); CST (Combinatorial study,  
 unclassified); PRP (Properties); BIOL (Biological study); CMBI  
 (Combinatorial study)  
 (QSAR modeling of AT1 receptor antagonists using ANN)  
 RN 156222-13-8 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-oxo-2-(1-  
 pyrrolidinyl)ethyl]-3-[(2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-  
 (CA INDEX NAME)



RN 156222-17-2 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-ethyl-3,5-dihydro-5-[2-oxo-2-(1-  
 piperidinyl)ethyl]-3-[(2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-  
 (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1149466 CAPLUS  
 DOCUMENT NUMBER: 145:410660  
 TITLE: imidazol derivatives for treatment of inflammatory and allergic disease  
 INVENTOR(S): Prous Blancafort, Josep  
 PATENT ASSIGNEE(S): Prous Science, S.A., Spain  
 SOURCE: Span., 12 pp.  
 CODEN: SPXXAD  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Spanish  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 2246742	A1	20060216	ES 2005-2163	20050906
ES 2246742	B1	20070201		
WO 2007028524	A2	20070315	WO 2006-EP8427	20060829
WO 2007028524	A3	20070531		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: ES 2005-2163 A 20050906

OTHER SOURCE(S): MARPAT 145:410660


AB The invention discloses the use of imidazole derivs. as leukotriene inhibitors for the treatment of inflammatory and allergic diseases. Compds. of the invention inhibited the association of leukotriene D4 with its receptor.

IT 912451-72-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (imidazol derivs. for treatment of inflammatory and allergic disease)

RN 912451-72-0 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 3,5-dihydro-5-(2-thienylmethyl)- (CA INDEX NAME)






L3 ANSWER 26 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1031450 CAPLUS  
 DOCUMENT NUMBER: 145:397273  
 TITLE: Preparation of 3-propenylcephem derivatives as  
 antibacterial agents  
 INVENTOR(S): Ishikura, Koji; Yamawaki, Kenji; Yokoo, Katsuki;  
 Yonezawa, Shuji; Kii, Makoto  
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 419pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006104141	A1	20061005	WO 2006-JP306280	20060328
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
JP 3928086	B2	20070613	JP 2006-523884	20060328
JP 2007119484	A	20070517	JP 2006-334023	20061212
PRIORITY APPLN. INFO.:			JP 2005-93962	A 20050329
			JP 2005-226577	A 20050804
			JP 2006-523884	A3 20060328
			WO 2006-JP306280	W 20060328

OTHER SOURCE(S): MARPAT 145:397273  
 GI



AB The title compds. I [Acyl represents an acyl group which can be used in the field of  $\beta$ -lactams; T represents S, SO or O; ring Q represents a heterocyclic group which may be substituted by a substituent other than "-Y1-Ar1-Y2-R1" and has a cationic N atom in the ring; Y1 and Y2 independently represent (1) a single bond, (2) a heteroatom-containing group selected from the group consisting of NR2, CO, NR2CO, CONR2, NR2CONR3, NR2SO2, SO2NR2, NR2SO2NR3 (where R2 and R3 independently represent a hydrogen or a lower alkyl), O, S, etc., or (3) a lower alkylene or lower alkenylene group which may be bound through a heteroatom-containing group as listed in the item (2); Ar1 represents a single bond, a carbocyclic group which may be substituted or a heterocyclic group which may be substituted;

R1 represents CONHCN, C(OH)=NCN or COOH or a biol. equivalent acidic group thereof; and the wavy line means a cis, trans or a mixture thereof] are prepared Compds. of this invention showed MIC values of 0.25 µg/mL to 0.5 µg/mL against *S. aureus* SMITH.

IT 911464-03-4P 911464-04-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 3-propenylcephem derivs. as antibacterial agents)

RN 911464-03-4 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[(2E)-3-[(6R,7R)-7-[[2-(2-amino-4-thiazolyl)-2-(ethoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propen-1-yl]-2-[(cyanoamino)carbonyl]-, inner salt, sodium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




● Na

RN 911464-04-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[(2E)-3-[(6R,7R)-7-[[2-(2-amino-4-thiazolyl)-2-(ethoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propen-1-yl]-2-[(cyanoamino)carbonyl]-1-methyl-, inner salt, sodium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




● Na

REFERENCE COUNT:

58


THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:934960 CAPLUS  
 DOCUMENT NUMBER: 145:489175  
 TITLE: Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A new class of pestivirus inhibitors  
 AUTHOR(S): Puerstinger, Gerhard; Paeshuyse, Jan; Herdewijn, Piet; Rozenski, Jef; De Clercq, Erik; Neyts, Johan  
 CORPORATE SOURCE: Institut fuer Pharmazie, Abteilung Pharmazeutische Chemie, Universitaet Innsbruck, Innsbruck, A-6020, Austria  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(20), 5345-5349  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 145:489175  
 GI




I

AB A class of inhibitors of pestiviruses, 5-substituted 2-phenyl-5H-imidazo[4,5-c]pyridines, e.g., I, is described. Modification of the substituent in position 5 resulted in analogs with high activity (EC50 < 100 nM) and selectivity (SI > 1000) against the pestivirus BVDV (bovine viral diarrhea virus).  
 IT 645420-73-1P 645420-76-4P 645420-79-7P  
 645420-80-0P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation, antipestiviral activity, and structure-activity relationship of imidazopyridines)  
 RN 645420-73-1 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 5-[(5-chloro-2-thienyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 645420-76-4 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-phenyl-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 645420-79-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-phenyl-5-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 645420-80-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-phenyl-5-(3-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:630269 CAPLUS

DOCUMENT NUMBER: 145:83341

TITLE: Preparation of the antiviral compound  
 5-[[3-(2,4-bis(trifluoromethyl)phenyl)isoxazol-5-yl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and its use in the treatment of HCV viral infections

INVENTOR(S): Bondy, Steven S.; Oare, David A.; Tse, Winston C.

PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006069193	A2	20060629	WO 2005-US46477	20051221
WO 2006069193	A3	20060810		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005319167	A1	20060629	AU 2005-319167	20051221
CA 2592388	A1	20060629	CA 2005-2592388	20051221
US 20060252791	A1	20061109	US 2005-316050	20051221
EP 1841765	A2	20071010	EP 2005-855097	20051221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR JP 2008524335 T 20080710 JP 2007-548448 20051221 US 20080188516 A1 20080807 US 2008-22557 20080130				
PRIORITY APPLN. INFO.:			US 2004-638215P	P 20041221
			US 2005-316050	B1 20051221
			WO 2005-US46477	W 20051221
AB	5-[[3-(2,4-Bis(trifluoromethyl)phenyl)isoxazol-5-yl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine is prepared and claimed for use in the treatment or prophylaxis of HCV viral infections.			
IT	858935-19-0P, 5-[[3-(2,4-Bis(Trifluoromethyl)phenyl)isoxazol-5-yl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of the antiviral compound 5-[[3-(2,4-bis(trifluoromethyl)phenyl)isoxazol-5-yl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and its use in the treatment of HCV viral infections)			
RN	858935-19-0 CAPLUS			
CN	5H-imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)			



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:381167 CAPLUS  
 DOCUMENT NUMBER: 144:432827  
 TITLE: Preparation of fused pyrimidine derivatives as insulin secretion accelerators  
 INVENTOR(S): Yonetoku, Yasuhiro; Negoro, Kenji; Onda, Kenichi; Hayakawa, Masahiko; Sasuga, Daisuke; Higawara, Takahiro; Iikubo, Kazuhiko; Moritomo, Hiroyuki; Yoshida, Shigeru; Ohishi, Takahide  
 PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan  
 SOURCE: PCT Int. Appl., 79 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006043490	A1	20060427	WO 2005-JP19000	20051017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2005297743 A1 20060427 AU 2005-297743 20051017 CA 2584666 A1 20060427 CA 2005-2584666 20051017 EP 1803710 A1 20070704 EP 2005-793361 20051017 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR CN 101044123 A 20070926 CN 2005-80035732 20051017 BR 2005016237 A 20080826 BR 2005-16237 20051017 IN 2007CN01589 A 20070831 IN 2007-CN1589 20070419 MX 200704769 A 20070625 MX 2007-4769 20070420 US 20080070896 A1 20080320 US 2007-577648 20070420 KR 2007084035 A 20070824 KR 2007-710353 20070507 NO 2007002542 A 20070718 NO 2007-2542 20070518 PRIORITY APPLN. INFO.: JP 2004-305374 A 20041020 WO 2005-JP19000 W 20051017 OTHER SOURCE(S): MARPAT 144:432827 GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [A = Q1, etc.; R1 = (un)substituted cyclopropyl, (un)substituted cyclobutyl, (un)substituted cyclopentyl, etc.; R2 = -NR21R22, (un)substituted cyclic amino; R21, R22 = H, alkyl, alkenyl, etc.] and their pharmaceutically acceptable salts were prepared For example, reaction of 4-chloro-2-(4-chloro-2,5-difluorophenyl)-5,7-dihydrothieno[3,4-d]pyrimidine 6,6-dioxide, e.g., prepared from 4-chloro-2,5-difluorobenzonitrile in 5 steps, with (R)-3-methylpiperidine-(R)-mandelic acid salt followed by treatment



with HCl afforded compound II hydrochloride. In insulin secretion accelerating assays, compound II hydrochloride exhibited the activity of 355%. Comps. I are claimed useful for the treatment of diabetes, obesity, etc.


IT 885036-51-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused pyrimidine derivs. as insulin secretion accelerators for treatment of diabetes, obesity, etc.)

RN 885036-51-1 CAPLUS

CN Thieno[3,4-d]pyrimidine, 2-(4-chloro-2,5-difluorophenyl)-5,7-dihydro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-, 6,6-dioxide, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:328559 CAPLUS

DOCUMENT NUMBER: 145:347777

TITLE: QSAR studies of angiotensin II AT1 receptor antagonists

AUTHOR(S): Xu, Jinyi; Ji, Nianning; Hua, Wei; Wu, Xiaoming

CORPORATE SOURCE: Department of Medicinal Chemistry, China  
Pharmaceutical University, Nanjing, 210009, Peop. Rep.  
China

SOURCE: Zhongguo Yaoke Daxue Xuebao (2005), 36(2), 99-105

CODEN: ZHYXE9; ISSN: 1000-5048

PUBLISHER: Zhongguo Yaoke Daxue

DOCUMENT TYPE: Journal

LANGUAGE: Chinese


AB The novel nonpeptide angiotensin II AT1 receptor antagonists with high potency were screened. First, the energy minimized conformations of 42 angiotensin II AT1 receptor antagonists selected were studied. Second, the anal. of regression between the structural parameters of selected compds. based on MM2 program calcn. or structural parameters of selected compds. based on CNDO/2 program calcn. and their AT1 receptor antagonistic activity was conducted. The QSAR information was obtained based on the calculated structural parameters and pA2 value of AII-induced contractions in the rabbit thoracic aortic rings of selected compds. The obtained QSAR parameters may be useful for future designing of novel AT1 receptor antagonists.

IT 910239-56-4, EMD 90423

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(QSAR studies of angiotensin II AT1 receptor antagonists)



RN 910239-56-4 CAPLUS

CN Carbamic acid, [[4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]-, butyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 31 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:1130640 CAPLUS  
 DOCUMENT NUMBER: 143:387050  
 TITLE: Preparation of aminoimidazo[4,5-d]pyridazinones and aminoimidazo[4,5-c]pyridinones as inhibitors of dipeptidylpeptidase IV  
 INVENTOR(S): Eckhardt, Matthias; Himmelsbach, Frank; Langkopf, Elke; Haeu, Norbert; Tadayyon, Mohammad; Thomas, Leo  
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.  
 SOURCE: PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097798	A1	20051020	WO 2005-EP3474	20050402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004017739	A1	20051027	DE 2004-102004017739	20040410
DE 102004025552	A1	20051222	DE 2004-102004025552	20040525
CA 2561210	A1	20051020	CA 2005-2561210	20050402
EP 1740589	A1	20070110	EP 2005-716507	20050402
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2007531780	T	20071108	JP 2007-506703	20050402
US 20050234235	A1	20051020	US 2005-102048	20050408
US 7179809	B2	20070220		
US 20070088038	A1	20070419	US 2006-609621	20061212
US 7476671	B2	20090113		
PRIORITY APPLN. INFO.:			DE 2004-102004017739A	20040410
			DE 2004-102004025552A	20040525
			US 2004-568137P	P 20040505
			US 2004-582265P	P 20040623
			WO 2005-EP3474	W 20050402
			US 2005-102048	A3 20050408
OTHER SOURCE(S):	MARPAT 143:387050			
GI				



AB Title compds. I [R1 = arylmethyl, arylethyl, heteroarylmethyl, etc.; X = N or CR5; R5 = H or alkyl; R2 = H, aryl, heteroaryl, etc.; R3 = (un)substituted cycloalkenylmethyl, alkenyl, alkynyl, etc.; R4 = NR6R7; R6 = H, alkyl, cycloalkyl, etc.; R7 = (un)substituted alkyl-R8; R8 = amino or alkylamino] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of dipeptidylpeptidase IV (DPP-IV). Thus, e.g., II was prepared by amination of 2-bromo-3-(2-buten-1-yl)-5-[(4-methyl-chinazolin-2-yl)-methyl]-3,5-dihydro[4,5-d]pyridazin-4-one (preparation given) with N-methyl-ethylenediamine. The activity of I was evaluated using fluorescence inhibition assays and it was revealed that selected compds. of the invention possessed IC50 values in the range of 1 up to 336 nM. I as inhibitor of DPP-IV should prove useful in the treatment of diseases such as but not limited to diabetes, obesity and arthritis. Pharmaceutical compds. comprising I are disclosed.

IT 1082368-37-3 1082368-45-3 1082368-65-7


RL: PRPH (Prophetic)

(Preparation of aminoimidazo[4,5-d]pyridazinones and

aminoimidazo[4,5-c]pyridinones as inhibitors of dipeptidylpeptidase IV)


RN 1082368-37-3 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-[(2-aminoethyl)methylamino]-3-(2-buten-1-yl)-3,5-dihydro-5-[(4-methyl-2-quinazolinyl)methyl]- (CA INDEX NAME)




RN 1082368-45-3 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-[(2-aminopropyl)methylamino]-3-(2-buty-  
n-1-yl)-3,5-dihydro-5-[(4-methyl-2-quinazolinyl)methyl]- (CA INDEX NAME)



RN 1082368-65-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




IT 866933-13-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of aminoimidazo[4,5-d]pyridazinones and  
aminoimidazo[4,5-d]pyridinones as inhibitors of dipeptidylpeptidase IV)

RN 866933-13-3 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-[(2-aminoethyl)methylamino]-3-(2-buty-1-  
yl)-3,5-dihydro-5-[(3-methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)




IT 866933-32-6P 866933-33-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of aminoimidazo[4,5-d]pyridazinones and  
aminoimidazo[4,5-d]pyridinones as inhibitors of dipeptidylpeptidase IV)


RN 866933-32-6 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-bromo-3-(2-buty-1-yl)-3,5-dihydro-5-[(3-  
methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)



RN 866933-33-7 CAPLUS

CN 4H-imidazo[4,5-c]pyridin-4-one, 3-(2-butyn-1-yl)-2-chloro-3,5-dihydro-5-[(3-methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)





REFERENCE COUNT: 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:612284 CAPLUS  
 DOCUMENT NUMBER: 143:133371  
 TITLE: Preparation of imidazo[4,5-c]pyridine derivatives as  
 antiviral agents  
 INVENTOR(S): Puerstinger, Gerhard; Bondy, Steven S.; Dowdy, Eric  
 Davis; Kim, Choung U.; Oare, David A.; Neyts, Johan;  
 Zia, Vahid  
 PATENT ASSIGNEE(S): K. U. Leuven Research & Development, Belg.; Gilead  
 Sciences, Inc.  
 SOURCE: PCT Int. Appl., 265 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063744	A2	20050714	WO 2004-US43112	20041221
WO 2005063744	A3	20050901		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004309390	A1	20050714	AU 2004-309390	20041221
CA 2549606	A1	20050714	CA 2004-2549606	20041221
US 20050222198	A1	20051006	US 2004-19830	20041221
EP 1706403	A2	20061004	EP 2004-815224	20041221
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1902198	A	20070124	CN 2004-80038144	20041221
JP 2007518720	T	20070712	JP 2006-547305	20041221
KR 2006132850	A	20061222	KR 2006-712554	20060622
US 20070244148	A1	20071018	US 2007-583814	20070604
PRIORITY APPLN. INFO.:			US 2003-532292P	P 20031222
			US 2004-533963P	P 20040102
			US 2004-590989P	P 20040726
			US 2004-590990P	P 20040726
			US 2004-591024P	P 20040726
			US 2004-591069P	P 20040726
			WO 2004-US43112	W 20041221
OTHER SOURCE(S):		CASREACT 143:133371; MARPAT 143:133371		
GI				




AB Title compds. I [dotted lines represent at least 3, optionally 4, double bonds; R1 = H, (un)substituted aryl, thioalkyl, etc.; Y = single bond, O, alkylene optionally containing 1-3 heteroatoms, etc.; R2 and R4 independently = H, alkyl, alkenyl, etc. with provisions; X = alkylene, alkenylene, alkynylene where each optionally may include one or more heteroatoms; R3 = (un)substituted aryl, aryloxy, arylthio, etc.; R5 = H, OH, CN, etc.; R6 and R7 are usually not present, but if they are then they are cyclopentyl or cyclohexyl] and their pharmaceutically acceptable salts, are prepared and disclosed as antiviral agents. Thus, e.g., II was prepared by coupling of 2-(2-fluorophenyl)-3H-imidazo[4,5-c]pyridine with 5-(chloromethyl)-3-(4-chlorophenyl)isoxazole. The activity of I was evaluated in an anti-HCV/Replicon assay system and it was revealed that substantially all of the compds. of the invention demonstrated activity of at least 1  $\mu$ M. I as antiviral agent should prove useful in the treatment of hepatitis C virus (HCV). Pharmaceutical compns. comprising I are disclosed.

IT 858935-21-4P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of imidazo[4,5-c]pyridine derivs. as antiviral agents)

RN 858935-21-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-[4-fluoro-2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)



IT 858935-18-9P 858935-19-0P 858935-20-3P  
 858935-29-2P 858935-30-5P 858935-31-6P  
 858935-38-3P 858935-39-4P 858935-40-7P  
 858935-41-8P 858935-42-9P 858935-43-0P  
 858935-44-1P 858935-45-2P 858935-47-4P




858935-49-6P 858935-60-1P 858935-63-4P  
 858935-64-5P 858935-68-9P 858935-70-3P  
 858935-72-5P 858935-74-7P 858935-76-9P  
 858935-78-1P 858935-80-5P 858935-82-7P  
 858935-83-8P 858935-84-9P 858936-58-0P  
 858936-59-1P 858936-64-8P 858936-65-9P  
 858936-67-1P 858936-68-2P 858936-69-3P  
 858936-70-6P 858936-71-7P 858936-72-8P  
 858936-73-9P 858936-74-0P 858936-75-1P  
 858936-76-2P 858936-77-3P 858936-78-4P  
 858936-79-5P 858936-80-8P 858936-81-9P  
 858936-82-0P 858936-83-1P 858936-84-2P  
 858936-85-3P 858936-86-4P 858936-87-5P  
 858936-88-6P 858936-89-7P 858936-90-0P  
 858936-91-1P 858937-37-8P 858937-38-9P  
 858937-39-0P 858937-40-3P 858937-41-4P  
 858937-42-5P 858937-43-6P 858937-44-7P  
 858937-45-8P 858938-53-1P 858938-54-2P  
 858938-55-3P 858938-56-4P 858938-57-5P  
 858938-58-6P 858938-59-7P 858938-60-0P  
 858938-61-1P 858938-62-2P 858938-63-3P  
 858938-64-4P 858938-65-5P 858938-66-6P  
 858938-67-7P 858938-68-8P 858938-69-9P  
 858938-70-2P 858938-71-3P 858938-72-4P  
 858938-73-5P 858938-74-6P 858938-75-7P  
 858938-76-8P 858938-77-9P 858938-78-0P  
 858938-79-1P 858938-81-5P 858938-82-6P  
 858938-83-7P 858938-84-8P 858938-85-9P  
 858938-86-0P 858938-87-1P 858938-88-2P  
 858938-89-3P 858938-90-6P 858938-94-0P  
 858938-95-1P 858939-15-8P 858939-16-9P  
 858939-17-0P 858939-18-1P 858939-19-2P  
 858939-20-5P 858939-21-6P 858939-22-7P  
 858939-23-8P 858939-24-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of imidazo[4,5-c]pyridine derivs. as antiviral agents)


RN 858935-18-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-  
 (2,3-difluorophenyl)- (CA INDEX NAME)




RN 858935-19-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]-5-  
 isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858935-20-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-(2-fluorophenyl)-5-[[3-(2-fluoro-4-(trifluoromethyl)phenyl)-5-isoxazolyl)methyl])- (CA INDEX NAME)




RN 858935-29-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-(2-fluorophenyl)-5-[[1-methyl-3-(trifluoromethyl)-1H-thieno[2,3-c]pyrazol-5-yl)methyl])- (CA INDEX NAME)




RN 858935-30-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl)methyl]-2-(2-fluorophenyl))- (CA INDEX NAME)




RN 858935-31-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-(2-fluorophenyl)-5-[(3-phenyl-5-isoxazolyl)methyl])- (CA INDEX NAME)




RN 858935-38-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 858935-39-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]- (CA INDEX NAME)




RN 858935-40-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 858935-41-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858935-42-9 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858935-43-0 CAPLUS  
 CN Quinoline, 4-chloro-6-[[2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridin-5-yl)methyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 858935-44-1 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl)methyl]- (CA INDEX NAME)




RN 858935-45-2 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[(2-phenyl-4-thiazolyl)methyl]- (CA INDEX NAME)



RN 858935-47-4 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[2-(2-thienyl)-4-thiazolyl)methyl]- (CA INDEX NAME)




RN 858935-49-6 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[5-(trifluoromethyl)-2-furanyl)methyl]- (CA INDEX NAME)




RN 858935-60-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858935-63-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[1-methyl-3-(trifluoromethyl)-1H-thieno[2,3-c]pyrazol-5-yl]methyl]- (CA INDEX NAME)




RN 858935-64-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858935-68-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 858935-70-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]- (CA INDEX NAME)




RN 858935-72-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-((2,3-difluorophenyl)-5-[[5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl]methyl])- (CA INDEX NAME)




RN 858935-74-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-((5-chloro-1,2,4-thiadiazol-3-yl)methyl)-2-((2,3-difluorophenyl))- (CA INDEX NAME)




RN 858935-76-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-((2,3-difluorophenyl)-5-[[3-(4-(1,1-dimethylethyl)phenyl)-1,2,4-oxadiazol-5-yl]methyl])- (CA INDEX NAME)




RN 858935-78-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-((2,3-difluorophenyl)-5-[[5-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl]methyl])- (CA INDEX NAME)




RN 858935-80-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[2-[4-(trifluoromethyl)phenyl]-4-thiazolyl)methyl]- (CA INDEX NAME)




RN 858935-82-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[(2-phenyl-4-thiazolyl)methyl]- (CA INDEX NAME)




RN 858935-83-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[5-(2-thienyl)-1,2,4-oxadiazol-3-yl)methyl]- (CA INDEX NAME)




RN 858935-84-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[2-(2-thienyl)-4-thiazolyl)methyl]- (CA INDEX NAME)




RN 858936-58-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl)methyl]-2-(3-thienyl)- (CA INDEX NAME)




RN 858936-59-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[(3-phenyl-5-isoxazolyl)methyl]-2-(3-thienyl)-  
(CA INDEX NAME)




RN 858936-64-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-65-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[2-(trifluoromethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 858936-67-1 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-dichlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)



RN 858936-68-2 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(trifluoromethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)






RN 858936-69-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858936-70-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-fluoro-2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-71-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2-(difluoromethoxy)phenyl]-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858936-72-8 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-73-9 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-bromo-2-fluorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858936-74-0 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2,4,6-trifluorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-75-1 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-fluoro-4-methylphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 858936-76-2 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2-fluoro-4-methylphenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-77-3 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2,4-dimethoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-78-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-fluoro-6-(trifluoromethyl)phenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-79-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-dichlorophenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-80-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-(4-(trifluoromethoxy)phenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-81-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2-(difluoromethoxy)phenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-82-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-bromo-2-fluorophenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-83-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-dimethoxyphenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-84-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-(2-fluoro-6-(trifluoromethyl)phenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-85-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-(2,4-dichlorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-86-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-(4-(trifluoromethoxy)phenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-87-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-2-(3-chloro-2-fluorophenyl)- (CA INDEX NAME)




RN 858936-88-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-[4-fluoro-2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-89-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-[2-(difluoromethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-90-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-91-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-bromo-2-fluorophenyl)-5-isoxazolyl]methyl]-2-(3-chloro-2-fluorophenyl)- (CA INDEX NAME)




RN 858937-37-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858937-38-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858937-39-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]methyl]- (CA INDEX NAME)




RN 858937-40-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]methyl]- (CA INDEX NAME)




RN 858937-41-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[5-(2,4-difluorophenyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 858937-42-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[5-(2,4-difluorophenyl)-3-pyridinyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858937-43-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858937-44-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858937-45-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-53-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methoxy-2-(trifluoromethyl)phenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 858938-54-2 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[[6-(2,4-difluorophenyl)-3-pyridazinyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)






RN 858938-55-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[(5-chloro-2-benzoxazolyl)methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-56-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-ethoxyphenyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858938-57-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methoxyphenyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858938-58-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methylphenyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858938-59-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-furanyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858938-60-0 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 2-((2,3-difluorophenyl)-5-([3-(2-thienyl)-5-isoxazolyl]methyl))- (CA INDEX NAME)




RN 858938-61-1 CAPLUS

CN Benzenamine, 4-[5-([2-((2,3-difluorophenyl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl)-3-isoxazolyl]-N,N-dimethyl)- (CA INDEX NAME)




RN 858938-62-2 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 5-([3-([1,1'-biphenyl]-4-yl)-5-isoxazolyl]methyl)-2-((2,3-difluorophenyl))- (CA INDEX NAME)




RN 858938-63-3 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 5-([3-(4-bromophenyl)-5-isoxazolyl]methyl)-2-((2,3-difluorophenyl))- (CA INDEX NAME)




RN 858938-64-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(phenylmethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-65-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(methylthio)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-66-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-fluoro-4-methoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-67-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chloro-2-fluorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-68-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-propoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-69-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-phenoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-70-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(1-methyl-1H-pyrrol-2-yl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-71-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(1-methylethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-72-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(5-chloro-2-thienyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-73-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(5-bromo-2-thienyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-74-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-butoxyphenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-75-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-(4-propoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-76-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(2-propen-1-yloxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-77-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[4-chloro-3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-78-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[4-bromo-3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-79-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[(1-phenyl-1H-pyrazol-3-yl)methyl]- (CA INDEX NAME)




RN 858938-81-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)-4-methyl- (CA INDEX NAME)




RN 858938-82-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)-7-methyl- (CA INDEX NAME)




RN 858938-83-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 7-chloro-2-(2,3-difluorophenyl)-5-[[3-(4-ethoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-84-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)-7-(trifluoromethyl)- (CA INDEX NAME)




RN 858938-85-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)-7-fluoro- (CA INDEX NAME)




RN 858938-86-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 858938-87-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 858938-88-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 858938-89-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)



RN 858938-90-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)



RN 858938-94-0 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-isoxazolyl)methyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 858935-21-4

CMF C23 H13 F5 N4 O





CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 858938-95-1 CAPLUS


CN 5H-imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-(4-fluoro-2-(trifluoromethyl)phenyl)-isoxazolyl]methyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 858939-15-8 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methoxy-2-methylphenyl)-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858939-16-9 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 5-[[3-(4-chloro-3-fluorophenyl)-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858939-17-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(1,1-dimethylethoxy)-3-fluorophenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858939-18-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(pentyloxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858939-19-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(3-furanyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858939-20-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[4-(cyclohexylmethoxy)phenyl]-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858939-21-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(5-methyl-4-hexen-1-yl)oxy]phenyl]-5-isoxazolyl]methyl- (CA INDEX NAME)




RN 858939-22-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(hexyloxy)phenyl]-5-isoxazolyl]methyl- (CA INDEX NAME)




RN 858939-23-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(2-ethylbutoxy)phenyl]-5-isoxazolyl]methyl- (CA INDEX NAME)




RN 858939-24-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[6-(2,4-difluorophenyl)-3-pyridinyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)



IT 1025000-09-2  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of imidazo[4,5-c]pyridine derivs. as antiviral agents)  
RN 1025000-09-2 CAPLUS  
CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[(6-iodo-3-pyridinyl)methyl]- (CA INDEX NAME)



L3 ANSWER 33 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:497492 CAPLUS

DOCUMENT NUMBER: 143:7727

TITLE: Preparation of 2,4-diaminopyrimidine derivatives as inhibitors of PKC-theta for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes

INVENTOR(S): Cardozo, Mario G.; Cogan, Derek; Cywin, Charles Lawrence; Dahmann, George; Disalvo, Darren; Ginn, John David; Prokopowicz, Anthony S.; Spero, Denice M.; Young, Erick Richard Roush

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 766,079.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050124640	A1	20050609	US 2004-933635	20040903
US 20040242613	A1	20041202	US 2004-766079	20040127
PRIORITY APPLN. INFO.:			US 2003-443700P	P 20030130
			US 2004-766079	A2 20040127

OTHER SOURCE(S): CASREACT 143:7727; MARPAT 143:7727

GI



AB Title compds. I [wherein R1 = (un)substituted heteroaryl/aryl/cyclo/cycloalkyl/alkyl, naphthyl, quinolinyl, etc.; R2 = (un)substituted -NH-CH2-(CH2)n-CH2-NR4R5, -NH-(CH2)p-phenylene-(CH2)q-NR4R5, -NH(CH2)p-X-R4, etc.; X = piperidinyl; n = 3-8; p = 1-3; q = 0-3; R4, R5 = independently H, amidino, (un)substituted aryl/alkyl; R3 = halo, CN, NO2, aminocarbonyl, (un)substituted alkyl, alkyloxycarbonyl; their tautomers, pharmaceutically

acceptable salts, solvates, or amino-protected derivs., with certain compds. excluded] were prepared as inhibitors of protein kinase C (PKC)-theta useful for treating immunol. disorders and type II diabetes. For example, II was prepared in 5 steps via amination of 2,4-dichloro-5-fluoropyrimidine with amine III and 2-chlorobenzylamine. Selected I inhibited PKC-theta with IC50 values  $\leq 0.3 \mu\text{M}$ . Thus, I are useful for treating a disease or disorder associated with T cells activation.


IT 736055-76-8P 736055-82-6P 736055-87-1P  
736055-90-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PKC-theta inhibitor; preparation of diaminopyrimidines as PKC-theta inhibitors for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes)


RN 736055-76-8 CAPLUS

CN 2-Pyrimidinamine, N-(phenylmethyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 736055-82-6 CAPLUS

CN 2-Pyrimidinamine, N-[(4-chlorophenyl)methyl]-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 736055-87-1 CAPLUS

CN 2-Pyrimidinamine, N-[(2-chlorophenyl)methyl]-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 736055-90-6 CAPLUS

CN 2-Pyrimidinamine, 5-nitro-N-(phenylmethyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




ACCESSION NUMBER: 2005:369265 CAPLUS  
 DOCUMENT NUMBER: 142:423892  
 TITLE: Alanyl aminopeptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases  
 INVENTOR(S): Ansorge, Siegfried; Bank, Ute; Nordhoff, Karsten; Tager, Michael; Striggow, Frank  
 PATENT ASSIGNEE(S): Institut Fur Medizintechnologie Magdeburg GmbH IMTM, Germany; Keyneurotek AG  
 SOURCE: PCT Int. Appl., 332 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037257	A2	20050428	WO 2004-EP11643	20041015
WO 2005037257	A3	20060914		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10348023	A1	20050519	DE 2003-10348023	20031015
AU 2004281536	A1	20050428	AU 2004-281536	20041015
CA 2542723	A1	20050428	CA 2004-2542723	20041015
EP 1673075	A2	20060628	EP 2004-790485	20041015
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1897928	A	20070117	CN 2004-80036456	20041015
JP 2007508349	T	20070405	JP 2006-534706	20041015
US 20070037752	A1	20070215	US 2006-575882	20060915
PRIORITY APPLN. INFO.:			DE 2003-10348023	A 20031015
			WO 2004-EP11643	W 20041015
OTHER SOURCE(S):	MARPAT 142:423892			
AB	The invention discloses substances which specifically inhibit peptidases splitting ala-p-nitroanilide for use in medicine. The invention further discloses the use of at least one such substance or at least one pharmaceutical or cosmetic composition containing such a substance for preventing and treating diseases, especially diseases with an overshooting immune response (autoimmune diseases, allergies, and transplant rejections), other chronic inflammatory diseases, neuronal diseases, brain damage, skin diseases (acne and psoriasis, among others), tumors, and special viral infections (including SARS).			
IT	850607-38-4 RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alanyl aminopeptidase inhibitors for treatment of immunol., inflammatory, neuronal, and other diseases)			
RN	850607-38-4 CAPLUS			
CN	3H-Imidazo[4,5-c]pyridine-6-carboxamide,			



N-(3-aminopropyl)-4,5,6,7-tetrahydro-3-[(2-nitrophenyl)methyl]-5-(2-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1127381 CAPLUS

DOCUMENT NUMBER: 142:74585

TITLE: Preparation of imidazopyridazinones and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of diabetes

INVENTOR(S): Eckhardt, Matthias; Hael, Norbert; Langkopf, Elke; Himmelsbach, Frank; Kauffmann-Hefner, Iris; Tadayyon, Mohammad; Mark, Michael

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111051	A1	20041223	WO 2004-EP6303	20040611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10327439	A1	20050105	DE 2003-10327439	20030618
US 20050026921	A1	20050203	US 2004-865719	20040610
CA 2529729	A1	20041223	CA 2004-2529729	20040611
EP 1641799	A1	20060405	EP 2004-736644	20040611
EP 1641799	B1	20080312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006527717	T	20061207	JP 2006-515894	20040611
AT 388952	T	20080315	AT 2004-736644	20040611
ES 2301996	T3	20080701	ES 2004-736644	20040611
PRIORITY APPLN. INFO.:			DE 2003-10327439	A 20030618
			US 2003-487309P	P 20030715
			WO 2004-EP6303	W 20040611

OTHER SOURCE(S): MARPAT 142:74585

GI



I



II

AB Title compds. I [R1 = alkyl substituted 3,4-dihydroquinolinyl, 3,4-dihydroisoquinolinyl, 1,4-dihydroquinazolinyl, etc.; R2 = H, F, Cl, etc.; R3 = (un)substituted alkyl, e.g., cycloalkyl, cycloalkenyl, aryl, etc.; R4 = (un)substituted azetidin-1-yl, pyrrolidin-1-yl; Y = N, C-R5; R5 = H, alkyl] and their pharmaceutically acceptable salts and formulations were prepared For example, TFA mediated deprotection of Boc-amine II (X = Boc) afforded claimed imidazopyridazinone II (X = H) in 63% yield. In dipeptidyl peptidase IV (DPP-IV) inhibition assays, 8-examples of compds. I exhibited IC50 values ranging from 3-58 nM, e.g., the IC50 value of imidazopyridazinone II (X = H) was 14 nM. Compds. I are claimed to be useful for the treatment of type I and type II diabetes mellitus.


IT 1066555-68-7 1066555-69-8 1066555-70-1  
1066555-72-3 1066555-76-7 1066555-78-9  
1066555-79-0 1066556-00-0 1066556-07-7  
1066556-17-9 1066556-18-0 1066556-29-3  
1066556-31-7 1066556-41-9 1066556-46-4  
1066556-48-6 1066556-55-5 1066556-58-8  
1066556-59-9 1066556-60-2 1066556-61-3

RL: PRPH (Prophetic)

(Preparation of imidazopyridazinones and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of diabetes)

RN 1066555-68-7 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[(8,9,10,11-tetrahydro-7H-cyclohept[c]isoquinolin-5-yl)methyl]- (CA INDEX NAME)




RN 1066555-69-8 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-5-[(3,4-dihydro-2H-pyrano[3,2-c]isoquinolin-6-yl)methyl]-3,5-dihydro- (CA


INDEX NAME)




RN 1066555-70-1 CAPLUS  
 CN 4H-Pyrano[3,2-c]isoquinolin-4-one,  
 6-[[2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-4,5-dihydro-4-oxo-5H-  
 imidazo[4,5-c]pyridin-5-yl]methyl]-2,3-dihydro- (CA INDEX NAME)



RN 1066555-72-3 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-5-  
 (benzo[h]quinolin-6-ylmethyl)-3-(2-butyn-1-yl)-3,5-dihydro- (CA INDEX  
 NAME)




RN 1066555-76-7 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-  
 3,5-dihydro-5-(thieno[3,2-b][1,4]benzoxazepin-9-ylmethyl)- (CA INDEX  
 NAME)




RN 1066555-78-9 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-  
3,5-dihydro-5-[(5-methyl-5H-dibenzo[d,f][1,3]diazepin-6-yl)methyl]- (CA  
INDEX NAME)



RN 1066555-79-0 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-5-  
(dibenz[d,f][1,3]oxazepin-6-ylmethyl)-3,5-dihydro-7-methyl-3-(3-methyl-2-  
buten-1-yl)- (CA INDEX NAME)



RN 1066556-00-0 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2E)-2-buten-1-  
yl-5-[(3,4-dihydro-2-quinolinyl)methyl]-3,5-dihydro-6,7-dimethyl- (CA  
INDEX NAME)

Double bond geometry as shown.



RN 1066556-07-7 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-  
5-[(3,4-dihydro-3-methyl-2-quinazolinyl)methyl]-3,5-dihydro- (CA INDEX  
NAME)



RN 1066556-17-9 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-((3-amino-1-piperidinyl)-3-(2E)-2-buten-1-yl)-3,5-dihydro-5-[(5,6,7,8-tetrafluoro-1,4-dihydro-1-methyl-2-quinazolinyl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 1066556-18-0 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-((3-amino-1-piperidinyl)-5-(4H-3,1-benzoxazin-2-ylmethyl)-3-(2-buten-1-yl)-3,5-dihydro-7-methyl- (CA INDEX NAME)




RN 1066556-29-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1066556-31-7 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-  
3,5-dihydro-5-[(2-methylfuro[3,2-c]isoquinolin-5-yl)methyl]- (CA INDEX  
NAME)




RN 1066556-41-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 1066556-46-4 CAPLUS  
CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2E)-2-buten-1-  
yl-5-(dibenz[b,f][1,4]oxazepin-11-ylmethyl)-3,5-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 1066556-48-6 CAPLUS  
CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(1E)-1-buten-1-  
yl-5-(dibenz[b,f][1,4]thiazepin-11-ylmethyl)-3,5-dihydro- (CA INDEX  
NAME)


Double bond geometry as shown.



RN 1066556-55-5 CAPLUS


CN 4H-imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(1E)-1-buten-1-yl-3,5-dihydro-5-(6-phenanthridinylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1066556-58-8 CAPLUS


CN 4H-imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-5-(benzo[f][1,7]naphthyridin-5-ylmethyl)-3-(2-butyn-1-yl)-3,5-dihydro- (CA INDEX NAME)



RN 1066556-59-9 CAPLUS


CN 4H-imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(pyrido[2,3-c]1,5-naphthyridin-6-ylmethyl)- (CA INDEX NAME)






RN 1066556-60-2 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[(1,2,3,4-tetrahydro-6-phenanthridinyl)methyl]- (CA INDEX NAME)



RN 1066556-61-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 36 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:795432 CAPLUS

DOCUMENT NUMBER: 142:8235

TITLE: Development of an Efficient and Scalable Process of a Respiratory Syncytial Virus Inhibitor

AUTHOR(S): Provencal, David P.; Gesenberg, Kirsten D.; Wang, Hua; Escobar, Carlos; Wong, Henry; Brown, Matthew A.; Staab, Andrew J.; Pendri, Yadagiri R.

CORPORATE SOURCE: Process Research and Development, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA

SOURCE: Organic Process Research & Development (2004), 8(6), 903-908

CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:8235


AB An improved process has been developed for compound 1, a respiratory syncytial virus (RSV) inhibitor. This improved process is convergent, safe, efficient, and useful to prepare compound 1 in kilogram quantities.

IT 797032-07-6P 797032-08-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(development of efficient and scalable process of respiratory syncytial virus inhibitor)

RN 797032-07-6 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-5-[[1-[4-(2,2-dimethyl-1-oxopropoxy)butyl]-1H-benzimidazol-2-yl]methyl]-2,3-dihydro-2-oxo-, chloride (1:1) (CA INDEX NAME)



● Cl<sup>-</sup>

RN 797032-08-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-3,5-bis[[1-[4-(2,2-dimethyl-1-oxopropoxy)butyl]-1H-benzimidazol-2-yl]methyl]-2,3-dihydro-2-oxo-, chloride (1:1) (CA INDEX NAME)



● Cl<sup>-</sup>

REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 37 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:648512 CAPLUS

DOCUMENT NUMBER: 141:190795

TITLE: Preparation of 2,4-diaminopyrimidine derivatives as inhibitors of PKC-theta for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes

INVENTOR(S): Cardozo, Mario G.; Cogan, Derek; Cywin, Charles Lawrence; Dahmann, Georg; Disalvo, Darren; Ginn, John David; Prokopowicz, Anthony S.; Spero, Denise M.; Young, Erick Richard Roush

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim Pharma GmbH & Co. KG

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067516	A1	20040812	WO 2004-US2240	20040127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
CA 2514612	A1	20040812	CA 2004-2514612	20040127
EP 1590334	A1	20051102	EP 2004-705675	20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515014	T	20060518	JP 2005-518568	20040127
PRIORITY APPLN. INFO.:			US 2003-443700P	P 20030130
			WO 2004-US2240	W 20040127
OTHER SOURCE(S):		MARPAT 141:190795		

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein R1 = (un)substituted heteroaryl/aryl/cyclo/cycloalkyl/alkyl, naphthyl, quinolinyl, etc.; R2 = (un)substituted -NH-CH2-(CH2)n-CH2-NR4R5, -NH-(CH2)p-phenylene-(CH2)q-NR4R5, -NH(CH2)p-X-R4, etc.; X = pyridinyl; n = 3-8; p = 1-3; q = 0-3; R4, R5 = independently H, amidino, (un)substituted aryl/alkyl; R3 = halo, CN, NO2, aminocarbonyl, (un)substituted alkyl, alkyloxycarbonyl; their tautomers, pharmaceutically acceptable salts, solvates, or amino-protected derivs., with certain compds. excluded] were prepared as inhibitors of protein kinase C (PKC)-theta useful for treating immunol. disorders and type II diabetes. For example, II was prepared in 5 steps via amination of 2,4-dichloro-5-fluoropyrimidine with amine III and 2-chlorobenzylamine. Selected I inhibited PKC-theta with IC50 values ≤ 0.3 μM. Thus, I are useful for treating a disease or disorder associated with T cells activation.

IT 736055-76-8P, 2-(Benzylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 736055-82-6P, 2-(4-Chlorobenzylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 736055-87-1P, 2-(2-Chlorobenzylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-

nitropyrimidine 736055-90-6P,


2-Benzylamino-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PKC-theta inhibitor; preparation of diaminopyrimidines as PKC-theta inhibitors for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes)


RN 736055-76-8 CAPLUS

CN 2-Pyrimidinamine, N-(phenylmethyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 736055-82-6 CAPLUS

CN 2-Pyrimidinamine, N-[(4-chlorophenyl)methyl]-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 736055-87-1 CAPLUS

CN 2-Pyrimidinamine, N-[(2-chlorophenyl)methyl]-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 736055-90-6 CAPLUS

CN 2-Pyrimidinamine, 5-nitro-N-(phenylmethyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



REFERENCE COUNT:


2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 38 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:589247 CAPLUS  
 DOCUMENT NUMBER: 141:140463  
 TITLE: Preparation of heterocyclic compounds as selective  
 phosphodiesterase V inhibitors  
 INVENTOR(S): Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji;  
 Kikkawa, Kohei  
 PATENT ASSIGNEE(S): Japan  
 SOURCE: U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S.  
 Ser. No. 258,545.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040142930	A1	20040722	US 2003-699804	20031104
US 7273868	B2	20070925		
JP 2002012587	A	20020115	JP 2000-277652	20000913
JP 3637961	B2	20050413		
WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20030229089	A1	20031211	US 2002-258545	20021025
US 7220736	B2	20070522		
US 20080027037	A1	20080131	US 2007-889749	20070816
AU 2008203475	A1	20080828	AU 2008-203475	20080804
PRIORITY APPLN. INFO.:			JP 2000-130371	A 20000428
			JP 2000-277652	A 20000913
			WO 2001-JP2034	W 20010315
			US 2002-258545	A2 20021025
			JP 1999-261852	A 19990916
			AU 2001-241142	A 20010315
			US 2003-699804	A3 20031104
			AU 2005-203687	A3 20050817

OTHER SOURCE(S): MARPAT 141:140463  
 GI



AB The title compds. (I) [X = CH, N; Y = NH, NR, S, O, CH:N, N:CH, N:N, CH:CHC(R5)N, CH:C(R5), N:C(R7); R1 = each (un)substituted lower alkoxy, amino, heterocyclyl containing N atom(s), HO, or heterocyclyloxy containing N atom(s), cyano; R2 = lower alkylamino or lower alkoxy each optionally substituted by an (un)substituted aryl, lower alkoxy group substituted by

an aromatic heterocyclic ring containing N atom(s), lower alkylamino group substituted by a (un)substituted heterocyclic ring, (un)substituted arylamino; R3 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkyl, lower alkoxy, lower cycloalkoxy, heterocyclyloxy containing N atom(s), or NH2; R4-R7 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkoxy, or NH2; R4, R5, R6 or R7 may combine with R3 to form a lactone ring Q or Q1; when X = N, Y = CH:N, or N:CH, R2 = an amino group monosubstituted by an (un)substituted arylmethyl, and R3 = (un)substituted lower alkyl, amino monosubstituted by an (un)substituted heterocyclyl-lower alkyl containing N atom(s) in the ring, heterocyclylamino containing N atom(s) in the ring, or (un)substituted lower cycloalkylamino, R1 = each (un)substituted lower alkoxy, amino, heterocyclyloxy containing N atom(s) in the ring, or cyano group] or pharmacol. acceptable salts thereof are prepared These compds. have excellent selective PDE V inhibitory activity and therefore, are useful as therapeutic or prophylactic drugs for treating various diseases due to functional disorders on cGMP-signaling, such as erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis. Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF and etherified with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.


IT 372115-31-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as selective phosphodiesterase V inhibitors for treating various diseases due to functional disorders on cGMP-signaling)

RN 372115-31-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[3-(3-chloro-4-methoxyphenyl)methyl]amino]-N-(3-hydroxypropyl)-2-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)






L3 ANSWER 39 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:561477 CAPLUS  
 DOCUMENT NUMBER: 141:257272  
 TITLE: New broad-spectrum parenteral cephalosporins exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Part 2: Synthesis and structure-activity relationships in the S-3578 series  
 AUTHOR(S): Yoshizawa, Hidenori; Kubota, Tadatoshi; Itani, Hikaru; Ishitobi, Hiroyuki; Miwa, Hideaki; Nishitani, Yasuhiro  
 CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi & Co., Ltd., Fukushima-ku, Osaka, 553-0002, Japan  
 SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(15), 4211-4219  
 CODEN: BMECEP; ISSN: 0968-0896  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Among prepared novel cephalosporin derivs. related to S-3578, a series of 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(Z)-ethoxyiminoacetamido]-3-[1-(aminoalkyl)-1H-pyrazolo[4,3-b]pyridinium-4-yl]methyl-3-cephem-4-carboxylate showed potent activity against both methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa and displayed good water solubility. These included I-IV.  
 IT 753483-29-3P 753483-30-6P 753483-31-7P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and structure-activity relations of S-3578 derivs.)  
 RN 753483-29-3 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 1-(3-aminopropyl)-5-[[[(6R,7R)-7-[[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(ethoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, chloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




● Cl<sup>-</sup>

RN 753483-30-6 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 3-(3-aminopropyl)-5-[[[(6R,7R)-7-[[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(ethoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, chloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● Cl<sup>-</sup>

RN 753483-31-7 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 2-(3-aminopropyl)-5-[[[(6R,7R)-7-[[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(ethoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, chloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● Cl<sup>-</sup>

REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 40 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:493705 CAPLUS

DOCUMENT NUMBER: 141:54352

TITLE: Production and use of novel substituted  
imidazopyridinones and imidazopyridazones as  
medicaments

INVENTOR(S): Huel, Norbert; Himmelsbach, Frank; Langkopf, Elke;  
Eckhardt, Matthias; Maier, Roland; Mark, Michael;  
Tadayyon, Mohammad; Kauffmann-Hefner, Iris

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.,  
Germany

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050658	A1	20040617	WO 2003-EP13648	20031203
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10256264	A1	20040624	DE 2002-10256264	20021203
DE 10309927	A1	20040916	DE 2003-10309927	20030307
US 20050020574	A1	20050127	US 2003-726214	20031202
US 7109192	B2	20060919		
CA 2508233	A1	20040617	CA 2003-2508233	20031203
AU 2003293757	A1	20040623	AU 2003-293757	20031203
EP 1569936	A1	20050907	EP 2003-789123	20031203
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006514980	T	20060518	JP 2004-570687	20031203
PRIORITY APPLN. INFO.:			DE 2002-10256264	A 20021203
			DE 2003-10309927	A 20030307
			US 2002-437438P	P 20021230
			US 2003-456598P	P 20030321
			WO 2003-EP13648	W 20031203

OTHER SOURCE(S): MARPAT 141:54352


GI



I



II



III

AB The invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones I (R1 = 5- to 7-membered cycloalkylenimino (optionally substituted with C1-3-alkyl), 6- to 7-membered cycloalkylenimino (4-methylene substituted, to 7-membered cycloalkylamino, etc.; R2 = CH2Ph (F-, Cl-, Br-, CN-substituted Ph), (un)branched C3-8-alkenyl, C3-5-alkynyl, C3-7-cycloalkylmethyl, C5-7-cycloalkylmethyl, urylmethyl, thienylmethyl, pyrrolylmethyl, thiazolylmethyl, ; R3 = (un)branched C1-6-alkyl, C1-6-haloalkyl, C1-6-cyanoalkyl, CHMePh, CH2CH(OH)Ph, CH2COPh (optionally substituted Ph), 3-methyl-2-oxo-2,3-dihydrobenzoxazolyl)carbonylmethyl, thienylcarbonylmethyl, mono- or bicyclic heteroaryl-(C1-6-alkyl); R4 = H, C1-3-alkyl; X = N, CR5; R5 = H, Me; etc.), the tautomers thereof, the stereoisomers thereof, the mixts. thereof and the salts thereof, which have valuable pharmacol. properties, especially an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV). Thus, I·HCl [R1 = 3-aminopiperidino, R2 = 2-butynyl, R3 = (1-naphthyl)methyl, R4 = H, X = N] was prepared from 4,5-dichloro-3-hydroxy-2H-pyridazine (II; Y1 = Y2 = Cl, Y3 = H) via N-alkylation with 1-(chloromethyl)naphthalene to give II [Y1 = Y2 = Cl, Y3 = (1-naphthyl)methyl], hydrolysis-nitration to II [Y1 = OH, Y2 = NO2, Y3 = (1-naphthyl)methyl], amination to give II [Y1 = NH2, Y2 = NO2, Y3 = (1-naphthyl)methyl], reduction to the 4,5-diamino derivative, cyclocondensation with thiocarbonyldiimidazole to give imidazopyridazine III [Z1 = SH, Z2 = H, Z3 = (1-naphthyl)methyl], S-methylation to III [Z1 = SMe, Z2 = H, Z3 = (1-naphthyl)methyl], N-alkylation with BrCH2C.tplbond.CMe to give III [Z1 = SMe, Z2 = CH2C.tplbond.CMe, Z3 = (1-naphthyl)methyl]; S-oxidation to give III [Z1 = SO2Me, Z2 = CH2C.tplbond.CMe, Z3 = (1-naphthyl)methyl],, amination with 3-(Boc-amino)piperidine and deprotection. The inhibitory effect of I [R1 = 3-aminopiperidino, R2 = 2-butynyl, R3 = (1-naphthyl)methyl, R4 = H] on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV) was tested [IC50 = 13 nM]. Formulations containing I in the forms of dragees, tablets, ampuls, hard-gel capsules, suppositories and suspensions are presented.

IT 1042165-93-4 1064164-73-3 1064164-74-4  
1064164-75-5 1064164-76-6 1064164-77-7  
1064164-79-9 1064164-80-2 1064164-81-3  
1064164-84-6 1064164-85-7 1064164-86-8  
1064164-88-0 1064164-89-1 1064164-90-4  
1064164-91-5 1064164-93-7 1064164-95-9  
1064164-96-0 1064164-98-2 1064164-99-3


1064165-01-0 1064165-02-1 1064165-03-2  
 1064165-04-3 1064165-05-4 1064165-15-6  
 1064165-17-8 1064165-18-9 1064165-19-0  
 1064165-20-3 1064165-21-4 1064165-22-5  
 1064165-23-6 1064165-24-7 1064165-25-8  
 1064165-26-9 1064165-28-1 1064165-58-7  
 1064165-60-1 1064165-61-2 1064165-63-4  
 1064165-85-0 1064165-86-1

RL: PRPH (Prophetic)

(Production and use of novel substituted imidazopyridinones and imidazopyridazones as medicaments)


RN 1042165-93-4 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyne-1-yl)-3,5-dihydro-5-[(3-methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)



RN 1064164-73-3 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(2-propen-1-yl)- (CA INDEX NAME)



RN 1064164-74-4 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-[(2E)-2-methyl-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 1064164-75-5 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(3-methyl-2-buten-1-yl)- (CA INDEX NAME)




RN 1064164-76-6 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(2-butyn-1-yl)- (CA INDEX NAME)




RN 1064164-77-7 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(2-cyclopenten-1-ylmethyl)- (CA INDEX NAME)




RN 1064164-79-9 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(phenylmethyl)- (CA INDEX NAME)



RN 1064164-80-2 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-furanylmethyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)- (CA INDEX NAME)



RN 1064164-81-3 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(3-furanylmethyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)- (CA INDEX NAME)






RN 1064164-84-6 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(2-methyl-2-propen-1-yl)- (CA INDEX NAME)




RN 1064164-85-7 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2,3-dimethyl-2-buten-1-yl)-3,5-dihydro-5-(1-isoquinolinylmethyl)- (CA INDEX NAME)




RN 1064164-86-8 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(2-propyn-1-yl)- (CA INDEX NAME)




RN 1064164-88-0 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(cyclopropylmethyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)- (CA INDEX NAME)



RN 1064164-89-1 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(1-cyclohexen-1-ylmethyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)- (CA INDEX NAME)




RN 1064164-90-4 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-[(3,5-difluorophenyl)methyl]-3,5-dihydro-5-(1-isoquinolinylmethyl)- (CA INDEX NAME)




RN 1064164-91-5 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(2-thienylmethyl)- (CA INDEX NAME)




RN 1064164-93-7 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-5-(1-isoquinolinylmethyl)-3-(3-thienylmethyl)- (CA INDEX NAME)




RN 1064164-95-9 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 1064164-96-0 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(4-pyrimidinylmethyl)- (CA INDEX NAME)




RN 1064164-98-2 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 1064164-99-3 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[(5-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1064165-01-0 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(4-isoquinolinylmethyl)- (CA INDEX NAME)




RN 1064165-02-1 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-5-(4-cinnolinylmethyl)-3,5-dihydro- (CA INDEX NAME)




RN 1064165-03-2 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(8-quinolinylmethyl)- (CA INDEX NAME)



RN 1064165-04-3 CAPLUS


CN 2(1H)-Quinolinone, 4-[[2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-1-methyl- (CA INDEX NAME)



RN 1064165-05-4 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2E)-2-buten-1-yl-3,5-dihydro-5-(1-isoquinolinylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1064165-15-6 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 1064165-17-8 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[(6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1064165-18-9 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[(4-methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)




RN 1064165-19-0 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(4-quinazolinylmethyl)- (CA INDEX NAME)




RN 1064165-20-3 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(4-quinolinylmethyl)- (CA INDEX NAME)




RN 1064165-21-4 CAPLUS

CN 2-(1H)-Quinolinone, 4-[[2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl]methyl]- (CA INDEX NAME)




RN 1064165-22-5 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-((2-quinolinylmethyl)- (CA INDEX NAME)




RN 1064165-23-6 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[(1-methyl-2-quinazolinyl)methyl]- (CA INDEX NAME)



RN 1064165-24-7 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[(1-methyl-1H-indazol-3-yl)methyl]- (CA INDEX NAME)




RN 1064165-25-8 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-5-(1,2-




benzothiazol-3-ylmethyl)-3-(2-butyn-1-yl)-3,5-dihydro- (CA INDEX NAME)




RN 1064165-26-9 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[2-(3-thienyl)ethyl]- (CA INDEX NAME)




RN 1064165-28-1 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[2-oxo-2-(3-thienyl)ethyl]- (CA INDEX NAME)




RN 1064165-58-7 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(2-quinazolinylmethyl)- (CA INDEX NAME)




RN 1064165-60-1 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 1064165-61-2 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-5-(1,2-benzisoxazol-3-ylmethyl)-3-(2-butyn-1-yl)-3,5-dihydro- (CA INDEX NAME)




RN 1064165-63-4 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2-butyn-1-yl)-3,5-dihydro-5-[2-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 1064165-85-0 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-3-(3-methyl-2-buten-1-yl)-5-(2-quinazolinylmethyl)- (CA INDEX NAME)



RN 1064165-86-1 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3-(2E)-2-buten-1-yl-3,5-dihydro-5-(2-quinazolinylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.




IT 705279-86-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and use of novel substituted imidazopyridinones and imidazopyridazones as inhibitors of dipeptidylpeptidase IV)

RN 705279-86-3 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(3-amino-1-piperidinyl)-3,5-dihydro-3-(3-methyl-2-buten-1-yl)-5-[(3-methyl-1-isoquinolinyl)methyl]- (CA INDEX NAME)




REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 41 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:467881 CAPLUS  
 DOCUMENT NUMBER: 141:38631  
 TITLE: Imidazole derivative, process for producing the same,  
 and use  
 INVENTOR(S): Kubo, Keiji; Kuroita, Takanobu; Imaeda, Yasuhiro;  
 Kawamura, Masaki  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 318 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048363	A1	20040610	WO 2003-JP14793	20031120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507026	A1	20040610	CA 2003-2507026	20031120
AU 2003284596	A1	20040618	AU 2003-284596	20031120
EP 1564213	A1	20050817	EP 2003-774086	20031120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004182730	A	20040702	JP 2003-392992	20031121
US 20070004736	A1	20070104	US 2006-535268	20060519
PRIORITY APPLN. INFO.:			JP 2002-338939	A 20021122
			WO 2003-JP14793	W 20031120
OTHER SOURCE(S):	MARPAT 141:38631			
GI				



AB Imidazole derivs. represented by the formula (I) [wherein R = each optionally substituted cyclic hydrocarbon group or heterocyclic group; W = a bond, optionally substituted divalent chain hydrocarbon group; X = optionally substituted divalent hydrocarbon group; Y = CO, S(O), S(O)<sub>2</sub>, a bond; ring A = each optionally substituted pyrrolidine ring, piperidine ring, or perhydroazepine ring; Z<sup>1</sup>, Z<sup>3</sup> = each independently a bond or optionally substituted divalent chain hydrocarbon group; Z<sup>2</sup> = N(R<sub>1</sub>), O, S(O), S(O)<sub>2</sub>, CO, CH(R<sub>1</sub>), a bond; ring B = an optionally substituted imidazole ring, provided that a substituent of the imidazole ring represented by B may be bonded to R<sub>1</sub> to form an optionally substituted ring; m = 0, 1, 2] are prepared. These imidazole derivs. are inhibitors of activated blood coagulation factor X (FXa) and useful as anticoagulants for the prevention and/or treatment of myocardial infarction, cerebral


infarction, deep venous thrombosis, pulmonary thromboembolism and embolism, obstructive arteriosclerosis, economy class syndromes, thromboembolism and embolism during or after surgery, or the second onset of deep venous thrombosis. Thus, 5-methyl-2-(4-piperidinyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one was condensed with 3-[(6-chloro-2-naphthyl)sulfonyl]propionic acid using HOBT, Et3N, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 to give 52% 2-[1-[3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl]-4-piperidinyl]-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one (II). II showed IC50 of 5.6 nM for inhibiting FXa. Pharmaceutical formulations, e.g. a gelatine capsule containing II, were described.

IT 701298-05-7P 701298-08-0P 701298-10-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazole derivs. as inhibitors of activated blood coagulation factor X and antithrombotics)  
 RN 701298-05-7 CAPLUS  
 CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 701298-08-0 CAPLUS  
 CN 1-Propanone, 3-[(5-chloro-2-naphthalenyl)sulfonyl]-1-[4-(3,4,6,7,8,9-hexahydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 701298-10-4 CAPLUS  
 CN 1-Propanone, 3-[(5-chloro-1H-indol-2-yl)sulfonyl]-1-[4-(3,4,6,7,8,9-hexahydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

IT 701301-08-8P 701301-10-2P 701301-14-6P  
701301-16-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of imidazole derivs. as inhibitors of activated blood  
coagulation factor X and antithrombotics)


RN 701301-08-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 701301-10-2 CAPLUS


CN Pyrido[4',3':4,5]imidazo[1,2-a]pyridine,  
1,2,3,4-tetrahydro-2-(4-piperidiny)-, hydrochloride (1:3) (CA INDEX  
NAME)



●3 HCl


RN 701301-14-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(3,4,6,7,8,9-hexahydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 701301-16-8 CAPLUS

CN Pyrido[4',3':4,5]imidazo[1,2-a]pyridine,  
1,2,3,4,6,7,8,9-octahydro-2-(4-piperidinyl)-, hydrochloride (1:3) (CA  
INDEX NAME)



● 3 HCl

REFERENCE COUNT:

26


THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 42 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:292024 CAPLUS  
 DOCUMENT NUMBER: 140:303665  
 TITLE: Preparation of pyrazole amides for treating HIV infections  
 INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, David Anthony; Selby, Matthew Duncan; Stuppel, Paul Anthony  
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029051	A1	20040408	WO 2003-IB4071	20030915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495338	A1	20040408	CA 2003-2495338	20030915
AU 2003263455	A1	20040419	AU 2003-263455	20030915
BR 2003014759	A	20050726	BR 2003-14759	20030915
EP 1556381	A1	20050727	EP 2003-798295	20030915
EP 1556381	B1	20080220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505625	T	20060216	JP 2005-501939	20030915
AT 386741	T	20080315	AT 2003-798295	20030915
ES 2298615	T3	20080516	ES 2003-798295	20030915
US 20050004129	A1	20050106	US 2003-669794	20030923
US 7157468	B2	20070102		
MX 2005002004	A	20050428	MX 2005-2004	20050218
PRIORITY APPLN. INFO.:			GB 2002-22375	A 20020926
			GB 2002-23357	A 20021008
			US 2002-433220P	P 20021213
			WO 2003-IB4071	W 20030915

OTHER SOURCE(S): MARPAT 140:303665  
 GI





AB The title compds. [I; WXY = (un)substituted 5-6 membered partially saturated or aromatic ring containing 0-3 N atoms wherein X = CH or N and Y = CH, or, when

X = CH, may also be N; R1 = a bond, alkylene, R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl; n = 0-2] which bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof, were prepared and formulated. Thus, reacting [4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetic acid (preparation given) with 5,6,7,8-tetrahydro-[1,6]naphthyridine afforded II. The compds. I were tested for inhibition of HIV-1 reverse transcriptase enzyme (data were given for representative compds. I). The compds. I are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).


IT 676994-37-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole amides for treating HIV infections)

RN 676994-37-9 CAPLUS

CN Ethanone, 2-[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]-1-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



REFERENCE COUNT:


1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 43 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:41468 CAPLUS  
 DOCUMENT NUMBER: 140:94047  
 TITLE: Preparation of imidazopyridines as viral inhibitors  
 INVENTOR(S): Neyts, Johan; Puerstinger, Gerhard; De Clercq, Erik  
 PATENT ASSIGNEE(S): K.U.Leuven Research & Development, Belg.; Gilead  
 Sciences, Inc.  
 SOURCE: PCT Int. Appl., 149 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005286	A2	20040115	WO 2003-BE117	20030703
WO 2004005286	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491243	A1	20040115	CA 2003-2491243	20030703
AU 2003243846	A1	20040123	AU 2003-243846	20030703
AU 2003243846	B2	20081120		
EP 1521754	A2	20050413	EP 2003-762361	20030703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012547	A	20050426	BR 2003-12547	20030703
CN 1678612	A	20051005	CN 2003-820142	20030703
CN 1328279	C	20070725		
JP 2005537248	T	20051208	JP 2004-518295	20030703
NZ 537473	A	20070223	NZ 2003-537473	20030703
MX 2004012965	A	20050516	MX 2004-12965	20041217
NO 2004005731	A	20050317	NO 2004-5731	20041230
US 20050239821	A1	20051027	US 2004-519756	20041230
HK 1082734	A1	20080118	HK 2006-101965	20060215
PRIORITY APPLN. INFO.:			GB 2002-15293	A 20020703
			GB 2003-13251	A 20030610
			WO 2003-BE117	W 20030703

OTHER SOURCE(S): MARPAT 140:94047  
 GI



I

AB The present invention relates to a pharmaceutical composition for the treatment

or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine I [R1 = H, (un)substituted aryl, heterocyclyl, cycloalkyl, cycloalkenyl; Y = a bond, O, S<sub>0</sub>m, (un)substituted NH, etc.; R2, R4 = H, alkyl, alkenyl, alkoxy, halo, etc.; X = divalent (un)saturated (un)substituted hydrocarbon group optionally including one or more heteroatoms; m = 0-2; R3 = (un)substituted aryl, aryloxy, arylthio, etc.; R5 = H, alkyl, alkoxy, etc.; R6, R7 = H, alkyl, cycloalkyl, Ph, etc.]. The invention also relates to processes for the preparation of compds. I and their use as a medicine or to treat or prevent viral infections. Thus, treating 2-(2,6-difluorophenyl)-1(3)H-imidazo[4,5-c]pyridine (preparation given) with 50% NaOH in DMF followed by addition of 2,6-difluorobenzyl bromide afforded 65% 2-(2,6-difluorophenyl)-5-[(2,6-difluorophenyl)methyl]-5H-imidazo[4,5-c]pyridine. The compds. I were tested for their anti-BVDV, anti-HCV, and anti-coxsackie activity (data given).

IT 645420-73-1P 645420-76-4P 645420-79-7P


645420-80-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridines as viral inhibitors)


RN 645420-73-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[(5-chloro-2-thienyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 645420-76-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-phenyl-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 645420-79-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-phenyl-5-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 645420-80-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-phenyl-5-(3-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 44 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:940967 CAPLUS

DOCUMENT NUMBER: 140:241867

TITLE: Formation equilibria of nickel complexes with glycyl-histidyl-lysine and two synthetic analogues  
AUTHOR(S): Conato, Chiara; Kozlowski, Henryk; Swiatek-Kozlowska, Jolanta; Mlynarz, Piotr; Remelli, Maurizio; Silvestri, Sergio

CORPORATE SOURCE: Department of Chemistry, University of Ferrara, Ferrara, I-44100, Italy

SOURCE: Journal of Inorganic Biochemistry (2004), 98(1), 153-160

CODEN: JIBIDJ; ISSN: 0162-0134

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Complex-formation equilibrium between the Ni(II) ion and the natural tripeptide glycyl-L-histidyl-L-lysine have been investigated. Two synthetic analogs, where the histidine residue has been substituted with L-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid (L-Spinacine) and L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), resp., have been considered, as well. Different exptl. techniques have been employed: potentiometry, calorimetry, visible spectrophotometry and CD spectroscopy. Structural hypotheses on the main complex species are suggested. Evidences on the formation of tetrameric species with the first ligand are shown. No involvement of the side-chain amino group of lysine residue in metal ion coordination was found.

IT 667914-81-0

RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)  
(thermodn. of nickel(2+) complexation with glycyl-histidyl-lysine and its synthetic analogs)

RN 667914-81-0 CAPLUS



CN Nickel, bis[N2-[[[(6S)-5-[(amino-κN)acetyl-κO]-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-6-yl]carbonyl]-L-lysinato]diaqua-, (OC-6-12)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 45 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:931364 CAPLUS  
 DOCUMENT NUMBER: 139:395937  
 TITLE: Preparation of imidazole derivatives as GABAA receptor agonists for treatment of human central nervous system disorders  
 INVENTOR(S): Maynard, George D.; Yuan, Jun; Luke, George P.; Currie, Kevin  
 PATENT ASSIGNEE(S): Neurogen Corporation, USA  
 SOURCE: PCT Int. Appl., 72 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097643	A1	20031127	WO 2003-US15578	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2486339	A1	20031127	CA 2003-2486339	20030515
AU 2003237881	A1	20031202	AU 2003-237881	20030515
US 20040014780	A1	20040122	US 2003-438496	20030515
US 6916827	B2	20050712		
EP 1506194	A1	20050216	EP 2003-736638	20030515
EP 1506194	B1	20060719		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006502974	T	20060126	JP 2004-505375	20030515
AT 333455	T	20060815	AT 2003-736638	20030515
ES 2273008	T3	20070501	ES 2003-736638	20030515
PRIORITY APPLN. INFO.:			US 2002-381302P	P 20020517
			WO 2003-US15578	W 20030515
OTHER SOURCE(S):	MARPAT 139:395937			
GI				



AB The title compds. I [wherein R1 = (un)substituted aryl or heteroaryl; R2 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkylalkyl; A and B = independently (un)substituted CH2 or NH] or pharmaceutically acceptable salts thereof are prepared as GABAA receptor agonists, and are useful for the treatment of central nervous system (CNS) disorders (no data). For example, the compound II was prepared in a multi-step synthesis.

Some of compds. I showed  $K_i$  of  $<10$  nM against GABAA receptor in rat.


IT 627077-97-8P 627077-98-9P 627077-99-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazole derivs. as GABAA receptor agonists for treatment of human central nervous system disorders)


RN 627077-97-8 CAPLUS

CN 3H-imidazo[4,5-c]pyridine, 3-ethyl-4,5,6,7-tetrahydro-5-(3-nitro-2-pyridinyl)-2-[[2-(2-thiazolyl)-1H-imidazol-1-yl]methyl]- (CA INDEX NAME)




RN 627077-98-9 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[1-ethyl-2-[[2-(6-fluoro-2-pyridinyl)-1H-imidazol-1-yl]methyl]-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)



RN 627077-99-0 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[1-ethyl-1,4,6,7-tetrahydro-2-[[2-(2-thiazolyl)-1H-imidazol-1-yl]methyl]-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




IT 627078-04-0P 627078-05-1P 627078-06-2P

627078-07-3P 627078-08-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazole derivs. as GABAA receptor agonists for treatment of human central nervous system disorders)


RN 627078-04-0 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(3-nitro-2-pyridinyl)-  
 (CA INDEX NAME)




RN 627078-05-1 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridine, 1-ethyl-4,5,6,7-tetrahydro-5-(3-nitro-2-pyridinyl)- (CA INDEX NAME)



RN 627078-06-2 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine, 3-ethyl-4,5,6,7-tetrahydro-5-(3-nitro-2-pyridinyl)- (CA INDEX NAME)




RN 627078-07-3 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridine-2-methanol, 1-ethyl-4,5,6,7-tetrahydro-5-(3-nitro-2-pyridinyl)- (CA INDEX NAME)



RN 627078-08-4 CAPLUS  
 CN 3-Pyridinecarbonitrile, 2-[1-ethyl-1,4,6,7-tetrahydro-2-(hydroxymethyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)





REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:757715 CAPLUS  
 DOCUMENT NUMBER: 139:261088  
 TITLE: Preparation of broad-spectrum cephem compounds  
 INVENTOR(S): Nishitani, Yasuhiro; Yamano, Yoshinori  
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 209 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078440	A1	20030925	WO 2003-JP3249	20030318
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2479354	A1	20030925	CA 2003-2479354	20030318
AU 2003221080	A1	20030929	AU 2003-221080	20030318
EP 1489084	A1	20041222	EP 2003-712748	20030318
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003008492	A	20050503	BR 2003-8492	20030318
CN 1653072	A	20050810	CN 2003-810969	20030318
MX 2004008320	A	20041126	MX 2004-8320	20040826
US 20050153950	A1	20050714	US 2004-507502	20040913
US 7384928	B2	20080610		

PRIORITY APPLN. INFO.:

JP 2002-73526 A 20020318  
 WO 2003-JP3249 W 20030318

OTHER SOURCE(S): MARPAT 139:261088

GI



AB Cephem compds. I (T is S, SO, or O; X is halogeno, CN, carbamoyl which may be substituted with lower alkyl, lower alkyl, lower alkoxy, or lower alkylthio; A is substituted lower alkylene (wherein the substituent is optionally substituted mono-lower alkyl, optionally substituted lower alkylidene, or optionally substituted lower alkylene); and Z+ is an

optionally substituted nitrogenous heterocyclic group having a cationic group), their ester, protected 7-aminothiazole, or pharmaceutically acceptable salts or solvates, are prepared I [X = Me, A = Me2C, T = S, Z = 1-(3-methylaminopropyl)-1H-imidazo[4,5-b]pyridinium-4-yl-] was prepared and showed antibacterial activities superior to that of ceftazidime.

IT 603999-83-3P 603999-95-7P 604000-13-7P  
604000-15-9P 604000-23-9P 604000-44-4P  
604000-46-6P 604000-50-2P 604000-52-4P  
604000-54-6P 604000-56-8P 604000-62-6P  
604000-84-2P 604001-10-7P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of broad-spectrum cephem compds.)

RN 603999-83-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxyimino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603999-95-7 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxyimino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 604000-13-7 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-3-(3-aminopropyl)-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 604000-15-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-(3-aminopropyl)-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


—NH<sub>2</sub>

RN 604000-23-9 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 2-amino-5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-


chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 604000-44-4 CAPLUS  
CN 1H-Imidazo[4,5-c]pyridinium, 2-amino-5-[[[(6R, 7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-1-methyl-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 604000-46-6 CAPLUS  
CN 3H-Imidazo[4,5-c]pyridinium, 5-[[[(6R, 7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2-(methylamino)-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 604000-50-2 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-(dimethylamino)-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 604000-52-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 2-amino-5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-[2-(methylamino)ethyl]-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


—NHMe

RN 604000-54-6 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-[(2-aminoethyl)methylamino]-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NH<sub>2</sub>


RN 604000-56-8 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-[[2-(methylamino)ethyl]amino]-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


~ NHMe

RN 604000-62-6 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 2-amino-5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-3-methyl-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 604000-84-2 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-



thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2-[(Z)-  
[(dimethylamino)methylene]amino]-1-[2-(methylamino)ethyl]-, inner salt  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

NHMe

RN 604001-10-7 CAPLUS  
CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-[[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-1-[2-(methylamino)ethyl]-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



— NHMe

REFERENCE COUNT:



18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 47 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:570644 CAPLUS  
 DOCUMENT NUMBER: 139:133575  
 TITLE: Preparation of bicyclic pyrimidinyl derivatives as adenosine receptor ligands  
 INVENTOR(S): Castelhana, Arlindo L.; McKibben, Bryan  
 PATENT ASSIGNEE(S): OSI Pharmaceuticals Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 105 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030139427	A1	20030724	US 2002-227378	20020823
PRIORITY APPLN. INFO.:			US 2002-227378	20020823
OTHER SOURCE(S):	MARPAT 139:133575			


GI



AB Title compds. I [Y = N, CR5 and X = N, CR6 wherein X, Y are both N or when Y = CR5, X = N or when X = CR6, Y = N; R1-2 = H, alkoxy, aminoalkyl, etc; R3-4 = H, alkyl, aryl, alkylaryl] are prepared For instance, 3-amino-4-carbamoylpyrazole is acylated with benzoyl chloride (Pyridine, 50°, 5-6 h), cyclized to the corresponding pyrazolopyrimidine (water, K2CO3, 100°, 16 h), converted to the chloride (POCl3, 106°, 2 h) and used for reactions with various amines to give the example compds., e.g., II. II has Ki = 76.7 nM for the adenosine A1 receptor, Ki = 242.7 nM for A2a and Ki = 1480.5 nM for A2b. I are useful for the treatment of.


IT 565236-32-0P 565236-33-1P 565236-34-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of bicyclic pyrazolo- imidazo- and triazolopyrimidinyl derivs. as adenosine receptor ligands)

RN 565236-32-0 CAPLUS  
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidine,  
 5-phenyl-7-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 565236-33-1 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 6-phenyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 565236-34-2 CAPLUS

CN 9H-Purine, 2-phenyl-6-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



L3 ANSWER 48 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:454286 CAPLUS  
 DOCUMENT NUMBER: 139:36534  
 TITLE: Preparation of arylpyrrolopyrimidines as adenosine A1 and A3 receptor inhibitors  
 INVENTOR(S): Castelhana, Arlindo L.; McKibben, Bryan; Werner, Douglas S.; Witter, David  
 PATENT ASSIGNEE(S): OSI Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 170 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048120	A2	20030612	WO 2002-US38055	20021127
WO 2003048120	A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2468673	A1	20030612	CA 2002-2468673	20021127
AU 2002360436	A1	20030617	AU 2002-360436	20021127
EP 1450811	A2	20040901	EP 2002-795691	20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005529062	T	20050929	JP 2003-549312	20021127
US 20050090513	A1	20050428	US 2004-497451	20041213
PRIORITY APPLN. INFO.:			US 2001-335273P	P 20011130
			US 2001-337274P	P 20011130
			WO 2002-US38055	W 20021127
OTHER SOURCE(S):		MARPAT 139:36534		
GI				



AB Arylpyrrolopyrimidines I [m = 0-3; R = halogen, alkyl, alkoxy, OH, NH2, alkylamino; R1 = H, (un)substituted alkyl, aryl, aralkyl; R2 = (un)substituted imidazole, pyrazole, attached through C] which specifically inhibit the adenosine A1 and A3 receptors were prepared. Thus, 4-chloro-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine was treated with histamine to give the 4-[2-(1H-imidazol-2-yl)ethyl]amino analog which had A3

inhibiting activity  $\geq 10$  times greater than that of reference compds.


IT 541503-89-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpyrrolopyrimidines as adenosine A1 and A3 receptor inhibitors)

RN 541503-89-3 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 3a,4,5,6,7,7a-hexahydro-5-(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)




REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 49 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:319721 CAPLUS  
 DOCUMENT NUMBER: 138:321292  
 TITLE: Preparation of 2,4,5-trisubstituted pyrimidines as  
 cyclin dependent kinase inhibitors  
 INVENTOR(S): Dahmann, Georg; Himmelsbach, Frank; Wittneben, Helmut;  
 Pautsch, Alexander; Prokopowicz, Anthony S.; Krist,  
 Bernd; Schnapp, Gisela; Steegmaier, Martin; Lenter,  
 Martin; Schoop, Andreas; Steurer, Steffen; Spevak,  
 Walter  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany; Boehringer  
 Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim  
 International G.m.b.H.  
 SOURCE: PCT Int. Appl., 278 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003032997	A1	20030424	WO 2002-EP11453	20021014
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2463989	A1	20030424	CA 2002-2463989	20021014
AU 2002340560	A1	20030428	AU 2002-340560	20021014
EP 1438053	A1	20040721	EP 2002-774710	20021014
EP 1438053	B1	20080910		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005509624	T	20050414	JP 2003-535800	20021014
AT 407678	T	20080915	AT 2002-774710	20021014
US 20030171359	A1	20030911	US 2002-271763	20021016
US 7173028	B2	20070206		
US 20060100211	A1	20060511	US 2005-313380	20051221
PRIORITY APPLN. INFO.:			US 2001-330145P	P 20011017
			WO 2002-EP11453	W 20021014
			US 2002-271763	A3 20021016
OTHER SOURCE(S):	MARPAT 138:321292			
GI				



AB Title compds. I [R1 = H, alkyl; R2 = (un)substituted alkyl; R3 = H, alkyl; R4 = (un)substituted alkyl; R5 = halo] and their pharmaceutically acceptable salts were prepared. For example, condensation of thiocyanatopyrimidine II, e.g., prepared from 3,4-dichloroaniline and 2-chloro-4-thiocyanato-5-nitropyrimidine in one step, and acetylaminooethylamine provided trisubstituted pyrimidine III in 88% yield. In CDK1/CyclinB1 kinase inhibition studies, 88-examples of compds. I exhibited IC50 values more than 100 nM. Compds. I are claimed useful for the treatment of diseases characterized by abnormal cell proliferation.

IT 514830-63-8P, 2-(4-Chlorophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514830-64-9P, 2-(3-Chlorophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514830-65-0P 514830-69-4P, 2-(4-Chlorophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514830-73-0P, 2-(3,5-Dichlorophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514830-74-1P, 2-(3-Chloro-4-fluorophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514830-76-3P, 2-(4-Carboxyphenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514830-78-5P, 2-(4-Bromophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514830-81-0P, 2-(3-Aminocarbonylphenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514830-82-1P, 2-[(4-(2-Carboxyethyl)phenyl)amino]-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514830-85-4P, 2-[(4-Phenylaminocarbonylphenyl)amino]-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514830-86-5P, 2-(4-Nitrophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514830-88-7P, 2-(4-Carboxyphenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514830-91-2P, 2-(4-Cyanophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514830-97-8P, 2-(3-Bromophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-




trifluoromethylpyrimidine 514831-19-7P,  
 2-(3,4-Dichlorophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514831-57-3P,  
 2-(3-Cyanophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514831-72-2P,  
 2-[(4-(2-Carboxyethyl)phenyl)amino]-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514831-73-3P,  
 2-(4-Amino-3,5-dichlorophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514831-74-4P,  
 2-(4-Aminocarbonylphenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514831-76-6P,  
 2-(4-Bromophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514831-77-7P,  
 2-Phenylamino-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514831-78-8P,  
 2-(3-Bromophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514831-81-3P,  
 2-(3-Nitrophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514831-84-6P,  
 2-(4-Fluorophenylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-nitropyrimidine 514832-22-5P,  
 2-(2-Naphthylamino)-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidine 514837-05-9P 514837-74-2P,  
 N,N-Dimethyl-4-[4-(3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-trifluoromethylpyrimidin-2-ylamino]phenylsulfonamide 514839-83-9P  
 , [5-Chloro-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)pyrimidin-2-yl] (1H-indazol-6-yl)amine 514839-86-2P,  
 4-[5-Chloro-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)pyrimidin-2-ylamino]-N,N-dimethylphenylsulfonamide 514839-90-8P,  
 (1H-Indazol-6-yl)-[5-methyl-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)pyrimidin-2-yl]amine 514839-92-0P,  
 [5-Methoxy-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)pyrimidin-2-yl] (4-piperidin-1-ylmethylphenyl)amine 514839-93-1P,  
 (3,4-Dichlorophenyl)-[5-methoxy-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)pyrimidin-2-yl]amine 514839-97-5P,  
 [5-Bromo-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)pyrimidin-2-yl] (1H-indazol-6-yl)amine 514839-99-7P,  
 N,N-Dimethyl-4-[5-methyl-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)pyrimidin-2-ylamino]phenylsulfonamide 514840-02-9P  
 514840-03-0P, [5-Isopropyl-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)pyrimidin-2-yl] (4-piperidin-1-ylmethylphenyl)amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of trisubstituted pyrimidines as cyclin dependent kinase inhibitors)


RN 514830-63-8 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514830-64-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514830-65-0 CAPLUS

CN 2-Pyrimidinamine, N-[4-(1-piperidinylmethyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514830-69-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514830-73-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dichlorophenyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514830-74-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-fluorophenyl)-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514830-76-3 CAPLUS

CN Benzoic acid, 4-[[4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514830-78-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-bromophenyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514830-81-0 CAPLUS

CN Benzamide, 3-[[5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514830-82-1 CAPLUS

CN Benzenepropanoic acid, 4-[[4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514830-85-4 CAPLUS

CN Benzamide, 4-[[5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 514830-86-5 CAPLUS

CN 2-Pyrimidinamine, 5-nitro-N-(4-nitrophenyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514830-88-7 CAPLUS

CN Benzoic acid, 4-[[5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514830-91-2 CAPLUS

CN Benzonitrile, 4-[[5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514830-97-8 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514831-19-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dichlorophenyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514831-57-3 CAPLUS

CN Benzonitrile, 3-[[5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514831-72-2 CAPLUS

CN Benzenepropanoic acid, 4-[[5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514831-73-3 CAPLUS

CN 1,4-Benzenediamine, 2,6-dichloro-N4-[5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 514831-74-4 CAPLUS

CN Benzamide, 4-[[5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514831-76-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-bromophenyl)-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514831-77-7 CAPLUS

CN 2-Pyrimidinamine, N-phenyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514831-78-8 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514831-81-3 CAPLUS


CN 2-Pyrimidinamine, 5-nitro-N-(3-nitrophenyl)-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514831-84-6 CAPLUS  
 CN 2-Pyrimidinamine, N-(4-fluorophenyl)-5-nitro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514832-22-5 CAPLUS  
 CN 2-Pyrimidinamine, N-2-naphthalenyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514837-05-9 CAPLUS  
 CN 2-Pyrimidinamine, N-[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)



RN 514837-74-2 CAPLUS  
 CN Benzenesulfonamide, N,N-dimethyl-4-[[4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514839-83-9 CAPLUS  
 CN 1H-Indazol-6-amine, N-[5-chloro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 514839-86-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 514839-90-8 CAPLUS

CN 1H-Indazol-6-amine, N-[5-methyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 514839-92-0 CAPLUS


CN 2-Pyrimidinamine, 5-methoxy-N-[4-(1-piperidinylmethyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



RN 514839-93-1 CAPLUS


CN 2-Pyrimidinamine, N-(3,4-dichlorophenyl)-5-methoxy-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)






RN 514839-97-5 CAPLUS

CN 1H-Indazol-6-amine, N-[5-bromo-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 514839-99-7 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[5-methyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 514840-02-9 CAPLUS

CN 2,5-Pyrimidinediamine, N5,N5-dimethyl-N2-[4-(1-piperidinylmethyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514840-03-0 CAPLUS


CN 2-Pyrimidinamine, 5-(1-methylethyl)-N-[4-(1-piperidinylmethyl)phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




IT 514842-53-6P, 2-Chloro-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-chloropyrimidine 514842-74-1P, 2-Chloro-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-methoxypyrimidine 514842-77-4P, 2-Chloro-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-bromopyrimidine 514842-79-6P, 2-Chloro-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-dimethylaminopyrimidine 514842-80-9P, 2-Chloro-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-isopropylpyrimidine 514843-44-8P, 2-Chloro-4-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-5-methylpyrimidine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of trisubstituted pyrimidines as cyclin dependent kinase inhibitors)  
 RN 514842-53-6 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine, 5-(2,5-dichloro-4-pyrimidinyl)-4,5,6,7-tetrahydro- (CA INDEX NAME)



RN 514842-74-1 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine, 5-(2-chloro-5-methoxy-4-pyrimidinyl)-4,5,6,7-tetrahydro- (CA INDEX NAME)




RN 514842-77-4 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine, 5-(5-bromo-2-chloro-4-pyrimidinyl)-4,5,6,7-tetrahydro- (CA INDEX NAME)




RN 514842-79-6 CAPLUS

CN 5-Pyrimidinamine, 2-chloro-N,N-dimethyl-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 514842-80-9 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 5-[2-chloro-5-(1-methylethyl)-4-pyrimidinyl]-4,5,6,7-tetrahydro- (CA INDEX NAME)



RN 514843-44-8 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 5-(2-chloro-5-methyl-4-pyrimidinyl)-4,5,6,7-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 50 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:238711 CAPLUS

DOCUMENT NUMBER: 138:395424

TITLE: Design and Structure-Activity Relationships of 2-Alkyl-3-aminomethyl-6-(3-methoxyphenyl)-7-methyl-8-(2-fluorobenzyl)imidazo[1,2-a]pyrimidin-5-ones as Potent GnRH Receptor Antagonists

AUTHOR(S): Zhu, Yun-Fei; Guo, Zhiqiang; Gross, Timothy D.; Gao, Yinghong; Connors, Patrick J., Jr.; Struthers, R. Scott; Xie, Qiu; Tucci, Fabio C.; Reinhart, Greg J.; Wu, Dongpei; Saunders, John; Chen, Chen

CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Exploratory Discovery, Neurocrine Biosciences Inc., San Diego, CA, 92121, USA

SOURCE: Journal of Medicinal Chemistry (2003), 46(9), 1769-1772

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:395424

AB SAR studies of 7-phenylpyrrolo[1,2-a]pyrimidin-4-ones and 2-phenylimidazo[1,2-a]pyrimidines as nonpeptide human GnRH receptor antagonists, lead us to believe that the aromatic ring at position-2 of the pyrimidines is no longer crucial for the binding once an aryl group is incorporated at position-6. We report here the use of a 2-alkyl group on the imidazo[1,2-a]pyrimidinone core to generate potent GnRH receptor antagonists. This discovery enabled us to obtain smaller but equally potent GnRH receptor antagonists.


IT 528859-54-3P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and structure-activity relationships of imidazolopyrimidones as GnRH receptor antagonists)

RN 528859-54-3 CAPLUS

CN Pyrido[4',3':4,5]imidazo[1,2-a]pyrimidin-4(1H)-one, 1-[(2-fluorophenyl)methyl]-6,7,8,9-tetrahydro-3-(3-methoxyphenyl)-2,9,9-trimethyl-7-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 51 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:154378 CAPLUS

DOCUMENT NUMBER: 138:205082

TITLE: Preparation of bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF- $\alpha$  converting enzyme (TACE) for treating inflammatory disorders

INVENTOR(S): Sheppeck, James; Duan, Jingwu

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company Patent Department, USA

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016248	A2	20030227	WO 2002-US26018	20020815
WO 2003016248	A3	20031023		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002324716	A1	20030303	AU 2002-324716	20020815
US 20030130257	A1	20030710	US 2002-219426	20020815
US 6770647	B2	20040803		

PRIORITY APPLN. INFO.:

US 2001-313052P P 20010817  
WO 2002-US26018 W 20020815

OTHER SOURCE(S): MARPAT 138:205082

GI



AB The title compds. [I; A = CONHOH, CONHOR5, CONHOR6, N(OH)COR5, N(OH)CHO, CH2SH; ring B, including B1 and B2, = (un)substituted 5-7 membered heterocyclic ring; B1, B2 consist of 0-3 carbon atoms and 0-1 heteroatoms

selected from O, N, and SOp and are substituted with 0-1 carbonyl groups; ring C = (un)substituted 5-10 membered aromatic ring consisting of 1-9 carbon atoms and 0-4 heteroatoms selected from O, N, and SOp; R1 = {4-[(2-methyl-4-quinolinyl)methoxy]phenyl}acetyl, {4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl, etc.; R5 = (un)substituted alkyl; R6 = Ph, naphthyl, cycloalkyl, etc.], useful as inhibitors of matrix metalloproteinases (MMP), TNF- $\alpha$  converting enzyme (TACE), aggrecanase, or a combination thereof, were prepared and formulated. E.g., a 5-step synthesis of II as bis-TFA salt, starting from 2,3-dimethylpyrazine, was given. A number of compds. I were found to exhibit Ki's of  $\leq 10$   $\mu$ M in MMP assays.


IT 1064661-27-3 1064661-29-5

RL: PRPH (Prophetic)

(Preparation of bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF- $\alpha$  converting enzyme (TACE) for treating inflammatory disorders)


RN 1064661-27-3 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-6-carboxamide, 4,5,6,7-tetrahydro-N-hydroxy-5-[[1,2,3,4-tetrahydro-6-[(2-methyl-4-quinolinyl)methyl]-1-isoquinolinyl]carbonyl]- (CA INDEX NAME)



RN 1064661-29-5 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-6-carboxamide, 4,5,6,7-tetrahydro-N-hydroxy-5-[[1,2,3,4-tetrahydro-6-[(2-methyl-4-quinolinyl)methoxy]-1-isoquinolinyl]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 52 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:641082 CAPLUS

DOCUMENT NUMBER: 138:170028

TITLE: Tetrahydrothienopyridylbutyltetrahydrobenzindoles: new selective ligands of the 5-HT<sub>7</sub> receptor  
AUTHOR(S): Kikuchi, Chika; Hiranuma, Toyokazu; Koyama, Masao  
CORPORATE SOURCE: Pharmaceutical Research Center, Meiji Seika Kaisha, Kohoku-ku, Yokohama, 222-8567, Japan  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(18), 2549-2552  
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:170028


AB The synthesis and the affinity for the 5-HT<sub>7</sub> receptor and other receptors of a novel series of fused-ring tetrahydropyridine derivs. are described. Some of the compds. showed high affinity for the 5-HT<sub>7</sub> receptor. Tetrahydrothienopyridylbutyltetrahydrobenzindoles are potent ligands for the 5-HT<sub>7</sub> receptor, with high selectivity over the 5-HT<sub>2</sub> receptor and other receptors. These compds. should be useful tools for clarifying the biol. role of the 5-HT<sub>7</sub> receptor.

IT 230301-50-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of tetrahydrothienopyridylbutyltetrahydrobenzindoles and related compds. as selective ligands for the 5-HT<sub>7</sub> receptor)

RN 230301-50-5 CAPLUS

CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 53 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:521731 CAPLUS

DOCUMENT NUMBER: 137:78966

TITLE: Preparation of substituted 3H-quinazolin-4-ones and 2H-benzo[1,2,4]thiadiazine-1,1-dioxides as alpha 1A/B adrenergic receptor antagonists for treatment of urinary tract disorders, sexual dysfunction, or pain

INVENTOR(S): Becker, Cyrus Kephra; Caroon, Jon Marie; Melville, Chris Richard; Padilla, Fernando; Pfister, Juerg Roland; Zhang, Xiaoming

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053558	A1	20020711	WO 2001-EP14885	20011217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432578	A1	20020711	CA 2001-2432578	20011217
CA 2432578	C	20080401		
AU 2002234586	A1	20020716	AU 2002-234586	20011217
BR 2001016662	A	20030923	BR 2001-16662	20011217
EP 1363899	A1	20031126	EP 2001-985417	20011217
EP 1363899	B1	20050511		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004519454	T	20040702	JP 2002-554677	20011217
JP 4031363	B2	20080109		
AT 295362	T	20050515	AT 2001-985417	20011217
ES 2241891	T3	20051101	ES 2001-985417	20011217
CN 1237060	C	20060118	CN 2001-821713	20011217
US 20030069230	A1	20030410	US 2002-40319	20020102
US 6900220	B2	20050531		
MX 2003005854	A	20030910	MX 2003-5854	20030626
ZA 2003005038	A	20040927	ZA 2003-5038	20030628
US 20050107365	A1	20050519	US 2004-971522	20041022
US 7091200	B2	20060815		

PRIORITY APPLN. INFO.:


US 2001-259337P	P	20010102
US 2001-325267P	P	20010927
WO 2001-EP14885	W	20011217
US 2002-40319	A3	20020102

OTHER SOURCE(S): MARPAT 137:78966

GI



I



II


- AB Title compds. I [wherein X = C or N; Y = C; A = fused 5-6 membered (hetero)aromatic ring; Z = CO or SO<sub>2</sub>; R = alkyl; R<sub>1</sub> = H, alkyl, or (un)substituted aryl(alkyl) or arylaminocarbonyl; R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> = independently H, alkyl, hydroxy(alkyl), alkoxy(alkyl), halo(alkyl), cyano(alkyl), or (un)substituted cycloalkyl(alkyl), aryl(alkyl), heterocyclyl(alkyl), heteroaryl(alkyl), amino(alkyl), ureido, sulfamoyl, acyl, carbamoyl, etc.; or C<sub>2</sub>R<sub>2</sub>R<sub>3</sub> = (un)substituted (hetero)aryl; and isomers, pharmaceutically acceptable salts, or solvates thereof] were prepared as selective alpha-1A/B adrenoceptor antagonists. For example, 3-chloro-6,7-dimethoxy-2H-benzo[1,2,4]thiadiazine-1,1-dioxide and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline were refluxed in methoxyethanol for 72 h to give II. In [3H]prazosin binding assays, the latter exhibited pK<sub>i</sub> values of 8.15, 8.79, and 7.18, resp., for binding toward α1A, α1B, and α1D adrenoceptor transfected CHO-K1 cells. Thus, I are useful for the treatment of urinary tract disorders and their symptoms, sexual dysfunction, or pain (no data). In addition, the subtype selectivity of I is expected to reduce the incidence of dose-limiting side effects, such as cardiovascular and CNS effects.
- IT 441065-08-3P, 2-(1-Benzyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy-3H-quinazolin-4-one 441065-09-4P, 6,7-Dimethoxy-2-(1-(m-tolyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-1H-quinazolin-4-one 441065-12-9P, 6,7-Dimethoxy-2-(1-phenyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-3H-quinazolin-4-one 441065-13-0P, 6,7-Dimethoxy-2-(3-phenyl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-3H-quinazolin-4-one 441065-14-1P, 6,7-Dimethoxy-2-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-3H-quinazolin-4-one 441065-16-3P, 2-[1-(4-Chlorophenyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy-3H-quinazolin-4-one 441065-17-4P, 6,7-Dimethoxy-2-[1-(naphthalen-2-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-3H-quinazolin-4-one 441065-18-5P, 6,7-Dimethoxy-2-[1-(4-methoxyphenyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-3H-quinazolin-4-one 441065-19-6P, 2-[1-(2-Chlorophenyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy-3H-quinazolin-4-one 441065-20-9P, 2-[1-(3-Chlorophenyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy-3H-quinazolin-4-one 441065-21-0P, 6,7-Dimethoxy-2-[1-(3-trifluoromethylphenyl)-1,4,6,7-tetrahydroimidazo[4,5-

c]pyridin-5-yl]-3H-quinazolin-4-one 441065-22-1P,  
 2-(1-Benzo[1,3]dioxol-5-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-  
 6,7-dimethoxy-3H-quinazolin-4-one 441065-23-2P,  
 2-(1-Isobutyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy-  
 1H-quinazolin-4-one 441065-24-3P,  
 6,7-Dimethoxy-2-[1-(3-methoxypropyl)-1,4,6,7-tetrahydroimidazo[4,5-  
 c]pyridin-5-yl]-1H-quinazolin-4-one 441065-25-4P,  
 2-(1-Cycloheptyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-6,7-  
 dimethoxy-1H-quinazolin-4-one 441065-26-5P,  
 2-(1-sec-Butyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy-  
 1H-quinazolin-4-one 441065-27-6P,  
 6,7-Dimethoxy-2-[1-(1-methylbutyl)-1,4,6,7-tetrahydroimidazo[4,5-d]pyridin-  
 5-yl]-1H-quinazolin-4-one 441065-28-7P,  
 6,7-Dimethoxy-2-[1-(2-methylbutyl)-1,4,6,7-tetrahydroimidazo[4,5-d]pyridin-  
 5-yl]-1H-quinazolin-4-one 441065-29-8P,  
 2-(1-Cyclohexyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-6,7-  
 dimethoxy-1H-quinazolin-4-one 441065-30-1P,  
 6,7-Dimethoxy-2-[1-(tetrahydrofuran-2-ylmethyl)-1,4,6,7-  
 tetrahydroimidazo[4,5-c]pyridin-5-yl]-1H-quinazolin-4-one  
 441065-31-2P, 2-(1-Cyclopentyl-1,4,6,7-tetrahydroimidazo[4,5-  
 c]pyridin-5-yl)-6,7-dimethoxy-1H-quinazolin-4-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(a1 adrenergic receptor antagonist; preparation of quinazolinones and  
 benzothiadiazines as a1 adrenergic receptor antagonists for  
 treatment of urinary tract disorders, sexual dysfunction, or pain)


RN 441065-08-3 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(phenylmethyl)-  
 5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-09-4 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(3-  
 methylphenyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-12-9 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-(1,4,6,7-tetrahydro-1-phenyl-5H-  
 imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 441065-13-0 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-(3,4,6,7-tetrahydro-3-phenyl-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 441065-14-1 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 441065-16-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-(4-chlorophenyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy- (CA INDEX NAME)




RN 441065-17-4 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(2-naphthalenyl)-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 441065-18-5 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(4-methoxyphenyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-19-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-(2-chlorophenyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy- (CA INDEX NAME)




RN 441065-20-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-(3-chlorophenyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy- (CA INDEX NAME)




RN 441065-21-0 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-[3-(trifluoromethyl)phenyl]-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-22-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-(1,3-benzodioxol-5-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy- (CA INDEX NAME)




RN 441065-23-2 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(2-methylpropyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-24-3 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(3-methoxypropyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-25-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-(1-cycloheptyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy- (CA INDEX NAME)




RN 441065-26-5 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(1-methylpropyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-27-6 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(1-methylbutyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-28-7 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(2-methylbutyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)




RN 441065-29-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(1-cyclohexyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy- (CA INDEX NAME)




RN 441065-30-1 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-[(tetrahydro-2-furanyl)methyl]-5H-imidazo[4,5-c]pyridin-5-yl]- (CA INDEX NAME)



RN 441065-31-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(1-cyclopentyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy- (CA INDEX NAME)



REFERENCE COUNT:



6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 54 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:315471 CAPLUS  
 DOCUMENT NUMBER: 136:325431  
 TITLE: Preparation of 2-biphenyl 4-piperidinyl ureas having muscarinic receptor antagonist activity  
 INVENTOR(S): Mammen, Mathai; Oare, David  
 PATENT ASSIGNEE(S): Theravance, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U. S. Ser. No.456,170, abandoned.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 31  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020049195	A1	20020425	US 2000-732514	20001207
US 6635764	B2	20031021		
US 6693202	B1	20040217	US 2000-645609	20000825
EP 1457488	A1	20040915	EP 2004-12859	20001207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
ES 2225275	T3	20050316	ES 2000-982493	20001207
ES 2243333	T3	20051201	ES 2000-983991	20001207
CN 1271054	C	20060823	CN 2000-816702	20001207
ZA 2002004553	A	20030908	ZA 2002-4553	20020606
ZA 2002004557	A	20030908	ZA 2002-4557	20020606
US 20040110229	A1	20040610	US 2003-425368	20030429
US 7456203	B2	20081125		
US 20040054187	A1	20040318	US 2003-426364	20030430
US 20040116706	A1	20040617	US 2003-426270	20030430
PRIORITY APPLN. INFO.:				
			US 1999-456170	B2 19991207
			US 1999-120287P	P 19990216
			US 1999-325725	B2 19990604
			US 2000-645609	A1 20000825
			EP 2000-982493	A3 20001207
			US 2000-732514	A1 20001207
OTHER SOURCE(S):				
GI				
MARPAT 136:325431				



AB The title compds. L1XL2 [L1 = I (wherein A = (hetero)aryl; B2 = NRA; Ra = H, alkyl, etc.; R1 = H, alkyl; R2 = heteroaryl, etc.; K1 = a bond, alkylene; K2 = a bond, CO, SO<sub>n</sub>, etc.; n = 0-2; B = heterocycloamino, heteroarylamino); X = a linker; L2 = an organic group comprising at least one primary, secondary, or tertiary amine] which are muscarinic receptor antagonists and agonists (biol. data given), were prepared and formulated. E.g., a 2-step preparation of the intermediate II [R = H] starting with biphenyl-2-isocyanate and 4-amino-N-benzylpiperidine, was given. Mass spec data for 643 compds. II [R = XL2] such as II [X = CH<sub>2</sub>CH(OH)CH<sub>2</sub>; L2 = 4-[2-(N-phenyl-N-methylamino)-2-oxoethyl]piperazin-1-yl], were presented.

IT 344433-19-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-biphenyl 4-piperidinyl ureas having muscarinic receptor antagonist activity)

RN 344433-19-8 CAPLUS

CN 3H-imidazo[4,5-c]pyridine-6-carboxylic acid,  
5-[9-[4-[[[1,1'-biphenyl]-2-ylamino]carbonyl]amino]-1-piperidinyl]nonyl]-  
4,5,6,7-tetrahydro-, (6S)- (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 2002:270662 CAPLUS

DOCUMENT NUMBER: 136:294827

TITLE: Preparation of imidazothiazole derivatives as ligands for metabotropic glutamate receptor

INVENTOR(S): Hayashibe, Satoshi; Itahana, Hirotsune; Okada, Shoji; Ohara, Atsuyuki; Negoro, Kenji; Nozawa, Shigenori; Kamikubo, Takashi; Sakamoto, Shuichi

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002105085	A	20020410	JP 2000-296124	20000928
PRIORITY APPLN. INFO.: OTHER SOURCE(S): GI	MARPAT 136:294827		JP 2000-296124	20000928



I

Q=



Q1=



AB The title compds. [I; R1, R2 = H, lower alkyl, cycloalkyl; R3 = H, lower alkyl; R4, R5 = H, halo, NO2, (un)substituted lower alkyl, aryl, heteroaryl, COR9, NHCO-O-lower alkyl, CR8:CR6R7, CR8R5aC(:CH2)R7; or R4 and R5 together represent Q, Q1; ring A = (un)substituted carbocyclic or aromatic heterocyclic ring optionally possessing 1 or 2 double bond(s); wherein the ring atoms are carbon atoms or may contain 1-3 heteroatoms; R6, R7 = H, (un)substituted lower alkyl, aryl, or heteroaryl, lower alkoxy, carbonyl, COR9, or R6 and R7 are combined together to represent cycloalkyl or (un)saturated heterocyclic ring; R6a = NR10R11; wherein R10, R11 = H, (un)substituted lower alkyl or R10 and R11 together form (un)substituted heteroaryl or saturated heterocyclic ring; X = O, H] or pharmacol. acceptable salts thereof are prepared. These compds. are useful as agonists and/or antagonists for metabotropic glutamate receptor (mGluR1), in particular in the prevention or treatment of cerebral infarction (no data). Thus, a solution of 2.5 g Et imidazo[2,1-b]thiazole-2-carboxylate in 100 mL methanol was treated with 30 mL 1 M aqueous NaOH, stirred at room temperature for 2 h, refluxed for 15 min,

cooled to room temperature, and treated with 1 M aqueous HCl followed by distilling off

the solvent under reduced pressure, to give crude imidazo[2,1-b]thiazole-2-carboxylic acid hydrochloride (II). II was dissolved in 30 mL DMF, treated with 3.3 mL N-methylmorpholine and 1.43 mL Et chloroformate at -10°, and stirred at the same temperature for 3 h to give, after workup and conversion into the HCl salt, N-cyclohexyl-N-methylimidazo[2,1-b]thiazole-2-carboxamide hydrochloride.

IT 409062-75-5P 409062-76-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of imidazothiazole derivs. as ligands for metabotropic glutamate receptor in prevention or treatment of cerebral infarction)

RN 409062-75-5 CAPLUS


CN Thiazolo[2',3':2,3]imidazo[4,5-c]pyridine-2-carboxamide,  
N-cyclohexyl-5,6,7,8-tetrahydro-N-methyl-6-(2-pyridinyl)-, hydrochloride  
(1:2) (CA INDEX NAME)



● 2 HCl

RN 409062-76-6 CAPLUS


CN Thiazolo[2',3':2,3]imidazo[4,5-c]pyridine-2-carboxamide,  
N-cyclohexyl-5,6,7,8-tetrahydro-N-methyl-6-(2-thiazolyl)-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 56 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:816647 CAPLUS  
 DOCUMENT NUMBER: 135:357948  
 TITLE: Preparation of heterocyclic compounds as  
 phosphodiesterase V (PDE V) inhibitors  
 INVENTOR(S): Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji;  
 Kikkawa, Kohei  
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 207 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041142	A	20011112	AU 2001-41142	20010315
CA 2407231	A1	20021023	CA 2001-2407231	20010315
EP 1277741	A1	20030122	EP 2001-912373	20010315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 522217	A	20040430	NZ 2001-522217	20010315
CN 1657523	A	20050824	CN 2004-10098098	20010315
AU 2001241142	B2	20050922	AU 2001-241142	20010315
US 20030229089	A1	20031211	US 2002-258545	20021025
US 7220736	B2	20070522		
MX 2002010693	A	20030310	MX 2002-10693	20021028
US 20040142930	A1	20040722	US 2003-699804	20031104
US 7273868	B2	20070925		
AU 2005203687	A1	20050908	AU 2005-203687	20050817
US 20080027037	A1	20080131	US 2007-889749	20070816
AU 2008203475	A1	20080828	AU 2008-203475	20080804
PRIORITY APPLN. INFO.:			JP 2000-130371	A 20000428
			JP 2000-277652	A 20000913
			AU 2001-241142	A 20010315
			AU 2001-41142	A3 20010315
			WO 2001-JP2034	W 20010315
			US 2002-258545	A2 20021025
			US 2003-699804	A3 20031104
			AU 2005-203687	A3 20050817
OTHER SOURCE(S):		MARPAT 135:357948		
GI				




AB Compds. of the general formula (I) or pharmacol. acceptable salts thereof [wherein X is :CH or N; Y is NH, NR<sub>4</sub>, S, O, CH:N, N:CH, N:N, CH:CH, or the like; R<sub>1</sub> is lower alkoxy, amino, a nitrogenous heterocyclic group, or a hydroxyl group substituted with a heterocyclic group (wherein each group may be substituted); R<sub>2</sub> is either a lower alkylamino or lower alkoxy group which may be substituted with aryl, or a lower alkoxy group substituted with a nitrogenous aromatic heterocyclic group; and R<sub>3</sub> is aryl, a nitrogenous heterocyclic group, lower alkyl, lower alkoxy, lower cycloalkoxy, a hydroxyl group substituted with a nitrogenous heterocyclic group, or amino (wherein each group may be substituted), or alternatively, R<sub>3</sub> and the substituent of Y may be united to form a lactone ring] or pharmacol. acceptable salts thereof are prepared. These compds. exhibit excellent PDE V inhibitory activity and are useful as preventive or therapeutic agents for various diseases due to dysfunction of the signal transduction through cGMP, in particular impotence, pulmonary hypertension, and diabetic renal failure paralysis (no data). Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF at room temperature for 30 min and then condensed with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine (preparation given) in THF at room temperature for 1 h to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.

IT 372115-31-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocyclic compds. as phosphodiesterase V inhibitors preventive or therapeutic agents for various diseases due to dysfunction of signal transduction through cGMP)

RN 372115-31-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[3-(3-chloro-4-methoxyphenyl)methyl]amino]-N-(3-hydroxypropyl)-2-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 57 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:676266 CAPLUS

DOCUMENT NUMBER: 135:226997

TITLE: Preparation of benzimidazolyl- or imidazopyridinyl-substituted phenyl dimethylpropionates as elastase inhibitors

INVENTOR(S): Statkow, Pierre; Straumann, Danielle; Chatterjee, Shyam; Alvarez-builla, Gomez Julio; Sunkel, Letelier Carlos; Fau, De Casa-juana Munoz Miguel; Minguez, Ortega Jose M.; Paz, Matia Martin M.

PATENT ASSIGNEE(S): Cermol S.A., Switz.

SOURCE: Eur. Pat. Appl., 43 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1132381	A1	20010912	EP 2000-104916	20000308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001066526	A1	20010913	WO 2001-IB327	20010306
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 135:226997

EP 2000-104916 A 20000308

GI



AB The title esters [I; X, X1 = H, alkyl, halo, NO2; Y, Y1 = H, alkyl, alkoxy, halo, dialkylamino; Z = H, dialkylaminoalkyl, piperidinylalkyl; V, W = CH, (un)substituted N] and their pharmacol. acceptable salts having an inhibitory activity of elastase (biol. data given), were prepared Thus, reacting 2-(4-hydroxyphenyl)benzimidazole with 2,2-dimethylpropionyl chloride in the presence of Et3N in CH2Cl2 afforded 85% I [X, X1, Y, Y1 = H; V, W = CH; Z = H; the ester function is attached to Ph ring at para-position].

IT 359772-39-7P 359772-42-2P 359772-44-4P


359772-46-6P 359772-48-8P 359772-50-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of benzimidazolyl- or imidazopyridinyl-substituted Ph  
 dimethylpropionates as elastase inhibitors)

RN 359772-39-7 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 4-[5-[2-(1-piperidinyl)ethyl]-5H-  
 imidazo[4,5-c]pyridin-2-yl]phenyl ester (CA INDEX NAME)




RN 359772-42-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 4-[5-[3-(1-piperidinyl)propyl]-5H-  
 imidazo[4,5-c]pyridin-2-yl]phenyl ester, ethanedioate (1:2) (CA INDEX  
 NAME)

CM 1

CRN 359772-41-1

CMF C25 H32 N4 O2



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 359772-44-4 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, 4-[5-[2-[4-[bis(4-fluorophenyl)methyl]-1-  
 piperazinyl]ethyl]-5H-imidazo[4,5-c]pyridin-2-yl]phenyl ester,  
 hydrochloride (1:1) (CA INDEX NAME)






● HCl

RN 359772-46-6 CAPLUS  
 CN Propanoic acid, 2,2-dimethyl-, 4-[5-[3-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]propyl]-5H-imidazo[4,5-c]pyridin-2-yl]phenyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 359772-48-8 CAPLUS  
 CN Propanoic acid, 2,2-dimethyl-, 4-[5-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethyl]-5H-imidazo[4,5-c]pyridin-2-yl]phenyl ester (CA INDEX NAME)



RN 359772-50-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 4-[5-[3-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]propyl]-5H-imidazo[4,5-c]pyridin-2-yl]phenyl ester (CA INDEX NAME)




IT 359772-95-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of benzimidazolyl- or imidazopyridinyl-substituted Ph dimethylpropionates as elastase inhibitors)

RN 359772-95-5 CAPLUS

CN Phenol, 4-[5-[2-(1-piperidinyl)ethyl]-5H-imidazo[4,5-c]pyridin-2-yl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr


IT 359772-57-9P 359772-58-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of benzimidazolyl- or imidazopyridinyl-substituted Ph

dimethylpropionates as elastase inhibitors)


RN 359772-57-9 CAPLUS

CN Phenol, 4-[5-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethyl]-5H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 359772-58-0 CAPLUS

CN Phenol, 4-[5-[3-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]propyl]-5H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 58 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:619582 CAPLUS

DOCUMENT NUMBER: 135:338737

TITLE: Comparative QSAR: Angiotensin II Antagonists

AUTHOR(S): Kurup, Alka; Garg, Rajni; Carini, D. J.; Hansch, Corwin

CORPORATE SOURCE: Department of Chemistry, Pomona College, Claremont, CA, 91711, USA

SOURCE: Chemical Reviews (Washington, D. C.) (2001), 101(9), 2727-2750

CODEN: CHREAY; ISSN: 0009-2665

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A QSAR study was carried out on nonpeptide angiotensin II antagonists which included a review of the literature on bioactivity and derivation of QSAR equations. The QSAR were divided into 4 groups according to the test system: rabbit, rat, guinea pig and human. Within each group, these are arranged according to potency (log I/C). Also listed is the CMR (calculated molar refractivity) which is similar to molar volume but contains a small element for polarizability, and Clog P values which give an assessment of the hydrophobic effects. The authors also used  $\pi$  as a measure of local hydrophobic binding sites. All the QSAR reported in the study were derived by the authors. The physicochem. parameters were autoloading from their C-QSAR databases and the QSAR regression anal. was executed with a C-QSAR program. The authors derived 39 QSAR equations which provide an overview of the structure-activity relationship for a variety of compds. To the authors knowledge, these are the first QSAR for angiotensin antagonists. The most important conclusion reached is the lack of importance of hydrophobic interactions with the receptors. The relevance of the biphenyl moiety for hydrophobicity is discussed and a model of the pharmacophore is presented.


IT 156222-13-8 156222-17-2 177263-98-8

177264-18-5 193753-32-1 193753-33-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(comparative QSAR of nonpeptide angiotensin II antagonists)


RN 156222-13-8 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-oxo-2-(1-pyrrolidinyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-  
(CA INDEX NAME)




RN 156222-17-2 CAPLUS


CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-ethyl-3,5-dihydro-5-[2-oxo-2-(1-piperidinyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-  
(CA INDEX NAME)




RN 177263-98-8 CAPLUS  
 CN Benzenepropanamide, N-[[4'-[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)



RN 177264-18-5 CAPLUS  
 CN Carbamic acid, N-[[4'-[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 193753-32-1 CAPLUS  
 CN Benzenepropanamide, N-[[4'-[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)



RN 193753-33-2 CAPLUS

CN Carbamic acid, N-[[4'-[[4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinylethyl)-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




REFERENCE COUNT:

73


THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 59 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:494661 CAPLUS  
 DOCUMENT NUMBER: 135:242187  
 TITLE: Synthesis of phenothiazine derivatives of spinaceamine and 2-azaspinaceamine  
 AUTHOR(S): Yutilov, Yu. M.; Smolyar, N. N.; Abramyan, M. G.; Tyurenkov, I. N.  
 CORPORATE SOURCE: Litvinenko Institute of Organic Chemistry, National Academy of Sciences of the Republic of Ukraine, Donetsk, Ukraine  
 SOURCE: Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2001), 35(1), 15-17  
 CODEN: PCJOAU; ISSN: 0091-150X  
 PUBLISHER: Consultants Bureau  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 135:242187  
 AB Triazolo[4,5-c]pyridines and imidazo[4,5-c]pyridines are added to 2-chloro-10-( $\beta$ -chloropropionyl)phenothiazine, then reduced to give the spinaceamine and azaspinaceamine phenothiazine derivs.  
 IT 360794-55-4P 360794-56-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis of phenothiazine derivs. of spinaceamine and 2-azaspinaceamine)  
 RN 360794-55-4 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 5-[3-(2-chloro-10H-phenothiazin-10-yl)-3-oxopropyl]-1-methyl-, chloride (1:1) (CA INDEX NAME)




● Cl<sup>-</sup>

RN 360794-56-5 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 5-[3-(2-chloro-10H-phenothiazin-10-yl)-3-oxopropyl]-1,2-dimethyl-, chloride (1:1) (CA INDEX NAME)



● C1<sup>-</sup>


IT 360794-59-8P 360794-60-1P 360794-61-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis of phenothiazine derivs. of spinaceamine and  
 2-azaspinaceamine)  
 RN 360794-59-8 CAPLUS  
 CN 1-Propanone, 1-(2-chloro-10H-phenothiazin-10-yl)-3-(1,4,6,7-tetrahydro-1,2-  
 methyl-5H-imidazo[4,5-c]pyridin-5-yl)-, hydrochloride (1:2) (CA INDEX  
 NAME)



●2 HCl


RN 360794-60-1 CAPLUS  
 CN 1-Propanone, 1-(2-chloro-10H-phenothiazin-10-yl)-3-(1,4,6,7-tetrahydro-1,2-  
 dimethyl-5H-imidazo[4,5-c]pyridin-5-yl)-, hydrochloride (1:2) (CA INDEX  
 NAME)





● 2 HCl

RN 360794-61-2 CAPLUS  
 CN 1-Propanone, 1-(2-chloro-10H-phenothiazin-10-yl)-3-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)





REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 60 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:435045 CAPLUS  
 DOCUMENT NUMBER: 135:46100  
 TITLE: Preparation of 2-biphenyl 4-piperidinyl ureas having  
 muscarinic receptor antagonist activity  
 INVENTOR(S): Mammen, Mathai; Oare, David  
 PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA  
 SOURCE: PCT Int. Appl., 162 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 31  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042213	A1	20010614	WO 2000-US33155	20001207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6693202	B1	20040217	US 2000-645609	20000825
CA 2392030	A1	20010614	CA 2000-2392030	20001207
BR 2000015963	A	20020806	BR 2000-15963	20001207
EP 1235803	A1	20020904	EP 2000-982493	20001207
EP 1235803	B1	20040714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002003677	A2	20030328	HU 2002-3677	20001207
JP 2003516391	T	20030513	JP 2001-543514	20001207
NZ 518722	A	20040326	NZ 2000-518722	20001207
AT 271039	T	20040715	AT 2000-982493	20001207
EP 1457488	A1	20040915	EP 2004-12859	20001207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
ES 2225275	T3	20050316	ES 2000-982493	20001207
AU 782232	B2	20050714	AU 2001-19518	20001207
ES 2243333	T3	20051201	ES 2000-983991	20001207
CN 1271054	C	20060823	CN 2000-816702	20001207
KR 748150	B1	20070809	KR 2002-707147	20020604
NO 2002002683	A	20020702	NO 2002-2683	20020606
NO 323544	B1	20070611		
ZA 2002004553	A	20030908	ZA 2002-4553	20020606
ZA 2002004557	A	20030908	ZA 2002-4557	20020606
MX 2002005602	A	20040910	MX 2002-5602	20020606
HR 2002000574	B1	20071231	HR 2002-574	20020704
HK 1049483	A1	20050218	HK 2003-101572	20030303
US 20040110229	A1	20040610	US 2003-425368	20030429
US 7456203	B2	20081125		
PRIORITY APPLN. INFO.:			US 1999-456170	A2 19991207
			US 1999-120287P	P 19990216
			US 1999-325725	B2 19990604
			US 2000-645609	A1 20000825
			EP 2000-982493	A3 20001207
			WO 2000-US33155	W 20001207

OTHER SOURCE(S): MARPAT 135:46100  
 GI



AB The title compds. L1XL2 [I; L1 = II (wherein A = (hetero)aryl; B2 = NRA; Ra = H, alkyl, etc.; R1 = H, alkyl; R2 = heteroaryl, etc.; K1 = a bond, alkylene; K2 = a bond, CO, SO<sub>n</sub>, etc.; n = 0-2; B = heterocycloamino, heteroarylamino); X = a linker; L2 = an organic group comprising at least one primary, secondary, or tertiary amine] which are muscarinic receptor antagonists and agonists (biol. data given), were prepared and formulated. E.g., a 2-step preparation of the intermediate III [R = H] starting with biphenyl-2-isocyanate and 4-amino-N-benzylpiperidine, was given. Mass spec data for 643 compds. III [R = XL2] were presented.


IT 344433-19-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 2-biphenyl 4-piperidinyl ureas having muscarinic receptor antagonist activity)

RN 344433-19-8 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-6-carboxylic acid,  
5-[9-[4-[[[1,1'-biphenyl]-2-ylamino]carbonyl]amino]-1-piperidinyl]nonyl]-  
4,5,6,7-tetrahydro-, (6S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 61 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:756706 CAPLUS

DOCUMENT NUMBER: 133:321882

TITLE: Preparation of substituted fused imidazoles for treatment and/or prevention of diseases and disorders related to the histamine H3 receptor

INVENTOR(S): Dorwald, Florencio Zaragoza; Andersen, Knud Erik; Jorgensen, Tine Krogh; Peschke, Bernd; Wulff, Birgitte Schjellerup; Pettersson, Ingrid; Rudolf, Klaus; Stenkamp, Dirk; Hurnaus, Rudolf; Muller, Stephan Georg; Krist, Bernd

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Boehringer Ingelheim International, G.m.b.H.

SOURCE: PCT Int. Appl., 169 pp.

DOCUMENT TYPE: CODEN: PIXXD2

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: English



PATENT INFORMATION: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063208	A1	20001026	WO 2000-DK179	20000413
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6908926	B1	20050621	US 2000-548081	20000412
EP 1173438	A1	20020123	EP 2000-918714	20000413
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002542245	T	20021210	JP 2000-612298	20000413
PRIORITY APPLN. INFO.:			DK 1999-508	A 19990416
			DK 1999-1345	A 19990922
			DK 2000-42	A 20000112
			US 1999-130192P	P 19990420
			US 1999-156496P	P 19990928
			US 2000-176709P	P 20000118
			WO 2000-DK179	W 20000413

OTHER SOURCE(S): MARPAT 133:321882

GI



- AB The title compds. [I; R1 = H, a functional group which can be converted to H in vivo; R2 = H, alkyl, halo, etc.; R3-R6 = H, CO2H, alkoxycarbonyl, etc.; m, n, p, q = 0-2; X = a bond, CH2, CO, etc.; Y = a bond, O, NR12 (R12 = H, alkyl, aryl, etc.); A = a bond, alkylene, alkenylene, etc.; Z = R13, OR13, SR13, etc. (R13 = H, alkyl, aryl, etc.)], useful for the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor (more particularly, useful for the treatment and/or prevention of diseases and disorders, in which an interaction with the histamine H3 receptor is beneficial), were prepared and formulated. E.g., treatment of 5-cyclohexylpentanoic acid with carbonyldiimidazole in DCM followed by addition of 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine in DCM afforded 24% II. Compds. I are effective at 0.05-10 mg/kg/day.
- IT 303019-87-6P 303020-61-3P 303020-64-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted fused imidazoles for treatment and/or prevention of diseases and disorders related to the histamine H3 receptor)
- RN 303019-87-6 CAPLUS
- CN 1-Propanone, 3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)




RN 303020-61-3 CAPLUS

CN Methanone, [4-(phenylmethyl)-1-piperidiny] (3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 303020-60-2

CMF C19 H24 N4 O



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 303020-64-6 CAPLUS

CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl) (3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (CA INDEX NAME)



REFERENCE COUNT:


1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 62 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:421114 CAPLUS  
 DOCUMENT NUMBER: 133:58803  
 TITLE: Preparation of 2-arylidole- or  
 -benzimidazolecarboxamidines and analogs as serine  
 protease inhibitors  
 INVENTOR(S): Allen, Darin Arthur; Hataye, Jason M.; Hruzewicz,  
 Witold N.; Kolesnikov, Aleksandr; Mackman, Richard  
 Laurence; Rai, Roopa; Spencer, Jeffrey R.; Verner,  
 Erik J.; Young, Wendy B.  
 PATENT ASSIGNEE(S): Axy's Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 187 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035886	A2	20000622	WO 1999-US30302	19991217
WO 2000035886	A3	20001026		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2355249	A1	20000622	CA 1999-2355249	19991217
EP 1140859	A2	20011010	EP 1999-968917	19991217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9916363	A	20011211	BR 1999-16363	19991217
HU 2001004987	A2	20020729	HU 2001-4987	19991217
HU 2001004987	A3	20020930		
EE 200100323	A	20020815	EE 2001-323	19991217
JP 2002532479	T	20021002	JP 2000-588148	19991217
NZ 512375	A	20031128	NZ 1999-512375	19991217
AU 779117	B2	20050106	AU 2000-27115	19991217
TR 200102533	T2	20060621	TR 2001-2533	19991217
NO 2001002980	A	20010801	NO 2001-2980	20010615
MX 2001006070	A	20010911	MX 2001-6070	20010615
US 6867200	B1	20050315	US 2002-868276	20020118
PRIORITY APPLN. INFO.:			US 1998-113007P	P 19981218
			WO 1999-US30302	W 19991217

OTHER SOURCE(S): MARPAT 133:58803  
 GI




AB R1Z1Z2R2 [I; R1 = H2NC(:NH), etc.; R2 = halo, OH, CO2H, phenyl(alkyl)oxy, etc.; Z1 = (un)substituted indolylene, -benzimidazolylene, etc.; Z2 = (un)substituted phenylene, pyridinediyl, etc.] were prepared Thus, 1-(3-bromo-2-hydroxy-5-methylphenyl)-3-(4-nitrophenyl)-1-propanone was condensed with 4-(H2NHN)C6H4C(:NH)NH2 and the product cyclized to give, after reduction, title compound II. Data for biol. activity of I were given.

IT 277311-63-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 2-arylindole- or -benzimidazolecarboxamides and analogs as serine protease inhibitors)

RN 277311-63-4 CAPLUS

CN 1H-Benzimidazole-6-carboximidamide,  
 2-[3-[5-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-iminoethyl]-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl]-2-hydroxyphenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 63 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:460401 CAPLUS

DOCUMENT NUMBER: 131:87906

TITLE: Preparation of tetrahydrobenzindole derivatives for treatment and prevention of diseases caused by abnormality in serotonin regulatory system

INVENTOR(S): Kikuchi, Chika; Ando, Takashi; Fuji, Kazuyuki; Okuno, Masayo; Satoh, Eriko; Shiiyama, Masako; Ushiroda, Osamu; Koyama, Masao; Hiranuma, Toyokazu

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan

SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933804	A1	19990708	WO 1998-JP5827	19981222
W: CA, CN, JP, KR, NO, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11189585	A	19990713	JP 1997-358381	19971225
CA 2316388	A1	19990708	CA 1998-2316388	19981222
EP 1057814	A1	20001206	EP 1998-961493	19981222
EP 1057814	B1	20050309		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 290527	T	20050315	AT 1998-961493	19981222
NO 2000003285	A	20000823	NO 2000-3285	20000622
NO 317293	B1	20041004		
US 6498251	B1	20021224	US 2001-582416	20010308
PRIORITY APPLN. INFO.:				
			JP 1997-358380	A 19971225
			JP 1997-358381	A 19971225
			JP 1998-85913	A 19980331
			JP 1998-136872	A 19980519
			JP 1998-229709	A 19980814
			JP 1998-319336	A 19981110
			WO 1998-JP5827	W 19981222

OTHER SOURCE(S): MARPAT 131:87906

GI



AB Compds. I [ $\alpha$  = Q1, etc.; R1 = H, alkyl, etc.; R2 = H, halo, etc.; X = NR10, etc. (R10 = H, etc.); n = 2 to 6; R3 = H, etc.] are prepared. Thus, 2a-(4-bromobutyl)-2a,3,4,5-tetrahydro-1H-benz[cd]indol-2-one 150 mg was reacted with 2,3,4,9-tetrahydro-1H-pyrido[2,4-b]indole 168 mg to give 2a-(4-(2,3,4,9-tetrahydro-1H-pyrido[2,4-b]indole)butyl)-2a,3,4,5-tetrahydro-1H-benz[cd]indol-2-one 73 mg, showing Ki values 227 nM in

affinity test to 5-HT<sub>7</sub> receptor, and 7 nM in affinity test to 5-HT<sub>2</sub> receptor.


IT 230301-50-5P 230301-52-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tetrahydrobenzindole derivs. for treatment and prevention of diseases caused by abnormality in serotonin regulatory system)


RN 230301-50-5 CAPLUS

CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]- (CA INDEX NAME)



RN 230301-52-7 CAPLUS

CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:375402 CAPLUS

DOCUMENT NUMBER: 131:19011

TITLE: Preparation of imidazolymethylthienopyridines, -azabenzimidazoles, and related compounds as inhibitors of farnesyl-protein transferase.

INVENTOR(S): Halczenko, Wasyl; Stump, Craig A.

PATENT ASSIGNEE(S): Merck &amp; Co., Inc., USA

SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9927929	A1	19990610	WO 1998-US25324	19981130
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6015817	A	20000118	US 1997-984732	19971204
CA 2311923	A1	19990610	CA 1998-2311923	19981130
AU 9916110	A	19990616	AU 1999-16110	19981130
EP 1035850	A1	20000920	EP 1998-960529	19981130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1997-984732	A1 19971204
			WO 1998-US25324	W 19981130
OTHER SOURCE(S):	MARPAT 131:19011			
GI				



AB Title compds. [I; Y = (R4)rVA1[C(R1a)2]nA2[C(R1a)2]n[W(R5)s]t[C(R1b)2]pX[C(R1c)2]q; Z = (CR2bR2c)u; Z1 = (CH2)u; R1a, R1b, R1c = H, (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, cyano, NO2, N3, R8O, N(R8)2, R8CONR8, etc.; R2a, R2b, R2c = H, [C(R11)2]vA3[C(R12)2]wR13; R2bR2c = O; R3a, R3b = H, (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, halo, perfluoroalkyl, cyano, R8CO, NO2, N3, N(R8)2, etc.; R4 = H, (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R8O, cyano, NO2, R8CO, N(R8)2, N3, etc.; R5 = H, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, F, Cl, Br, R8O, R8O2C, N3, N(R8)2, NO2, R8CO, N3, etc.; R8 = H, alkyl, PhCH2, F3CCCH2, aryl; R11, R12 = H, (substituted) alkyl, aryl, heterocyclyl,


cycloalkyl, alkenyl, halo, R8O, N3, N(R8)2, etc.; R13 = H, (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, allyloxy, cyano, NO2, R8CO, N3, N(R8)2, etc.; A1, A2 = bond, CH:CH, C.tplbond.C, CO, CONR8, O, NR8, S, SO, SO2, etc.; A3 = bond, CH:CH, C.tplbond.C, COO, S, SO, SO2, etc.; J, K, L = N, NH, S, O, CH; V = H, heterocyclyl, aryl, alkenyl, (heteroatom-interrupted) alkyl; W = heterocyclyl; X = bond, S, SO, SO2, O, CO; dotted lines = optional double bonds; r = 0-5; n, p, q = 0-4; s = 1, 2; t = 0, 1; u = 0-2; with provisos), were prepared as drugs (no data). Thus, 4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride, 1-(4-cyanobenzyl)-5-imidazolecarboxaldehyde, Et3N, 4Å mol. sieves, and NaBH(OAc)3 were stirred in CHCl2CHCl2 for 16 h to give 5-[1-(4-cyanobenzyl)-5-imidazolymethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine.

IT 226386-45-4P 226386-49-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of imidazolymethylthienopyridines, -azabenzimidazoles, and related compds. as inhibitors of farnesyl-protein transferase)


RN 226386-45-4 CAPLUS

CN Benzonitrile, 4-[[5-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)-1H-imidazol-1-yl]methyl]- (CA INDEX NAME)



RN 226386-49-8 CAPLUS

CN Benzonitrile, 4-[[5-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)-1H-imidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)



●<sub>4</sub> HCl

REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 65 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:120508 CAPLUS

DOCUMENT NUMBER: 128:249173

ORIGINAL REFERENCE NO.: 128:49249a

TITLE: Synthesis of glycyl-L-spinacine and study of its protonation and Cu(II) complex-formation equilibria in aqueous solution

AUTHOR(S): Conato, Chiara; Remelli, Maurizio; Guerrini, Remo; Pulidori, Fernando

CORPORATE SOURCE: Department of Chemistry, University of Ferrara, Ferrara, I-44100, Italy

SOURCE: Annali di Chimica (Rome) (1998), 88(1-2), 91-102  
CODEN: ANCRAI; ISSN: 0003-4592

PUBLISHER: Societa Chimica Italiana

DOCUMENT TYPE: Journal


LANGUAGE: English

AB A new dipeptide, glycyl-L-spinacine, was synthesized and fully characterized. Protonation consts. were determined and binary Cu(II) complex formation equilibrium investigated in an aqueous solution (25°, I = 0.1 mol dm<sup>-3</sup>, KNO<sub>3</sub>) using the potentiometric and spectrophotometric techniques. Formation of mononuclear and binuclear complex species was found. Binding sites and structure hypotheses are discussed from exptl. and literature data available.

IT 205066-93-9  
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)  
(stability constant)




RN 205066-93-9 CAPLUS

CN Copper, bis[5-[(amino-κN)acetyl-κO]-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylato]-, [SP-4-1-(S),(S)]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 66 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:481748 CAPLUS  
 DOCUMENT NUMBER: 127:205517  
 ORIGINAL REFERENCE NO.: 127:39955a,39958a  
 TITLE: Synthesis of 'A' ring isomazole oxypropanolamines via  
 hydrolysis of 1H-imidazo[4,5-c]pyridine  
 oxazolidin-2-ones  
 AUTHOR(S): Barraclough, Paul; Gillam, Janet; King, W. Richard;  
 Nobbs, Malcolm S.; Vine, Susan J.  
 CORPORATE SOURCE: Department Medicinal Chemistry, Wellcome Research  
 Laboratories, Beckenham, Kent, BR3 3BS, UK  
 SOURCE: Journal of Chemical Research, Synopses (1997), (6),  
 196-197  
 CODEN: JRP5DC; ISSN: 0308-2342  
 PUBLISHER: Royal Society of Chemistry  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 127:205517  
 GI



AB The base-catalyzed hydrolysis of oxazolidin-2-one I gives an  
 oxypropanolamine II and 4,5-dihydro-1H-imidazo[4,5-c]pyridin-4-ones,  
 e.g., III, and may occur by a BAL mechanism.  
 IT 194732-33-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of isomazole oxypropanolamines via hydrolysis of  
 imidazopyridine oxazolidinone)  
 RN 194732-33-7 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-(2,4-dimethoxyphenyl)-3,5-dihydro-5-[1-  
 (1-methylethyl)-3-azetidyl]- (CA INDEX NAME)



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 67 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:478037 CAPLUS

DOCUMENT NUMBER: 127:161749

ORIGINAL REFERENCE NO.: 127:31359a,31362a

TITLE: Novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines. Potent angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes

AUTHOR(S): Mederski, WWKR; Dorsch, D.; Osswald, M.; Schwartz, H.; Beier, N.; Christadler, M.; Minck, KO; Schelling, P.; Schmitges, CJ

CORPORATE SOURCE: Preclinical Pharmaceutical Research, Medicinal Chemistry, Merck KGaA, Darmstadt, 64271, Germany

SOURCE: European Journal of Medicinal Chemistry (1997), 32(6), 479-491

CODEN: EJMCAS; ISSN: 0223-5234

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis and pharmacol. activity of balanced high affinity non-peptide angiotensin II antagonists of the AT1 and AT2 subtype receptors have been presented. A series of previously prepared AT1 selective 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]-pyridines were modified at four different positions in order to increase the AT2 binding affinity by maintaining the nanomolar activity for the AT1 receptor. The targeted AT2/AT1 IC50 binding ratio of .apprx. 1 was achieved with a number of compds. possessing a small alkyl chain at C-2, different acetamide groups at N-5 and a 3-fluoro and 2'-carboxamidomethyl substituent at the biphenylmethyl moiety. These modifications led to an analog which exhibited an AT2/AT1 ratio of 0.74, a subnanomolar AT1 antagonistic potency (0.18 nM) and a high metabolic stability in rat and monkey liver microsomes in vitro. After oral administration of 3 mg/kg to cynomolgus monkeys, EMD 90423 (potassium salt of the active analog) demonstrated good efficacy and a long duration of action as an antihypertensive agent.

IT 177263-98-8P 177264-18-5P 193753-32-1P  
193753-33-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of 4-oxo-3H-imidazo[4,5-c]pyridines as angiotensin II receptor antagonists with high affinity for both AT1 and AT2 subtypes)


RN 177263-98-8 CAPLUS

CN Benzenepropanamide, N-[[4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)

RN 177264-18-5 CAPLUS


CN Carbamic acid, N-[[4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)






RN 193753-32-1 CAPLUS

CN Benzenepropanamide, N-[[4'-[[4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)



RN 193753-33-2 CAPLUS

CN Carbamic acid, N-[[4'-[[4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




IT 193753-08-1P 193753-17-2P 193753-36-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-oxo-3H-imidazo[4,5-c]pyridines as angiotensin II receptor antagonists with high affinity for both AT1 and AT2 subtypes)


RN 193753-08-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-N-(1,1-dimethylethyl)-3'-fluoro- (CA INDEX NAME)




RN 193753-17-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 193753-36-5 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 3-[(4-bromo-2-fluorophenyl)methyl]-3,5-dihydro-5-[2-oxo-2-(1-piperidinyl)ethyl]-2-propyl- (CA INDEX NAME)



REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1997:4343 CAPLUS

DOCUMENT NUMBER: 126:75181

ORIGINAL REFERENCE NO.: 126:14557a,14560a

TITLE: Preparation of erythromycins as bactericides

INVENTOR(S): Agouridas, Constantin; Chantot, Jean Francois; Denis, Alexis; Gouin d'Ambrieres, Solange; Le Martret, Odile

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.

SOURCE: Fr. Demande, 50 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2732684	A1	19961011	FR 1995-4089	19950406
FR 2732684	B1	19970430		
IN 1995DE01167	A	20070112	IN 1995-DE1167	19950623
IN 2008DE01348	A	20080725	IN 2008-DE1348	20080605
PRIORITY APPLN. INFO.:			FR 1995-4089	A 19950406
			IN 1995-DE1167	A3 19950623

OTHER SOURCE(S): MARPAT 126:75181

GI



AB Title erythromycins I (R = substituted heterocycle, n = 3-5, Z = H, carboxylate) were prepared as bactericides. Thus, 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribohexopyranosyl)oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-phenyl-1H-imidazol-1-yl)butyl)imino))erythromycin was prepared and tested for its antibacterial activity.

IT 173838-26-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP

(Preparation)


(preparation of erythromycins as bactericides)

RN 173838-26-1 CAPLUS


CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-11,12-[[[4-(5H-imidazo[4,5-c]pyridin-5-yl)butyl]imino]carbonyloxy]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 69 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:466897 CAPLUS

DOCUMENT NUMBER: 125:142545

ORIGINAL REFERENCE NO.: 125:26677a,26680a

TITLE: Preparation of heterocyclic LTA4 hydrolase inhibitors

INVENTOR(S): Chandrakumar, Nizal Samuel; Chen, Barbara Baosheng; Clare, Michael; Desai, Bipinchandra Nanubhai; Djuric, Steven Wakefield; Docter, Stephan Hermann; Gasiecki, Alan Frank; Haack, Richard Arthur; Liang, Chi-Dean; et al.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: PCT Int. Appl., 342 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611192	A1	19960418	WO 1995-US12365	19951010
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5585492	A	19961217	US 1994-321183	19941011
US 5719306	A	19980217	US 1995-466010	19950606
CA 2202371	A1	19960418	CA 1995-2202371	19951010
AU 9536865	A	19960502	AU 1995-36865	19951010
EP 804427	A1	19971105	EP 1995-934554	19951010
EP 804427	B1	20020918		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 10512848	T	19981208	JP 1996-512608	19951010
EP 1221441	A2	20020710	EP 2002-6764	19951010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 224381	T	20021015	AT 1995-934554	19951010
PT 804427	T	20030131	PT 1995-934554	19951010
ES 2183886	T3	20030401	ES 1995-934554	19951010
PRIORITY APPLN. INFO.:			US 1994-321183	A1 19941011
			EP 1995-934554	A3 19951010
			WO 1995-US12365	W 19951010

OTHER SOURCE(S): MARPAT 125:142545

GI



AB The title compds. Ar1QAr2YRZ [Ar1, Ar2 = (un)substituted aryl; Z = (un)substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or (an) (un)substituted monocyclic or bicyclic nitrogen-containing heteroarom. moiety; Q, Y = linking group; R = alkylene], useful in the treatment of inflammatory diseases which are mediated by LTB4 production [e.g., psoriasis (no data), ulcerative colitis (no data), irritable bowel syndrome (no data), and asthma (no data)], are prepared Thus, 4-phenoxyphenol was condensed with 1-(2-chloroethyl)pyrrolidine

hydrochloride, producing pyrrolidine I, which demonstrated a IC50 of 30 nM in a recombinant human LTA4 hydrolase assay.


IT 179399-04-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic LTA4 hydrolase inhibitors)

RN 179399-04-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[2,3-dihydro-5-(phenylmethyl)-2-benzofuranyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 70 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:452004 CAPLUS

DOCUMENT NUMBER: 125:142725

ORIGINAL REFERENCE NO.: 125:26717a,26720a

TITLE: LTA4-Hydrolase inhibitors, pharmaceutical

compositions, and methods of use

INVENTOR(S): Chandrakumar, Nizal Samuel; Chen, Barbara Baosheng; Clare, Michael; Desai, Bipinchandra Nanubhai; Djuric, Steven Wakefield; Docter, Stephan Hermann; Gasiecki, Alan Frank; Haack, Richard Arthur; Liang, Chi-Dean; et al.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: PCT Int. Appl., 362 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 9610999	A2	19960418	WO 1995-US12367	19951010
WO 9610999	A3	19960919		
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6506876	B1	20030114	US 1994-321184	19941011
US 5723492	A	19980303	US 1995-469606	19950606
CA 2202368	A1	19960418	CA 1995-2202368	19951010
AU 9536866	A	19960502	AU 1995-36866	19951010
EP 786992	A2	19970806	EP 1995-934555	19951010
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
JP 10512542	T	19981202	JP 1995-512609	19951010
PRIORITY APPLN. INFO.:			US 1994-321184	A1 19941011
			WO 1995-US12367	W 19951010

OTHER SOURCE(S): MARPAT 125:142725

GI



II



@ HCl III

AB The invention provides compds. Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof [wherein Ar1 and Ar2 = (un)substituted




(hetero)aryl moieties; Z = (un)substituted N-containing moiety which may be an acyclic, cyclic, or bicyclic amine, or an (un)substituted monocyclic or bicyclic, N-containing, heteroarom. moiety; Q = O, CH<sub>2</sub>, OCH<sub>2</sub>, CH<sub>2</sub>O, NH, NHCH<sub>2</sub>, CH<sub>2</sub>NH, CF<sub>2</sub>, CH:CH, CH<sub>2</sub>CH<sub>2</sub>, or bond; R = alkylene moiety; Y = O, S, NH, S(O), S(O)<sub>2</sub>; Z is bound to R through a N atom]. I and their pharmaceutical comps. are useful in the treatment of inflammatory diseases which are mediated by LTB<sub>4</sub> production, such as psoriasis, ulcerative colitis, inflammatory bowel disease, and asthma. Over 500 examples cover syntheses of various I and precursors, plus results of 3 bioassays. For instance, etherification of 1-(2-hydroxyethyl)pyrrolidine with 2-bromothiazole and NaH gave 74% 2-(2-pyrrolidinoethoxy)thiazole, which was lithiated with BuLi and treated with PhCHO to give the 5-( $\alpha$ -hydroxybenzyl) derivative in 66% yield. This was reduced with Et<sub>3</sub>SiH and CF<sub>3</sub>CO<sub>2</sub>H to give 74% title compound II. In a recombinant human LTA<sub>4</sub> hydrolase assay, title compound III had IC<sub>50</sub> of 2 nM.

IT 179022-94-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of (hetero)aryloxyalkylamines and analogs as LTA<sub>4</sub> hydrolase inhibitors)

RN 179022-94-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[2,3-dihydro-5-(phenylmethyl)-2-benzofuranyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 71 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:337875 CAPLUS

DOCUMENT NUMBER: 125:10809

ORIGINAL REFERENCE NO.: 125:2373a,2376a

TITLE: Preparation of imidazopyridines as cardiovascular agents

INVENTOR(S): Mederski, Werner; Osswald, Mathias; Schelling, Pierre; Minck, Klaus-Otto; Beier, Norbert; Lues, Ingeborg; Dorsch, Dieter

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 702013	A2	19960320	EP 1995-113840	19950904
EP 702013	A3	19960508		
EP 702013	B1	20010613		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4432860	A1	19960321	DE 1994-4432860	19940915
ES 2159589	T3	20011016	ES 1995-113840	19950904
PT 702013	T	20011030	PT 1995-113840	19950904
AU 9531715	A	19960328	AU 1995-31715	19950908
AU 702722	B2	19990304		
SK 282116	B6	20011106	SK 1995-1123	19950911
CA 2158225	A1	19960316	CA 1995-2158225	19950913
CN 1129702	A	19960828	CN 1995-116867	19950913
CN 1046942	C	19991201		
CZ 286739	B6	20000614	CZ 1995-2362	19950913
NO 9503624	A	19960318	NO 1995-3624	19950914
JP 08081466	A	19960326	JP 1995-260957	19950914
ZA 9507754	A	19960409	ZA 1995-7754	19950914
HU 74939	A2	19970328	HU 1995-2688	19950914
HU 220042	B	20011028		
US 5684015	A	19971104	US 1995-528305	19950914
RU 2156251	C2	20000920	RU 1995-115970	19950914
GR 3036339	T3	20011130	GR 2001-401191	20010807
PRIORITY APPLN. INFO.:			DE 1994-4432860	A 19940915

OTHER SOURCE(S): MARPAT 125:10809

GI




AB 3,4-R1(RH2C)C6H4C6H4R2-2 [I; R = imidazopyridinyl group Q; R1 = halo, alkyl, CF3; R2 = alkanoylamino sulfonyl, (un)substituted SO2NHBz, etc.; R3 = (alkoxy)alkyl, alkoxy, alkenyl, etc.; H, (un)substituted alkyl, etc.] were pred. as angiotensin II inhibitors (no data). Thus, QH (R3 = Bu, R4 = H) was alkylated by I (R = Br, R1 = F, R2 = SO2NHMe3) and the product converted in 3 addnl. steps to title compound II.

IT 177263-98-8P 177264-10-7P 177264-18-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazopyridines as cardiovascular agents)


RN 177263-98-8 CAPLUS

CN Benzenepropanamide, N-[[4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)




RN 177264-10-7 CAPLUS

CN Cyclopentanepropanamide, N-[[4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)



RN 177264-18-5 CAPLUS

CN Carbamic acid, N-[[4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)



L3 ANSWER 72 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:119185 CAPLUS

DOCUMENT NUMBER: 124:317157

ORIGINAL REFERENCE NO.: 124:58821a,58824a

TITLE: Platelet activating factor antagonists:  
imidazopyridine indoles

INVENTOR(S): Summers, James B., Jr.; Davidsen, Steven K.; Curtin,  
Michael L.; Heyman, H. Robin; Sheppard, George S.; Xu,  
Lianhong; Carrera, George M., Jr.; Garland, Robert B.  
PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S., 59 pp. Cont.-in-part of U.S. Ser. No. 324,631.  
CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5486525	A	19960123	US 1994-347528	19941205
CA 2176247	A1	19950622	CA 1994-2176247	19941208
WO 9516687	A1	19950622	WO 1994-US14112	19941208
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9513036	A	19950703	AU 1995-13036	19941208
AU 690620	B2	19980430		
EP 734386	A1	19961002	EP 1995-904287	19941208
EP 734386	B1	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 212992	T	20020215	AT 1995-904287	19941208
PT 734386	T	20020731	PT 1995-904287	19941208
ES 2173171	T3	20021016	ES 1995-904287	19941208
PRIORITY APPLN. INFO.:			US 1993-168564	B2 19931216
			US 1994-324631	A2 19941018
			US 1994-347528	A 19941205
			WO 1994-US14112	W 19941208
OTHER SOURCE(S):		CASREACT 124:317157; MARPAT 124:317157		
GI				




I



II



III




AB The present invention relates to compds. of formula I wherein: R1 = one or more of the groups independently selected from, e.g., H, halo, OH, cyano; R2 is selected from the group consisting of, e.g., H, alkyl of one to 6 C atoms; R3 is selected from the group consisting of H and alkyl of one to six C atoms; L1 = e.g., CO, COCH2NR4 where R4 = e.g., H, alkyl of one to six C atoms; Ar1 is radical II where Y is O, S, or CH:CH, Z is N or CH, R11 = e.g., H, alkyl of one to six C atoms; L2 is selected from, e.g., a valence bond, (un)substituted straight-chain alkylene of one to six C atoms; Ar2 is selected from, e.g., substituted benzimidazol-1-yl, imidazopyridine group III where R13 = e.g., alkyl of one to six C atoms, alkenyl of two to six C atoms; R14 and R15 are independently selected from, e.g., H, alkyl of one to six C atoms, alkenyl of two to six C atoms; and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation. Thus, e.g., carbamoylation of 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole (preparation given) with dimethylcarbamoyl chloride afforded 1-N,N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole (IV) which exhibited Ki = 56 nM for inhibition of specific [3H]C18-PAF binding.

IT 170498-03-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(imidazopyridine indoles as platelet activating factor antagonists)

RN 170498-03-0 CAPLUS

CN 1H-Indole-1-carboxamide, 6-(4-fluorophenyl)-N,N-dimethyl-3-[6-(2-methyl-5H-imidazo[4,5-c]pyridin-5-yl)-1-oxohexyl]- (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 73 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:997457 CAPLUS

DOCUMENT NUMBER: 124:176809

ORIGINAL REFERENCE NO.: 124:32815a,32818a

TITLE: Erythromycin derivatives, their process of preparation and their use as medicaments.

INVENTOR(S): Agouridas, Constantin; Chantot, Jean-Francois; Denis, Alexis; Gouin d'Ambrieres, Solange; Le Martret, Odile

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.

SOURCE: Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 680967	A1	19951108	EP 1995-400987	19950502
EP 680967	B1	19981014		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
FR 2719587	A1	19951110	FR 1994-5368	19940503
FR 2719587	B1	19960712		
IL 113245	A	19991130	IL 1995-113245	19950404
US 5635485	A	19970603	US 1995-426067	19950421
JP 08053489	A	19960227	JP 1995-128791	19950501
JP 2992540	B2	19991220		
CA 2189271	A1	19951109	CA 1995-2189271	19950502
CA 2189271	C	20051227		
WO 9529929	A1	19951109	WO 1995-FR565	19950502
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9524499	A	19951129	AU 1995-24499	19950502
AU 684027	B2	19971127		
ZA 9503501	A	19960502	ZA 1995-3501	19950502
HU 75698	A2	19970528	HU 1996-3038	19950502
CN 1151746	A	19970611	CN 1995-193911	19950502
CN 1052984	C	20000531		
BR 9507700	A	19970819	BR 1995-7700	19950502
RO 113350	B1	19980630	RO 1996-2081	19950502
AT 172203	T	19981015	AT 1995-400987	19950502
ES 2122472	T3	19981216	ES 1995-400987	19950502
RU 2144036	C1	20000110	RU 1996-123129	19950502
EE 3263	B1	20000417	EE 1996-151	19950502
HU 219599	B	20010528	HU 1999-4687	19950502
SK 281707	B6	20010710	SK 1996-1402	19950502
PL 182034	B1	20011031	PL 1995-317071	19950502
CZ 293455	B6	20040512	CZ 1996-3214	19950502
FI 9604395	A	19961031	FI 1996-4395	19961031
FI 111263	B1	20030630		
LV 11739	B	19970820	LV 1996-421	19961101
BG 63087	B1	20010330	BG 1996-100951	19961101
NO 9604654	A	19961104	NO 1996-4654	19961104
NO 308853	B1	20001106		
US 6100404	A	20000808	US 1997-780861	19970109
JP 11152296	A	19990608	JP 1998-251817	19980824
JP 3998828	B2	20071031		
HK 1010732	A1	20000519	HK 1998-111758	19981105
CN 1229082	A	19990922	CN 1998-123072	19981207



CN 1088709	C	20020807		
JP 2007045847	A	20070222	JP 2006-314281	20061121
JP 2007269810	A	20071018	JP 2007-150991	20070606
PRIORITY APPLN. INFO.:			FR 1994-5368	A 19940503
			US 1995-426067	A3 19950421
			JP 1995-128791	A3 19950501
			HU 1996-3038	A 19950502
			WO 1995-FR565	W 19950502
			JP 1998-251817	A3 19980824

OTHER SOURCE(S): MARPAT 124:176809

GI



AB Erythromycin cyclic carbamates I [R = (CH<sub>2</sub>)<sub>n</sub>R<sub>1</sub>; R<sub>1</sub> = heteroaryl; Z = H, ester group; n = 3-5] were prepared. Thus, I [n = 4, R<sub>1</sub> = 4-phenyl-1-imidazolyl, Z = Ac, II] was obtained by treating the 12-imidazolecarboxylate with 4-(4-phenyl-1-imidazolyl)-1-butanamine. II had a min. inhibitory concentration against Staphylococcus aureus 011UC4 of 0.04 µg/mL and also had activity against Haemophilus influenzae (no data).


IT 173838-26-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and bactericidal activity of erythromycin cyclic carbamates)

RN 173838-26-1 CAPLUS


CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-11,12-[[[4-(5H-imidazo[4,5-c]pyridin-5-yl)butyl]imino]carbonyloxy]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



ACCESSION NUMBER: 1995:959351 CAPLUS

DOCUMENT NUMBER: 124:175940

ORIGINAL REFERENCE NO.: 124:32627a,32630a

TITLE: 4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridines: potent arylacetic acid-derived AT1 antagonists with improved affinity for the AT2 receptor

AUTHOR(S): Mederski, Werner W. K. R.; Dorsch, Dieter; Osswald, Mathias; Beier, Norbert; Lues, Ingeborg; Minck, Klaus-Otto; Schelling, Pierre; Ladstetter, Bernhard J. Preclinical Pharmaceutical Res., Inst. Pharmacokinetics and Metab., Grafing, 85567, Germany

CORPORATE SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(22), 2665-70


SOURCE: CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I


AB The replacement of dimethylacetamide with arylacetic acid esters and acetamides at the imidazo[4,5-c]pyridine 5-position of EMD 66684 (I, R = X, R1 = H, R2 = NMe2) imparts affinity for the AT2 receptor. The highest affinity was found with the phenylacetic acid iso-Pr ester moiety, which led to compound I (R = H, R1 = Ph, R2 = isopropoxy) with an IC50 value of 32 nM (AT2) and an AT2/AT1 ratio of 5.

IT 173542-04-6P 173542-05-7P 173542-06-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and angiotensin antagonist activity of)

RN 173542-04-6 CAPLUS


CN 4H-imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-(4-morpholinyl)-2-oxo-1-phenylethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-  
(CA INDEX NAME)



RN 173542-05-7 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-oxo-1-phenyl-2-(1-pyrrolidinylethyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-  
 (CA INDEX NAME)



RN 173542-06-8 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-oxo-1-phenyl-2-(1-piperidinylolethyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-  
 (CA INDEX NAME)



ACCESSION NUMBER: 1995:928154 CAPLUS

DOCUMENT NUMBER: 123:340121

ORIGINAL REFERENCE NO.: 123:61043a, 61046a

TITLE: Preparation of 3-[(imidazopyridylalkyl)benzoyl]indoles

and analogs as platelet activating factor antagonists  
Summers, James B., Jr.; Davidsen, Steven K.; Curtin,  
Michael L.; Heyman, H. Robin; Sheppard, George S.; Xu,

Lianhong; Carrera, George M., Jr.; Garland, Robert B.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 160 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9516687	A1	19950622	WO 1994-US14112	19941208
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5486525	A	19960123	US 1994-347528	19941205
CA 2176247	A1	19950622	CA 1994-2176247	19941208
AU 9513036	A	19950703	AU 1995-13036	19941208
AU 690620	B2	19980430		
EP 734386	A1	19961002	EP 1995-904287	19941208
EP 734386	B1	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 212992	T	20020215	AT 1995-904287	19941208
PRIORITY APPLN. INFO.:			US 1993-168564	A 19931216
			US 1994-324631	A 19941018
			US 1994-347528	A 19941205
			WO 1994-US14112	W 19941208

OTHER SOURCE(S): MARPAT 123:340121

GI



AB Title compds. [I; R = Z1Z2Z3R4; R1 = H, halo, alkyl, alkoxy, etc.; R2 = H, (carboxy)alkyl, aminoalkyl, etc.; R3 = H, alkyl; R4 = (hetero)annelated imidazolyl, etc.; Z1 = CO, CONH, C(:NNH2), etc.; Z2 = bond, phenylene, heteroarylene, etc.; Z3 = bond, (un)substituted alkylene] were prepared Thus, 4-bromoindole was converted in 4 steps to I (R = COC6H4CH2NH2, R1 = 4-Br, R2 = CONMe2, R3 = H) which was N-alkylated by 4-ethoxy-3-nitropyridine and the product converted in 2 steps to title compound II (R1 = Br). The latter was alkylated by Me3SnC.tplbond.CSiMe3 to give, after deprotection, II (R1 = C.tplbond.CH) which had Ki of 0.6nM for platelet activating factor inhibition in vitro.


IT 170498-03-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-[(imidazopyridylalkyl)benzoyl]indoles and analogs as platelet activating factor antagonists)

RN 170498-03-0 CAPLUS

CN 1H-Indole-1-carboxamide, 6-(4-fluorophenyl)-N,N-dimethyl-3-[6-(2-methyl-5H-imidazo[4,5-c]pyridin-5-yl)-1-oxohexyl]- (CA INDEX NAME)




REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 76 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:896125 CAPLUS  
 DOCUMENT NUMBER: 123:313956  
 ORIGINAL REFERENCE NO.: 123:56283a  
 TITLE: Preparation of imidazo[4,5-c]pyridine pharmaceuticals  
 INVENTOR(S): Mederski, Werner; Dorsch, Dieter; Osswald, Mathias;  
 Beier, Norbert; Schelling, Pierre; Minck, Klaus-Otto;  
 Lues, Ingeborg  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: Ger. Offen., 20 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4341453	A1	19950608	DE 1993-4341453	19931206
EP 657452	A1	19950614	EP 1994-118416	19941123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
HU 72595	A2	19960528	HU 1994-3451	19941201
CA 2137213	A1	19950607	CA 1994-2137213	19941202
AU 9479190	A	19950615	AU 1994-79190	19941202
NO 9404689	A	19950607	NO 1994-4689	19941205
ZA 9409664	A	19950815	ZA 1994-9664	19941205
CN 1109056	A	19950927	CN 1994-119893	19941205
US 5532276	A	19960702	US 1994-353309	19941205
JP 07196656	A	19950801	JP 1994-302170	19941206
PRIORITY APPLN. INFO.: MARPAT 123:313956			DE 1993-4341453	A 19931206
OTHER SOURCE(S):				
GI				



I

AB The title comps. [I; A1 = (un)substituted Ph, (un)substituted naphthyl, heterocycllyl, etc.; R1 = alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted CO2H, CN, NO2, 1H-5-tetrazolyl; R3 = (un)substituted NH2, cycloalkoxy, naphthyloxy, etc.; R4 = H, halogen; X = NHCO, CONH, CCH(CO2H), etc.; Y = O, S] [e.g., 2-butyl-3-(2'-carboxybiphenyl)-4-

methyl)-4,5-dihydro-4-oxo-5-( $\alpha$ -N,N-dimethylcarbamoylbenzyl)-3H-imidazo[4,5-c]pyridine], useful as pharmaceuticals (no data), are prepared and I-containing formulations presented.

IT 169755-10-6P 169755-49-1P 169755-50-4P

169755-51-5P 169755-53-7P 169755-54-8P


169755-55-9P 169755-56-0P 169755-57-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazo[4,5-c]pyridine pharmaceuticals)


RN 169755-10-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-1-phenyl-2-(1-pyrrolidinyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(CA INDEX NAME)



RN 169755-49-1 CAPLUS

CN 4H-imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-oxo-1-phenyl-2-(1-pyrrolidinyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, potassium salt (1:1) (CA INDEX NAME)




● K

RN 169755-50-4 CAPLUS


CN 4H-imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-oxo-1-phenyl-2-(1-piperidinyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, potassium salt (1:1) (CA INDEX NAME)






● K

RN 169755-51-5 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-(4-morpholinyl)-2-oxo-1-phenylethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, potassium salt (1:1) (CA INDEX NAME)




● K

RN 169755-53-7 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-ethyl-3,5-dihydro-5-[2-(4-morpholinyl)-2-oxo-1-phenylethyl]-2-(1-piperidinylethyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, potassium salt (1:1) (CA INDEX NAME)




● K

RN 169755-54-8 CAPLUS  
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 3,5-dihydro-5-[2-(4-methyl-1-piperazinyl)-2-oxo-1-phenylethyl]-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 169755-55-9 CAPLUS  
 CN 1-Piperazinecarboxaldehyde, 4-[2-[3,4-dihydro-4-oxo-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5H-imidazo[4,5-c]pyridin-5-yl]-2-phenylacetyl]-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 169755-56-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[3,4-dihydro-4-oxo-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5H-imidazo[4,5-c]pyridin-5-yl]-2-phenylacetyl]-, ethyl ester, potassium salt (1:1) (CA INDEX NAME)



● K


RN 169755-57-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[3,4-dihydro-4-oxo-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5H-imidazo[4,5-c]pyridin-5-yl]-2-phenylacetyl]-, 1,1-dimethylethyl ester, potassium salt (1:1) (CA INDEX NAME)




● K


IT 169755-10-6P 169755-11-7P 169755-12-8P  
 169755-13-9P 169755-14-0P 169755-15-1P  
 169755-16-2P 169755-17-3P 169755-18-4P  
 169755-22-0P 169755-23-1P 169755-24-2P  
 169755-25-3P 169755-26-4P 169755-27-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of imidazo[4,5-c]pyridine pharmaceuticals from)  
 RN 169755-10-6 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-1-  
 phenyl-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-  
 (CA INDEX NAME)



RN 169755-11-7 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-1-  
 phenyl-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA  
 INDEX NAME)




RN 169755-12-8 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-butyl-5-[2-(2,6-dimethyl-1-  
 piperidinyl)-2-oxo-1-phenylethyl]-4,5-dihydro-4-oxo-3H-imidazo[4,5-  
 c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 169755-13-9 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'--[2-butyl-5-[2-(3,4-dihydro-1(2H)-quinolinyl)-2-oxo-1-phenylethyl]-4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 169755-14-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'--[2-butyl-4,5-dihydro-5-[2-(4-morpholinyl)-2-oxo-1-phenylethyl]-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 169755-15-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'--[2-butyl-4,5-dihydro-5-[2-(4-methyl-1-piperazinyl)-2-oxo-1-phenylethyl]-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 169755-16-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[2-butyl-5-[2-(4-formyl-1-piperazinyl)-2-oxo-1-phenylethyl]-4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 169755-17-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[2-butyl-3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl]-2-phenylacetyl]-, ethyl ester (CA INDEX NAME)




RN 169755-18-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[2-butyl-3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl]-2-phenylacetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 169755-22-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[2-ethyl-4,5-dihydro-4-oxo-5-[2-oxo-1-phenyl-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 169755-23-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[4,5-dihydro-5-[2-(4-morpholinyl)-2-oxo-1-phenylethyl]-4-oxo-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)




RN 169755-24-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[4,5-dihydro-5-[2-(4-methyl-1-piperazinyl)-2-oxo-1-phenylethyl]-4-oxo-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)




RN 169755-25-3 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[5-[2-(4-formyl-1-piperazinyl)-2-oxo-1-phenylethyl]-4,5-dihydro-4-oxo-2-propyl-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)




RN 169755-26-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3,4-dihydro-4-oxo-2-propyl-5H-imidazo[4,5-c]pyridin-5-yl]-2-phenylacetyl]-, ethyl ester (CA INDEX NAME)



RN 169755-27-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3,4-dihydro-4-oxo-2-propyl-5H-imidazo[4,5-c]pyridin-5-yl]-2-phenylacetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)






L3 ANSWER 77 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:797249 CAPLUS  
 DOCUMENT NUMBER: 123:198617  
 ORIGINAL REFERENCE NO.: 123:35452h,35453a  
 TITLE: Imides as inhibitors of TNF alpha  
 INVENTOR(S): Muller, George W.  
 PATENT ASSIGNEE(S): Celgene Corp., USA  
 SOURCE: PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9501348	A2	19950112	WO 1994-US7411	19940701
WO 9501348	A3	19950309		
W: AU, CA, CZ, FI, HU, JP, KR, NZ, PL, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2166315	A1	19950112	CA 1994-2166315	19940701
CA 2166315	C	20060404		
CA 2531868	A1	19950112	CA 1994-2531868	19940701
CA 2626178	A1	19950112	CA 1994-2626178	19940701
AU 9472167	A	19950124	AU 1994-72167	19940701
AU 687843	B2	19980305		
EP 706521	A1	19960417	EP 1994-921439	19940701
EP 706521	B1	20021002		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09500872	T	19970128	JP 1995-503648	19940701
JP 3971794	B2	20070905		
HU 75312	A2	19970528	HU 1996-3	19940701
EP 1004580	A2	20000531	EP 2000-200491	19940701
EP 1004580	A3	20021002		
EP 1004580	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1004581	A2	20000531	EP 2000-200492	19940701
EP 1004581	A3	20020814		
EP 1004581	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1004572	A2	20000531	EP 2000-200498	19940701
EP 1004572	A3	20021002		
EP 1004572	B1	20060308		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
PL 180377	B1	20010131	PL 1994-312386	19940701
RU 2174516	C2	20011010	RU 1996-102001	19940701
AT 225344	T	20021015	AT 1994-921439	19940701
PT 706521	T	20030228	PT 1994-921439	19940701
ES 2184765	T3	20030416	ES 1994-921439	19940701
AT 277036	T	20041015	AT 2000-200492	19940701
EP 1477486	A2	20041117	EP 2004-77075	19940701
EP 1477486	A3	20041215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
CZ 294444	B6	20050112	CZ 2003-663	19940701
PT 1004581	T	20050131	PT 2000-200492	19940701
ES 2226696	T3	20050401	ES 2000-200492	19940701
AT 319678	T	20060315	AT 2000-200498	19940701
PT 1004572	T	20060630	PT 2000-200498	19940701
ES 2258956	T3	20060916	ES 2000-200498	19940701
AT 348809	T	20070115	AT 2000-200491	19940701
ES 2278574	T3	20070816	ES 2000-200491	19940701
FI 9506362	A	19960226	FI 1995-6362	19951229

FI 114984	B1	20050215		
EP 1956017	A1	20080813	EP 2008-9864	19980528
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 6476052	B1	20021105	US 2000-633908	20000807
HK 1025769	A1	20050408	HK 2000-104989	20000810
HK 1025765	A1	20060818	HK 2000-104991	20000810
HK 1025770	A1	20070316	HK 2000-104990	20000810
US 20030144325	A1	20030731	US 2003-337602	20030106
US 7119106	B2	20061010		
FI 2004000593	A	20040427	FI 2004-593	20040427
US 20060160854	A1	20060720	US 2005-280333	20051117
JP 2006131647	A	20060525	JP 2006-39629	20060216
JP 2006169261	A	20060629	JP 2006-39624	20060216
JP 2006188529	A	20060720	JP 2006-39633	20060216
JP 2006188530	A	20060720	JP 2006-39637	20060216
US 20060178402	A1	20060810	US 2006-401862	20060412
US 20060183910	A1	20060817	US 2006-401858	20060412
PRIORITY APPLN. INFO.:				
			US 1993-87510	A 19930702
			CA 1994-2166315	A3 19940701
			CA 1994-2531868	A3 19940701
			EP 1994-921439	A3 19940701
			EP 2000-200492	A3 19940701
			JP 1995-503648	A3 19940701
			WO 1994-US7411	W 19940701
			US 1996-690258	A1 19960724
			US 1996-701494	A1 19960822
			US 1997-48278	A 19970530
			US 1997-48278P	P 19970530
			WO 1997-US13375	A1 19970724
			EP 1998-924959	A3 19980528
			EP 2004-77432	A3 19980528
			US 1999-230389	B3 19990507
			US 2000-543809	A1 20000406
			US 2001-781179	A1 20010212
			US 2003-337602	A3 20030106

OTHER SOURCE(S): MARPAT 123:198617  
GI



AB A variety of cyclic imides and certain acyclic analogs and/or precursors are inhibitors of tumor necrosis factor  $\alpha$  (no data) and can be used to combat cachexia, endotoxic shock, and retrovirus replication. One subgroup of the compds. is I [ $R^1$  = divalent residue of 3,4-pyridine, pyrrolidine, imidazole, naphthalene, thiophene, or C2-6 alkane (un)substituted by (un)substituted Ph;  $R^2$  = CO, SO<sub>2</sub>; n = 1-3]. A typical


embodiment from a different subgroup is Me 3-phthalimido-3-(3,4-dimethoxyphenyl)propionate, i.e. II, which was prepared from 3,4-(MeO)2C6H3CH(NH2)CH2CO2H by conversion to the Me ester hydrochloride with SOCl2 and MeOH (66%) and reaction of this with N-(carboethoxy)phthalimide in the presence of Na2CO3 in aqueous MeCN (92%). A total of 93 synthetic examples and 6 formulations are given.

IT 167887-30-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of cyclic imides and analogs as TNF- $\alpha$  inhibitors)

RN 167887-30-1 CAPLUS

CN 4H-Imidazo[4,5-c]pyridine-4,6(5H)-dione, 5-(2,6-dioxo-3-piperidiny1)- (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1995:750512 CAPLUS

DOCUMENT NUMBER: 123:143899

ORIGINAL REFERENCE NO.: 123:25637a, 25640a

TITLE: Preparation of  
3-(4-biphenylmethyl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine derivatives as angiotensin II antagonists

INVENTOR(S): Honma, Yasushi; Sekine, Yasuo; Nomura, Sumihiro;

Naito, Kazuaki; Narita, Hiroshi

PATENT ASSIGNEE(S): Tanabe Seiyaku Co, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 34 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06312926	A	19941108	JP 1994-31109	19940301
PRIORITY APPLN. INFO.:			JP 1994-31109	A 19940301
			JP 1993-43108	19930304

OTHER SOURCE(S): MARPAT 123:143899

GI



I



II

AB The title compds. [I; R1 = H, lower alkyl; R2 = H, lower alkylsulfonyl, C(O)R, CH2R; wherein R = (un)substituted lower alkyl, lower alkoxy, 5- or 6-membered monocyclic heterocyclyl, (un)substituted Ph, H, (un)substituted NH2, lower alkenyl; R3 = optionally esterified CO2H; ring A = Ph optionally having substituents] and pharmacol. acceptable salts are prepared. An angiotensin II antagonist for the treatment and prevention of hypertension, nephritis, diabetic nephritis, primary aldosteronism, arteriosclerosis, dementia, brain circulation failure, chronic heart failure, and/or angina pectoris contains the compound I as the active ingredient. Thus, Me 5-diphenylacetyl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine-4-carboxylate was dissolved in DMF, treated with NaH under ice-cooling, and condensed with [2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl bromide to give, after detritylation with HCl in CHCl3/MeOH and saponification with 1 N aqueous NaOH in MeOH, title compound (II.2Na; R1 = H,

R2 = COCHPh2) and its 1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl regioisomer. II.2Na (R1 = Pr, R2 = Ac) at 3 + 10<sup>-7</sup> M in vitro inhibited 100% the angiotensin II-induced contraction of guinea pig aorta and at 3.0 mg/kg

p.o. in vivo lowered the blood pressure of spontaneous hypertensive rats by 45 mmHg. It at 3 mg/kg administered in duodenum of dogs in vivo also inhibited 80% the angiotensin II-induced hypertension.


IT 166813-47-4P 166813-51-0P 166813-57-6P  
166813-58-7P 166813-61-2P 166813-67-8P  
166813-68-9P 166813-69-0P 166813-72-5P  
166813-73-6P 166813-76-9P 166813-83-8P  
166814-08-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (biphenylmethyl)tetrahydroimidazo[4,5-c]pyridine derivs. as angiotensin II antagonists for treatment of diseases)


RN 166813-47-4 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-5-(2-thienylcarbonyl)-, methyl ester (CA INDEX NAME)



RN 166813-51-0 CAPLUS


CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-5-(2-thienylcarbonyl)-, sodium salt (1:2) (CA INDEX NAME)



● 2 Na


RN 166813-57-6 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, methyl ester (CA INDEX NAME)




RN 166813-58-7 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(2-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 166813-61-2 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(3-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 166813-67-8 CAPLUS


CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-5-(2-furanylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 166813-68-9 CAPLUS


CN 3H-imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(2-furanylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 166813-69-0 CAPLUS

CN 3H-imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(3-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 166813-72-5 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
 2-butyl-5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:2) (CA INDEX NAME)



●2 Na

RN 166813-73-6 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
 2-butyl-4,5,6,7-tetrahydro-5-(2-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:2) (CA INDEX NAME)






● 2 Na

RN 166813-76-9 CAPLUS


CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(3-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 166813-83-8 CAPLUS


CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
5-(2-furanylcabonyl)-4,5,6,7-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 166814-08-0 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
5-(2-furanylcabonyl)-4,5,6,7-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-

yl)[1,1'-biphenyl]-4-yl)methyl]-, sodium salt (1:2) (CA INDEX NAME)



●2 Na

L3 ANSWER 79 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:721205 CAPLUS

DOCUMENT NUMBER: 123:111747

ORIGINAL REFERENCE NO.: 123:19957a,19960a

TITLE: Preparation of antibacterial 1-methylcarbapenem derivatives

INVENTOR(S): Oida, Sadao; Tanaka, Teruo; Konosu, Toshuki; Mori, Makoto; Myaoka, Takeo; Tajima, Kazu

PATENT ASSIGNEE(S): Sankyo Co, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07101959	A	19950418	JP 1993-244299	19930930
PRIORITY APPLN. INFO.:			JP 1993-244299	19930930
OTHER SOURCE(S):	MARPAT 123:111747			

GI



I

AB Title compds. I [R1 = H, protecting group; R2 = H, protecting group, alkyl, alkenyl, C(:NR3); R3 = H, protecting group; R4 = H, alkyl, amino; A = cyclic substituent], useful as antibacterials (no data), are prepared Thus, (2S,4S)-4-acetylthio-1-(4-nitrobenzyloxycarbonyl)-2-[(1S,4S)-5-(4-nitrobenzyloxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]carbonylpyrrolidine (preparation given) was treated with NaOMe in MeOH-THF and the product was reacted with (1R,5R,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-(diphenylphosphoryloxy)carbapenem-3-carboxylic acid 4-nitrobenzyl ester in MeCN containing diisopropylethylamine to give (1R,5S,6S)-6-(R)-1-hydroxyethyl-1-methyl-2-[(2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-[(2S,4S)-5-(4-nitrobenzyloxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]carbonyl]pyrrolidin-4-yl]thio]carbapenem-3-carboxylic acid 4-nitrobenzyl ester. Pharmaceutical compns. containing I are described.


IT 165893-60-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of antibacterial 1-methylcarbapenem derivs.)

RN 165893-60-7 CAPLUS


CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-3-[[1-[(4-nitrophenyl)methoxy]carbonyl]-5-[(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S\*,5S\*),4a,5b,6b(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 165893-88-9P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of antibacterial 1-methylcarbapenem derivs.)  
 RN 165893-88-9 CAPLUS  
 CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,  
 6-(1-hydroxyethyl)-4-methyl-7-oxo-3-[[5-[(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)carbonyl]-3-pyrrolidinyl]thio]-,  
 monohydrochloride, [4R-[3(3S\*,5S\*),4 $\alpha$ ,5 $\beta$ ,6 $\beta$ (R\*)]]- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

PATENT INFORMATION:

GT




1H-Imidazo[4,5-c]pyridinium, 5-[[7-[(2-amino-4-thiazolyl)(methoxyvinyl)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-

azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2,3-dihydro-2-(nitromethylene)-,  
inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 162095-60-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2,3-dihydro-2-(nitromethylene)-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 162095-61-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2-(cyanoamino)-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)



RN 162095-62-7 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-(cyanoamino)-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)



RN 162095-63-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 162095-64-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-1-methyl-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 162095-65-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.






RN 162095-66-1 CAPLUS

1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 162095-67-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(fluoromethoxy)amino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.





REFERENCE COUNT:


2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 81 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:284618 CAPLUS  
 DOCUMENT NUMBER: 122:161011  
 ORIGINAL REFERENCE NO.: 122:29693a,29696a  
 TITLE: The syntheses of (±)-villagorgin A and villagorgin B  
 AUTHOR(S): Grazul, Richard M.; Kuehne, Martin E.  
 CORPORATE SOURCE: Dep. Chemistry, Univ. Vermont, Burlington, VT, 05405, USA  
 SOURCE: Natural Product Letters (1994), 5(3), 187-95  
 CODEN: NPLEEF; ISSN: 1057-5634  
 PUBLISHER: Harwood  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 122:161011  
 GI




AB The marine indole alkaloid villagorgin A (I) was synthesized by reduction and cyclization of an indolyethylimidazopyridinium salt II. Its oxidation with mercuric acetate gave villagorgin B.  
 IT 161197-60-0P 161197-61-1P 161197-62-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (syntheses of villagorgin A and villagorgin B)  
 RN 161197-60-0 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridinium, 5-[2-(1H-indol-3-yl)ethyl]-3-[[2-(trimethylsilyl)ethoxy]methyl]-, bromide (1:1) (CA INDEX NAME)




RN 161197-61-1 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 5-[2-(1H-indol-3-yl)ethyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-, bromide (1:1) (CA INDEX NAME)




RN 161197-62-2 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine, 4,5-dihydro-5-[2-(1H-indol-3-yl)ethyl]-3-[[2-(trimethylsilyl)ethoxy]methyl]- (CA INDEX NAME)



IT 161197-59-7P 161197-63-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (syntheses of villagorgin A and villagorgin B)  
 RN 161197-59-7 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridinium, 5-[2-(1H-indol-3-yl)ethyl]-, bromide (1:1)  
 (CA INDEX NAME)



RN 161197-63-3 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridine, 4,5-dihydro-5-[2-(1H-indol-3-yl)ethyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]- (CA INDEX NAME)





L3 ANSWER 82 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:680647 CAPLUS

DOCUMENT NUMBER: 121:280647

ORIGINAL REFERENCE NO.: 121:51239a,51242a

TITLE: Preparation of  
[(tetrazolylbiphenyl)methyl]imidazo[4,5-c]pyridines  
and related compounds as angiotensin II antagonists

INVENTOR(S): Mederski, Werner; Dorsch, Dieter; Osswald, Mathias;  
Beier, Norbert; Schelling, Pierre; Lues, Ingeborg;  
Minck, Klaus Otto

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Eur. Pat. Appl., 30 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 574846	A2	19931222	EP 1993-109410	19930611
EP 574846	A3	19940706		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4305602	A1	19931223	DE 1993-4305602	19930224
AU 9341238	A	19931223	AU 1993-41238	19930611
AU 669895	B2	19960627		
CZ 283081	B6	19971217	CZ 1993-1145	19930611
CA 2098473	A1	19931218	CA 1993-2098473	19930615
NO 9302218	A	19931220	NO 1993-2218	19930616
ZA 9304289	A	19940117	ZA 1993-4289	19930616
CN 1082545	A	19940223	CN 1993-107194	19930617
CN 1038511	C	19980527		
HU 64761	A2	19940228	HU 1993-1766	19930617
JP 06056832	A	19940301	JP 1993-146312	19930617
US 5476857	A	19951219	US 1993-77592	19930617
PL 173777	B1	19980430	PL 1993-299368	19930617
PRIORITY APPLN. INFO.:				
			DE 1992-4219818	A 19920617
			DE 1993-4305602	A 19930224

OTHER SOURCE(S): MARPAT 121:280647

GI



I

AB Title compds. [I; R1 = alkyl, alkenyl, alkynyl, cycloalkylalkyl, etc.; R2 = H, CO2H, alkoxycarbonyl, cyano, NO2, acylamino, 1H-tetrazol-5-yl; R3 = substituted alkenyl, etc.; R4 = H, halo; X = null, NHCO, OCH(CO2H), NHCH(CO2H), CH2C(CO2H), CH2C(CN), etc.; Y = O, S], were prepared as


angiotensin II antagonists (no data). Thus, valeric acid and 4-amino-1,2-dihydro-2-oxo-3-[2'-(1H-5-tetrazolyl)biphenyl-4-methylamino]-1-(N,N-dimethylcarbamoylmethyl)pyridine (preparation given) were heated 5 h in polyphosphoric acid at 140° to give 2-butyl-4,5-dihydro-5-(N,N-dimethylcarbamoylmethyl)-4-oxo-3-[2'-(1H-5-tetrazolyl)biphenyl-4-methyl]-3H-imidazo[4,5-c]pyridine. Generic I drug formulations are given.

IT 156221-95-3P 156221-97-5P 156222-13-8P  
156222-17-2P 158938-69-3P 158938-70-6P  
158938-76-2P 158938-81-9P 158938-82-0P  
158938-83-1P 158938-84-2P 158938-85-3P  
158938-86-4P 158938-87-5P 158938-88-6P  
158938-90-0P 158938-91-1P 158938-92-2P  
158938-93-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as angiotensin II antagonist)


RN 156221-95-3 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-pyrrolidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)




RN 156221-97-5 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-ethyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)




RN 156222-13-8 CAPLUS

CN 4H-imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-oxo-2-(1-pyrrolidinyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 156222-17-2 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-ethyl-3,5-dihydro-5-[2-oxo-2-(1-piperidinyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 158938-69-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[2-butyl-3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-N,N-diethyl- (CA INDEX NAME)



RN 158938-70-6 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-butyl-5-[2-[4-[(4-fluorophenyl)sulfonyl]-1-piperazinyl]-2-oxoethyl]-4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)






RN 158938-76-2 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[[3-(3-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 158938-81-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[2-butyl-3,4-dihydro-4-oxo-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-N,N-diethyl- (CA INDEX NAME)




RN 158938-82-0 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-5-[2-[4-[(4-fluorophenyl)sulfonyl]-1-piperazinyl]-2-oxoethyl]-3,5-dihydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 158938-83-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-ethyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(4-oxo-1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)




RN 158938-84-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-ethyl-4,5-dihydro-5-[2-[4-(2-methoxyphenyl)-1-piperidinyl]-2-oxoethyl]-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 158938-85-3 CAPLUS

CN Acetamide, N-[1-[2-[3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-2-ethyl-3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 158938-86-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-ethyl-4,5-dihydro-5-[2-[4-(2-morpholinyl)-2-oxoethyl]-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 158938-87-5 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-ethyl-4,5-dihydro-5-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 158938-88-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-ethyl-4,5-dihydro-5-[2-[4-(2-nitrophenyl)-1-piperazinyl]-2-oxoethyl]-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)




RN 158938-90-0 CAPLUS

CN Acetamide, N-[1-[2-[2-ethyl-3,4-dihydro-4-oxo-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5H-imidazo[4,5-c]pyridin-5-yl]acetyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 158938-91-1 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-ethyl-3,5-dihydro-5-[2-(4-morpholinyl)-2-oxoethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 158938-92-2 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-ethyl-3,5-dihydro-5-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 158938-93-3 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-ethyl-3,5-dihydro-5-[2-[4-(2-nitrophenyl)-1-piperazinyl]-2-oxoethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




IT 158938-99-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as intermediate for angiotensin II antagonist)


RN 158938-99-9 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[[3-(3-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-3-[[2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)





L3 ANSWER 83 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1994:483197 CAPLUS  
 DOCUMENT NUMBER: 121:83197  
 ORIGINAL REFERENCE NO.: 121:14953a,14956a  
 TITLE: Non-Peptide Angiotensin II Receptor Antagonists:  
 Synthesis and Biological Activity of a Series of Novel  
 4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridine  
 Derivatives  
 AUTHOR(S): Mederski, Werner W. K. R.; Dorsch, Dieter; Bokel,  
 Heinz-Hermann; Beier, Norbert; Lues, Ingeborg;  
 Schelling, Pierre  
 CORPORATE SOURCE: Preclinical Pharmaceutical Research, E. Merck,  
 Darmstadt, 64271, Germany  
 SOURCE: Journal of Medicinal Chemistry (1994), 37(11), 1632-45  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB A series of novel non-peptide angiotensin II receptor antagonists containing 2,3,5-trisubstituted 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine was prepared via several synthetic routes. Their affinity for angiotensin II receptors was established in a binding assay experiment and in an isolated-organ test. Mols. with small alkyl groups at C-2 and the (methylbiphenyl)tetrazole moiety at N-3 were the preferred compds. with affinities and potencies in the nanomolar range. Variations at the N-5 position modulate the activity. Substitution at N-5 with various benzyl groups led to derivs. with in vitro potencies in the nanomolar range, which were equivalent to those of losartan in these assays. Replacement of the N-5 hydrogen with acetic acid esters or, in particular, acetamides gave mols. with increased activity. The most potent was the amide I (R = CONEt2), which is superior to L-158,809 in vitro. Two prototypes were selected as their potassium salts for in vivo testing as antihypertensives. I (R = Ph, CONMe2) reduced blood pressure dose-dependently in spontaneously hypertensive rats when administered i.v. In this assay, I (R = CONMe2) is superior to losartan.

IT 150694-46-5P 156222-13-8P 156222-17-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and angiotensin antagonist activity of)


RN 150694-46-5 CAPLUS

CN 4H-imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-(2-thienylmethyl)- (CA INDEX NAME)




RN 156222-13-8 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-[2-oxo-2-(1-pyrrolyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 156222-17-2 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-ethyl-3,5-dihydro-5-[2-oxo-2-(1-piperidinyl)ethyl]-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




IT 150674-31-0P 156221-95-3P 156221-97-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, in preparation of angiotensin antagonist imidazopyridinones)


RN 150674-31-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[2-butyl-4,5-dihydro-4-oxo-5-(2-thienylmethyl)-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)




RN 156221-95-3 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'--[2-butyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-pyrrolidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl- (CA INDEX NAME)



RN 156221-97-5 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'--[2-ethyl-4,5-dihydro-4-oxo-5-[2-oxo-2-(1-piperidinyl)ethyl]-3H-imidazo[4,5-c]pyridin-3-yl]methyl- (CA INDEX NAME)





L3 ANSWER 84 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:134491 CAPLUS

DOCUMENT NUMBER: 120:134491

ORIGINAL REFERENCE NO.: 120:23695a,23698a

TITLE: Preparation of imidazopyridine derivatives as drugs.

INVENTOR(S): Mederski, Werner; Dorsch, Dieter; Beier, Norbert;

Schelling, Pierre; Lues, Ingeborg; Minck, Klaus

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Ger. Offen., 9 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4211474	A1	19931007	DE 1992-4211474	19920406
EP 564960	A1	19931013	EP 1993-105254	19930330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2093290	A1	19931007	CA 1993-2093290	19930402
NO 9301302	A	19931007	NO 1993-1302	19930405
AU 9336731	A	19931014	AU 1993-36731	19930405
ZA 9302459	A	19931020	ZA 1993-2459	19930405
HU 64342	A2	19931228	HU 1993-999	19930406
JP 06025239	A	19940201	JP 1993-79806	19930406
CN 1082045	A	19940216	CN 1993-103877	19930406
PRIORITY APPLN. INFO.:			DE 1992-4211474	A 19920406

OTHER SOURCE(S): MARPAT 120:134491

GI



I

AB Title compds. [I; R1 = H, A; R2 = H, halo, OH, OA, CO2H, CO2A, CONH2, cyano, NO2, amino, tetrazolyl, etc.; R3 = H, cyanoalkyl, aralkyl, cycloalkyl, heterocyclylalkyl, (substituted) aralkyl, acylalkyl, heteroarylcarbonylalkyl, etc.; R4 = H, halo; Y = O, S; A = alkyl, alkenyl, alkynyl], were prepared as angiotensin II antagonists (no data). Thus, 2-butyl-4,5-dihydro-4-oxo-1(or 3)-H-imidazo[4,5-c]pyridine (preparation from 3,4-diamino-2-chloropyridine and valeric acid given) was stirred with K2CO3 and Me 4-bromomethylbenzoate in DMF to give 2-butyl-3,5-bis-4-methoxycarbonylbenzyl-4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine. Pharmaceutical I formulations are given.


IT 152460-50-9P 152460-57-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as angiotensin II antagonist)

RN 152460-50-9 CAPLUS


CN Benzoic acid, 4-[[2-butyl-4,5-dihydro-4-oxo-5-(2-thienylmethyl)-3H-

imidazo[4,5-c]pyridin-3-yl)methyl)- (CA INDEX NAME)



RN 152460-57-6 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-5-((2H-tetrazol-5-yl)methyl)-3-[[4-(2H-tetrazol-5-yl)phenyl)methyl]- (CA INDEX NAME)



ACCESSION NUMBER: 1993:603420 CAPLUS

DOCUMENT NUMBER: 119:203420

ORIGINAL REFERENCE NO.: 119:36285a,36288a

TITLE: Preparation of imidazopyridine derivatives with

angiotensin-II antagonist properties

INVENTOR(S): Mederski, Werner; Dorsch, Dieter; Beier, Norbert;  
Schelling, Pierre; Lues, Ingeborg; Minck, Klaus Otto

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 547514	A2	19930623	EP 1992-121110	19921211
EP 547514	A3	19930714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4141788	A1	19930624	DE 1991-4141788	19911218
CA 2085094	A1	19930619	CA 1992-2085094	19921210
AU 9230191	A	19930624	AU 1992-30191	19921216
AU 653281	B2	19940922		
NO 9204890	A	19930621	NO 1992-4890	19921217
ZA 9209790	A	19930623	ZA 1992-9790	19921217
US 5242928	A	19930907	US 1992-991888	19921217
HU 67086	A2	19950130	HU 1992-3994	19921217
JP 05279360	A	19931026	JP 1992-338917	19921218
PRIORITY APPLN. INFO.:			DE 1991-4141788	A 19911218
OTHER SOURCE(S):	MARPAT 119:203420			
GI				



I



II

AB Title compds. [I; R1 = alkyl, alkenyl, alkynyl; R2 = H, CO2H, alkoxy, carbonyl, CH3, NO2, NHCOR5, NHSO2R5, 1H-tetrazol-5-yl; R3 = acylalkyl, heteroarylalkyl; R4 = H, halo; R5 = (fluoro)alkyl; X = null, NHCO, OCH(CO2H), NHCH(CO2H), CH2C(CO2H), CH2C(CN), etc.; Y = O, S] were prepared as angiotensin II antagonists (no data). Thus, valeric acid was


heated with 4-amino-1,2-dihydro-2-oxo-3-[2'-(1H-5-tetrazolyl)biphenyl]-4-methylamino-[1-(2-thienylmethyl)pyridine (preparation given) in polyphosphonic acid at 140° followed by aqueous NaOH workup to give title compound II.

IT 150674-29-6P 150694-46-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as angiotensin II antagonist)


RN 150674-29-6 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 5-[2-(2-benzofuranyl)-2-oxoethyl]-2-butyl-3,5-dihydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 150694-46-5 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-(2-thienylmethyl)- (CA INDEX NAME)




IT 150674-31-0P 150674-36-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as intermediate for angiotensin II antagonist)

RN 150674-31-0 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[5-[2-(2-benzofuranyl)-2-oxoethyl]-2-butyl-4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)



RN 150674-36-5 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[5-[2-(2-benzofuranyl)-2-oxoethyl]-2-butyl-4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridin-3-yl]methyl]- (CA INDEX NAME)

NAME)



L3 ANSWER 86 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:495528 CAPLUS

DOCUMENT NUMBER: 119:95528

ORIGINAL REFERENCE NO.: 119:17236h,17237a

TITLE: Preparation of  
3-(biphenylmethyl)-4,5-6,7-tetrahydroimidazo[4,5-  
c]pyridines as angiotensin II antagonists

INVENTOR(S): Honma, Yasushi; Sekine, Yasuo; Nomura, Sumihiro;

Naito, Kazuaki; Narita, Hiroshi

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 531874	A1	19930317	EP 1992-114976	19920902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9222057	A	19930311	AU 1992-22057	19920902
AU 644540	B2	19931209		
CA 2077419	A1	19930311	CA 1992-2077419	19920902
CA 2077419	C	19980825		
IL 103020	A	19981030	IL 1992-103020	19920902
US 5409936	A	19950425	US 1992-940336	19920903
JP 05279361	A	19931026	JP 1992-239078	19920908
JP 2564784	B2	19961218		
JP 05279362	A	19931026	JP 1992-239079	19920908
JP 2564785	B2	19961218		
KR 159538	B1	19981201	KR 1992-16408	19920908
CN 1070912	A	19930414	CN 1992-110594	19920910
CN 1039323	C	19980729		
FI 98368	B	19970228	FI 1992-4044	19920910
FI 98368	C	19970610		
US 5424316	A	19950613	US 1993-58925	19930510
US 5510354	A	19960423	US 1995-405201	19950316
PRIORITY APPLN. INFO.:			JP 1991-308561	A 19910910
			JP 1992-53043	A 19920127
			US 1992-940336	A3 19920903
			US 1993-58925	A3 19930510

OTHER SOURCE(S): MARPAT 119:95528

GI




AB Title compds. [I; R1 = H, alkyl; R2 = H, alkylsulfonyl, R4(:Z); R3 = CO2H, alkoxy carbonyl; R4 = (substituted) alkyl; Z = O, (H,H); ring A may be substituted], were prepared as angiotensin II antagonists (no data). Thus, Me 5-diphenylacetyl-4,5,6,7-tetrahydroimidazo[4,5-c]pyrimidine-4-carboxylate (preparation given), [2'-(1-trityl-1H-tetrazol-5-yl)biphen-4-yl]methyl bromide, and NaH were stirred in DMF at ice temperature-room temperature to give Me 5-diphenylacetyl-3-[2'-(1-trityl-1H-tetrazol-5-yl)biphen-4-yl]methyl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine-4-carboxylate, together with the 1-substituted imidazopyridine. I were said to show significant hypotensive activity at 3 mg/kg orally in rats together with low toxicity.

IT 166813-47-4P 166813-51-0P 166813-57-6P  
166813-58-7P 166813-61-2P 166813-67-8P  
166813-68-9P 166813-69-0P 166813-72-5P  
166813-73-6P 166813-76-9P 166813-83-8P  
166814-08-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as angiotensin II antagonist)


RN 166813-47-4 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-(2-thienylcarbonyl)-, methyl ester (CA INDEX NAME)



RN 166813-51-0 CAPLUS


CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-(2-thienylcarbonyl)-, sodium salt (1:2) (CA INDEX NAME)



● 2 Na


RN 166813-57-6 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 166813-58-7 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(2-furanylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 166813-61-2 CAPLUS


CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(3-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 166813-67-8 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(2-furanylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester, sodium salt (1:1) (CA INDEX NAME)






● Na

RN 166813-68-9 CAPLUS


CN 3H-imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(2-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester, sodium salt (1:1) (CA  
INDEX NAME)



● Na


RN 166813-69-0 CAPLUS

CN 3H-imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(3-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester, sodium salt (1:1) (CA  
INDEX NAME)




● Na

RN 166813-72-5 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
 2-butyl-5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:2) (CA INDEX NAME)



●2 Na


RN 166813-73-6 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
 2-butyl-4,5,6,7-tetrahydro-5-(2-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 166813-76-9 CAPLUS


CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
2-butyl-4,5,6,7-tetrahydro-5-(3-pyridinylcarbonyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 166813-83-8 CAPLUS


CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
5-(2-furanylcabonyl)-4,5,6,7-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 166814-08-0 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine-4-carboxylic acid,  
5-(2-furanylcabonyl)-4,5,6,7-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-

yl)[1,1'-biphenyl]-4-yl)methyl]-, sodium salt (1:2) (CA INDEX NAME)



●2 Na

L3 ANSWER 87 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:254907 CAPLUS

DOCUMENT NUMBER: 118:254907

ORIGINAL REFERENCE NO.: 118:44301a, 44304a

TITLE: Preparation of  
(tetrazolyl)biphenylmethylimidazopyridines as  
angiotensin II antagonists.

INVENTOR(S): Mederski, Werner; Sombroek, Johannes; Schelling,  
Pierre; Beier, Norbert; Lues, Inger; Minck, Klaus Otto

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Eur. Pat. Appl., 25 pp.

CODEN: EPXXDW





DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 505893	A1	19920930	EP 1992-104571	19920317
EP 505893	B1	20000621		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
DE 4110019	A1	19921001	DE 1991-4110019	19910327
DE 4110019	C2	20000413		
CZ 280591	B6	19960214	CZ 1992-782	19920316
AT 194005	T	20000715	AT 1992-104571	19920317
ES 2148156	T3	20001016	ES 1992-104571	19920317
PT 505893	T	20001229	PT 1992-104571	19920317
AU 9213141	A	19921001	AU 1992-13141	19920323
AU 655458	B2	19941222		
CA 2063926	A1	19920928	CA 1992-2063926	19920325
CA 2063926	C	20021001		
JP 05125077	A	19930521	JP 1992-98606	19920326
JP 3382963	B2	20030304		
HU 63165	A2	19930728	HU 1992-932	19920326
HU 221010	B1	20020729		
GR 3034230	T3	20001229	GR 2000-401915	20000818
PRIORITY APPLN. INFO.:			DE 1991-4110019	A 19910327
OTHER SOURCE(S):	MARPAT 118:254907			
GI				




AB Title compds. I [R = Q1, Q2, etc.; R1 = A, C2-6 alkenyl, C2-6 alkynyl; R2 = CO2H, CO2A, cyano, NO2, NH2, NHCOR5, NHSO2R5, 5-tetrazolyl; R3 = H, halo, A, OA, NO2; R4 = H, R5, cyanoalkyl, 5-tetrazolyl-C1-6 alkyl, CO2A, (substituted) C7-11 aralkyl, Q3, etc.; R5 = C1-4 (fluoro)alkyl; R6 = H, halo; X = bond, CO, O, NHCO, CONH, CH2O, OCH2; Y = O, S; A = C1-6 alkyl; halo = F, Cl, Br, iodo] were prepared as angiotensin II antagonists useful as antihypertensives and for the treatment of aldosteronism and congestive heart failure (no data). Thus, cyclocondensation of 3,4-diamino-2-chloropyridine with valeric acid and N-alkylation of the product by 4'-bromomethyl-2-cyanobiphenyl gave 2-butyl-3-(2'-cyanobiphenyl-4-methyl)-4-chloro-3H-imidazo[4,5-c]pyridine. Oxidation of the latter by MeCO2Ag in HOAc gave title compound I [R = Q1; R1 = Bu; R2 = cyano; R3 = R4 = R6 = H; Y = O; X = bond]. Formulations containing I were prepared

IT 145047-14-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, as angiotensin II antagonist)

RN 145047-14-9 CAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 2-butyl-3,5-dihydro-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)



L3 ANSWER 88 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:233766 CAPLUS

DOCUMENT NUMBER: 118:233766

ORIGINAL REFERENCE NO.: 118:40479a,40482a

TITLE: Preparation of 3-(fused pyridinimethyl)cephalosporins as antibiotics

INVENTOR(S): Kim, Choong Sup; An, Seung Ho; Cho, Sung Ki; Ahn, Yang Soo; Choi, Kyoung Eob; Kim, Je Hak; Yun, Rok Lim; Park, Sung Yong; Yoon, Yeo Hong; Lyu, Chun Seon

PATENT ASSIGNEE(S): Cheil Foods and Chemicals, Inc., S. Korea

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9222556	A1	19921223	WO 1992-KR16	19920518
W: AT, AU, BG, CA, CH, DE, ES, FI, GB, HU, JP, NL, RU, SE				
RW: BE, FR, IT				
KR 174824	B1	19990201	KR 1991-9930	19910615
KR 182862	B1	19990501	KR 1992-2067	19920212
CA 2111459	A1	19921223	CA 1992-2111459	19920518
AU 9217861	A	19930112	AU 1992-17861	19920518
CH 683342	A5	19940228	CH 1993-481	19920518
EP 589914	A1	19940406	EP 1992-910520	19920518
R: FR, IT				
GB 2271569	A	19940420	GB 1993-24280	19920518
GB 2271569	B	19950531		
DE 4291862	T0	19940505	DE 1992-4291862	19920518
ZA 9203900	A	19930224	ZA 1992-3900	19920527
US 5281589	A	19940125	US 1992-896667	19920610
SE 9304027	A	19931203	SE 1993-4027	19931203
PRIORITY APPLN. INFO.:			KR 1991-9930	A 19910615
			KR 1992-2067	A 19920212
			WO 1992-KR16	A 19920518

OTHER SOURCE(S): MARPAT 118:233766

GI



AB Title compds. [I; R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (CH2)mF, CR4R5(CH2)y COR6; m = 1-3; R4,R5 = H, alkyl; CR4R5 = C3-7cycloalkyl; R6 = OH, amino, alkoxy; y = 0-3; R2,R3 = H, alkyl, amino, carboxyalkyl, hydroxyalkyl, cycloalkyl; n = 1,2; the 2-oxoheterocyclo moiety is fused at the (2,3) or (3,4) positions of the pyridine ring] were prepared Thus,  $\beta$ -[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-acetoxymethyl-3-cephem-4-carboxylic acid in CH2Cl2 was treated

successively with N-methyl-N-(trimethylsilyl)trifluoroacetamide and then with Me3SiI to give an oil which in MeCN/THF was treated with 2,3(1H,4H)-dioxopyrazino[5,6-c]pyridine (preparation given) silylated with N,O-bis(trimethylsilyl)acetamide to give 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[2,3(1H,4H)-dioxopyrazino[5,6-c]pyridiniummethyl]-3-cephem-4-carboxylate. The latter had MIC of 3.125 µg/mL against *Pseudomonas aeruginosa*.

IT 146950-52-9P 146950-53-0P 146950-54-1P  
146950-55-2P 146950-57-4P 146950-58-5P  
146950-59-6P 146950-61-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of, as antibacterial)

RN 146950-52-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 146950-53-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-1-methyl-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.






RN 146950-54-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-amino-5-[[ (6R,7R)-7-[[ (2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 146950-55-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[ (6R,7R)-7-[[ (2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-1-(2-hydroxyethyl)-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 146950-57-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-4-thiazolyl)-2-[(fluoromethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 146950-58-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R,7R)-7-[[[(2Z)-2-(2-amino-4-thiazolyl)-2-[(fluoromethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-1-methyl-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 146950-59-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-amino-5-[[[(6R, 7R)-7-[[[(2Z)-2-(2-amino-4-thiazolyl)-2-[(fluoromethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 146950-61-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[(6R, 7R)-7-[[[(2Z)-2-(2-amino-4-thiazolyl)-2-[(carboxymethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dihydro-2-oxo-, inner salt (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



ACCESSION NUMBER: 1992:633918 CAPLUS

DOCUMENT NUMBER: 117:233918

ORIGINAL REFERENCE NO.: 117:40455a,40458a

TITLE: New bronchodilators. 1. 1,5-Substituted

1H-imidazo[4,5-c]quinolin-4(5H)-ones

AUTHOR(S): Suzuki, Fumio; Kuroda, Takeshi; Nakasato, Yoshisuke;

Manabe, Haruhiko; Ohmori, Kenji; Kitamura, Shigeto;

Ichikawa, Shunji; Ohno, Tetsuji

CORPORATE SOURCE: Pharm. Res. Lab., Kyowa Hakko Kogyo Co., Ltd.,

Shizuoka, 411, Japan

SOURCE: Journal of Medicinal Chemistry (1992), 35(22), 4045-53


CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:233918

GI



I



II


AB A series of novel xanthine-based tricyclic heterocycles, 1H-imidazo[4,5-c]quinolin-4(5H)-ones I [R1 = Me, CH2Ph, Et, Bu, Ph, etc., R2 = H, Ph, Me, 2-furyl, OH, etc., R3 = Me, Et, Bu, CH2Ph, CH2CO2H, etc., X = H, 7-Cl, 8-Cl, 9-Me, 8-Me, 7,8-(MeO)2], was designed, synthesized, and tested as potential active bronchodilators. Thus, reacting imidazoquinolines II with AcOH/H2O2 and Ac2O followed by alkylation gave I. Inhibition of the Schulz-Dale (SD) reaction-induced contraction in trachea and inhibition of antigen inhalation-induced bronchospasm in passively sensitized guinea pigs served as primary in vitro and in vivo assays, resp. The bronchodilatory activity of these heterocycles was considerably varied with the nature of substituents at the 5-position. The most active substituents at the 2 5-positions on the benzene ring were found to be hydrogen, n-Bu, and hydrogen, resp. I (R1 = Me, R2 = H, R3 = Bu, X = H) (III, KF15570) reduced bronchoconstriction produced by antigen (Konzett-Roessler preparation in anesthetized guinea pigs, ED50 = 0.42 mg/kg, i.v.) more efficiently than aminophylline (ethylenediamine salt of theophylline, ED50 = 7.8 mg/kg, i.v.) but had fewer side effects on the heart and CNS than theophylline. III and its derivs. showed weak adenosine antagonism and phosphodiesterase (PDE) inhibition which could not account for their potent bronchodilation.

IT 133305-94-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and bronchodilating activity of)


RN 133305-94-9 CAPLUS

CN 4H-Imidazo[4,5-c]quinolin-4-one, 5-(2-furanylmethyl)-1,5-dihydro-1-methyl-  
(CA INDEX NAME)



L3 ANSWER 90 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:128504 CAPLUS  
 DOCUMENT NUMBER: 116:128504  
 ORIGINAL REFERENCE NO.: 116:21743a, 21746a  
 TITLE: Preparation of  
 3-(3-pyridinio-1-propenyl)cephalosporins and analogs  
 as antibiotics  
 INVENTOR(S): Aszodi, Jozsef; Chantot, Jean Francois; Gouin  
 d'Ambrieres, Solange  
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.  
 SOURCE: Eur. Pat. Appl., 65 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 462009	A1	19911218	EP 1991-401570	19910613
EP 462009	B1	19981028		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2663332	A1	19911220	FR 1990-7491	19900615
FR 2663332	B1	19971107		
IL 98318	A	19960131	IL 1991-98318	19910531
IL 114629	A	19970610	IL 1991-114629	19910531
ZA 9104457	A	19920826	ZA 1991-4457	19910611
JP 04230289	A	19920819	JP 1991-167421	19910613
JP 3080692	B2	20000828		
AT 172733	T	19981115	AT 1991-401570	19910613
ES 2124698	T3	19990216	ES 1991-401570	19910613
CA 2044700	A1	19911216	CA 1991-2044700	19910614
AU 9178370	A	19911219	AU 1991-78370	19910614
AU 643289	B2	19931111		
HU 58101	A2	19920128	HU 1991-1985	19910614
CZ 282244	B6	19970611	CZ 1991-1830	19910614
SK 280156	B6	19990910	SK 1991-1830	19910614
RU 2078085	C1	19970427	RU 1992-5052193	19920803
US 5416080	A	19950516	US 1993-80572	19930621
PRIORITY APPLN. INFO.:			FR 1990-7491	A 19900615
			IL 1991-98318	A3 19910531
			US 1991-715510	B1 19910614
OTHER SOURCE(S):		MARPAT 116:128504		
GI				




AB Title compds. [I; A = H, alkali metal atom, ester residue, neg. charge, etc.; R = thiazolylloximinoacetyl group Q; A1 = groups cited for A; R1 = N-attached heteroaryl, quaternary ammonium group, etc.; R2,R3 = H, acyl; R4 = H; 6- and 7-positions have (R)-configuration] were prepared Thus, I (A = CHPh2, R = H, R1 = Cl) was condensed with QOH (A1 = CHPh2, R2 = R3 = CH2OCH2CH2OMe, R4 = CPh3) and the product condensed with thieno[2,3-b]pyridine to give, after deprotection and ion exchange, I [A = H, R = Q, R1 = thieno[2,3-b]pyridinio, A1 = R2 = R3 = R4 = H] as an internal salt. The latter had MIC of 1.25 µg/mL against *Pseudomonas Aeruginosa* in vitro.

IT 139151-22-7P 139151-33-0P 139211-39-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in preparation of antibiotics)


RN 139151-22-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[3-[7-[[[1-[3,4-bis[(2-methoxyethoxy)methoxy]phenyl]-2-(diphenylmethoxy)-2-oxoethoxy]imino][2-[(triphenylmethyl)amino]-4-thiazolyl]acetyl]amino]-2-[[4-(methoxyphenyl)methoxy]carbonyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propenyl]-2-methyl-, iodide, [6R-[3(E),6α,7β(Z)]]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A









— Me

RN 139151-33-0 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridinium, 5-[3-[7-[[[1-[3,4-bis[(2-methoxyethoxy)methoxy]phenyl]-2-(diphenylmethoxy)-2-oxoethoxy]imino][2-[(triphenylmethyl)amino]-4-thiazolyl]acetyl]amino]-2-[[4-(methoxyphenyl)methoxy]carbonyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propenyl]-2,3-dimethyl-, iodide, [6R-[3(E),6a,7β(Z)]]-(9CI) (CA INDEX NAME)



Absolute stereochemistry.  
 Double bond geometry as shown.



RN 139211-39-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[3-[7-[[[1-[3,4-bis[(2-methoxyethoxy)methoxy]phenyl]-2-(diphenylmethoxy)-2-oxoethoxy]imino][2-[(triphenylmethyl)amino]-4-thiazolyl]acetyl]amino]-2-[[4-methoxyphenyl)methoxy]carbonyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propenyl]-1,2-dimethyl-, iodide, [6R-[3(E),6α,7β(Z)]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



IT 139150-91-7P 139151-01-2P 139151-03-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of, as antibiotic)

RN 139150-91-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[3-[7-[[[(2-amino-4-thiazolyl)][[carboxy(3,4-dihydroxyphenyl)methoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propenyl]-2-methyl-, iodide, [6R-[3(E),6α,7β(Z)]]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 139150-90-6

CMF C30 H27 N8 O9 S2


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 139151-01-2 CAPLUS

CN 1H-imidazo[4,5-c]pyridinium, 5-[3-[7-[(2-amino-4-thiazolyl)][carboxy(3,4-dihydroxyphenyl)methoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propenyl]-1,2-dimethyl-, iodide, [6R-[3(E),6α,7β(Z)]]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 139151-00-1

CMF C31 H29 N8 O9 S2


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 139151-03-4 CAPLUS

CN 3H-imidazo[4,5-c]pyridinium, 5-[3-[7-[(2-amino-4-thiazolyl)][carboxy(3,4-dihydroxyphenyl)methoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propenyl]-2,3-dimethyl-, iodide, [6R-[3(E),6 $\alpha$ ,7 $\beta$ (Z)]]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 139151-02-3

CMF C31 H29 N8 O9 S2


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L3 ANSWER 91 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:228919 CAPLUS

DOCUMENT NUMBER: 114:228919

ORIGINAL REFERENCE NO.: 114:38620h,38621a

TITLE: Preparation of  
5-(heteroarylalkyl)imidazo[4,5-c]pyridines as  
platelet-activating factor (PAF) antagonists

INVENTOR(S): Khanna, Ish K.; Weier, Richard M.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: U.S., 17 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4990518	A	19910205	US 1989-406674	19890913
CA 2025084	A1	19910314	CA 1990-2025084	19900911
EP 417745	A2	19910320	EP 1990-117520	19900911
EP 417745	A3	19911106		
EP 417745	B1	19931103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 96795	T	19931115	AT 1990-117520	19900911
ES 2059942	T3	19941116	ES 1990-117520	19900911
JP 03109386	A	19910509	JP 1990-242304	19900912
PRIORITY APPLN. INFO.:				
			US 1989-406674	A 19890913
			EP 1990-117520	A 19900911

OTHER SOURCE(S): MARPAT 114:228919

GI



AB The title compds. [I; R1, R2 = straight or branched C1-15 alkyl or C3-15 alkenyl, (substituted) C3-8 cycloalkyl or Ph; Het = (substituted) pyridine or heterocycle ring having 5 atoms selected from C, N, O, or S; n = 1-5; R3 = substituents at one or more of the 4, 6, or 7 positions selected from H, C1-6 alkyl, Br, Cl, F, or C1-6 alkoxy; R4 = H, C1-4 alkyl], useful for the treatment of PAF-mediated diseases or disorders (e.g. inflammation, cardiovascular disorder, and asthma), are prepared Thus, to a stirred solution of imidazopyridine in AcNMe2, 6-chloromethyl-N,N-dicyclopentylnicotinamide was added and the mixture was slowly heated to 80-85° and stirred 20-60 h to give a title compound (II). II in vitro inhibited PAF-induced platelet aggregation with IC50 of 0.1-1.0 μM.

IT 133789-31-8P 133789-32-9P 133789-33-0P

133789-34-1P 133789-35-2P 133789-36-3P

133789-37-4P 133789-38-5P 133789-39-6P


133789-40-9P 133789-41-0P 133794-32-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as platelet activating factor antagonist)


RN 133789-31-8 CAPLUS

CN 3-Pyridinecarboxamide, N,N-dicyclopentyl-6-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)- (CA INDEX NAME)




RN 133789-32-9 CAPLUS

CN 2-Furancarboxamide, N-cyclohexyl-5-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)-N-methyl- (CA INDEX NAME)




RN 133789-33-0 CAPLUS

CN 2-Furancarboxamide, N-cyclohexyl-N-cyclopentyl-5-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)- (CA INDEX NAME)



RN 133789-34-1 CAPLUS


CN 3-Pyridinecarboxamide, N-cyclohexyl-6-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)-N-(1-methylethyl)- (CA INDEX NAME)



RN 133789-35-2 CAPLUS


CN 3-Pyridinecarboxamide, 6-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)-N-(1-methylethyl)-N-phenyl- (CA INDEX NAME)






RN 133789-36-3 CAPLUS

CN 3-Pyridinecarboxamide, N,N-dicyclopentyl-6-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)-2-methoxy- (CA INDEX NAME)




RN 133789-37-4 CAPLUS

CN 3-Pyridinecarboxamide, N,N-dicyclopentyl-6-[3-(5H-imidazo[4,5-c]pyridin-5-yl)propyl]- (CA INDEX NAME)




RN 133789-38-5 CAPLUS

CN 3-Pyridinecarboxamide, N,N-dicyclopentyl-6-[2-(5H-imidazo[4,5-c]pyridin-5-yl)ethyl]- (CA INDEX NAME)




RN 133789-39-6 CAPLUS

CN 2-Pyridinecarboxamide, N,N-dicyclopentyl-5-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)- (CA INDEX NAME)




RN 133789-40-9 CAPLUS

CN 2-Pyridinecarboxamide, N-cyclopentyl-N-ethyl-5-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)- (CA INDEX NAME)




RN 133789-41-0 CAPLUS

CN 2-Furancarboxamide, N-cyclohexyl-5-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)-N-(2-methyl-2-propen-1-yl)- (CA INDEX NAME)




RN 133794-32-8 CAPLUS

CN 2-Furancarboxamide, N-cyclohexyl-5-(5H-imidazo[4,5-c]pyridin-5-ylmethyl)-N-(1-methylethyl)- (CA INDEX NAME)




ACCESSION NUMBER: 1991:185499 CAPLUS  
 DOCUMENT NUMBER: 114:185499  
 ORIGINAL REFERENCE NO.: 114:31335a,31338a  
 TITLE: Preparation of imidazoquinolone derivatives useful for treatment of respiratory disorders  
 INVENTOR(S): Suzuki, Fumio; Kuroda, Takeshi; Nakazato, Yoshisuke; Manabe, Harushiko; Ohmori, Kenji  
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 45 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 386722	A1	19900912	EP 1990-104336	19900307
EP 386722	B1	19950726		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2011504	A1	19900907	CA 1990-2011504	19900305
CA 2011504	C	19980602		
US 4994468	A	19910219	US 1990-489025	19900305
JP 03264585	A	19911125	JP 1990-54590	19900306
PRIORITY APPLN. INFO.:			JP 1989-54148	A 19890307
			JP 1990-42014	19900222
OTHER SOURCE(S):	MARPAT 114:185499			
GI				



AB Title compds. I (R1 H, alkyl, cycloalkyl, alkenyl, aralkyl, aralkenyl, (substituted) aryl; X = N, R2C, R2 = H, HO, alkyl, cycloalkyl, alkenyl, aralkyl, etc.; Y = O, S; R3 = alkyl, cycloalkyl, alkoxyalkyl, alkenyl, aralkyl, aralkenyl, heterocyclalkyl; R4, R5 = H, alkyl, F3C, cycloalkyl, halo, HO, alkoxy etc.) or a salt thereof, showing bronchodilatory and antiallergic activities, are prepared  
 4-Hydroxy-1-methyl-1H-imidazo[4,5-c]quinoline in DMF and NaH were added with ice cooling, followed by stirring at 50° and BuI was added to give I (R1 = Me; R3 = Bu; R4 = R5 = H; X = CH; Y = O) (II). II showed bronchodilatory effect IC50 0.0034 µM; antiallergy effect min. effective dosage <10 mg/kg and a superior or equivalent effect to theophylline or exptl. asthma. The LD50 in mice was >300 mg/kg. Pharmaceutical formulations comprising II are given.  
 IT 133305-94-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, as drug)  
 RN 133305-94-9 CAPLUS  
 CN 4H-Imidazo[4,5-c]quinolin-4-one, 5-(2-furanylmethyl)-1,5-dihydro-1-methyl- (CA INDEX NAME)



L3 ANSWER 93 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:452068 CAPLUS

DOCUMENT NUMBER: 113:52068

ORIGINAL REFERENCE NO.: 113:8637a,8640a

TITLE: Synthesis and biological evaluation of a series of

AUTHOR(S): parenteral 3'-quaternary ammonium cephalosporins  
Brown, Raymond F.; Kinnick, Michael D.; Morin, John  
M., Jr.; Vasileff, Robert T.; Counter, Fred T.;  
Davidson, Edward O.; Ensminger, Paul W.; Eudaly,  
Judith A.; Kasher, Jeffrey S.; et al.

CORPORATE SOURCE: Lilly Corp. Cent., Eli Lilly and Co., Indianapolis,  
IN, 46285, USA

SOURCE: Journal of Medicinal Chemistry (1990), 33(8), 2114-21


CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:52068

GI



AB The preparation and biol. evaluation of a series of  
7β-[2-(2-aminothiazol-4-yl)-2-(Z)-methoximinoacetamide]cephalosporins  
(I where R = e.g., pyridinyl, quinolinyl), substituted at the 3'-position  
with monocyclic or bicyclic nitrogen-containing heterocycles, are described.  
The resulting family of parenteral compds. displayed a broad spectrum of  
antibacterial activity. Some compds. exhibit a similar level of Gram-neg.  
activity to that of the "third-generation" cephalosporins with increased  
staphylococcal activity. The in vitro and in vivo antimicrobial activity,  
structure-activity relations, β-lactamase stability, and in vitro and  
in vivo pharmacol. evaluations are presented.

IT 98382-98-0P 98383-01-8P 98383-04-1P

98383-05-2P 98401-29-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)


(preparation and antibacterial activity of)

RN 98382-98-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[[7-[(2-amino-4-  
thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-  
azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt,  
[6R-[6α,7β(2)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-01-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-methyl-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-04-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-(2-thienyl)-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-05-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2-phenyl-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98401-29-7 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2-phenyl-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



IT 98383-00-7P 98383-02-9P 98383-03-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and antibacterial and anticholinergic activities of)  
 RN 98383-00-7 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 98383-02-9 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1,2-dimethyl-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.






RN 98383-03-0 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2,3-dimethyl-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



ACCESSION NUMBER: 1990:406230 CAPLUS

DOCUMENT NUMBER: 113:6230

ORIGINAL REFERENCE NO.: 113:1207a,1210a

TITLE: Synthesis of imidazole-fused heterocycles: reaction of 3,4,6,7-tetrahydro-2-hydroxypyrido[3,4-d]imidazole-4,6-dione with hydrazines and amines

AUTHOR(S): Zoorob, H. H.; Khodeir, M. N. M.; Waly, M. A.; Amer, F. A.

CORPORATE SOURCE: Fac. Sci., Mansoura Univ., El-Mansoura, Egypt  
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1990), 29B(1), 29-33


CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:6230


GI




I



II



III



IV


AB Reaction of the title compound with  $N_2H_4 \cdot H_2O$  affords either hydrazide I, imidazopyridine II, imidazodiazepine III ( $R = H$ ), or dimer IV, depending upon the reaction conditions. With  $MeNHNHMe$  in  $AcOH$ , the product is III ( $R = Me$ ), and with  $PhNHNH_2$  the product again depends on the reaction conditions.

IT 127574-22-5P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 127574-22-5 CAPLUS

CN [5,5'-Bi-5H-imidazo[4,5-c]pyridine]-2,2',4,4',6,6'-(1H,1'H)-hexone, 3,3',7,7'-tetrahydro- (CA INDEX NAME)



L3 ANSWER 95 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:118541 CAPLUS  
DOCUMENT NUMBER: 112:118541  
ORIGINAL REFERENCE NO.: 112:20071a, 20074a  
TITLE: 1-Carbacephalosporin antibiotics and their preparation  
INVENTOR(S): Cook, Gwendolyn Kay; McDonald, John Hampton, III  
PATENT ASSIGNEE(S): Eli Lilly and Co., USA  
SOURCE: Eur. Pat. Appl., 36 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 327239	A1	19890809	EP 1989-300640	19890124
EP 327239	B1	19940622		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
JP 02001487	A	19900105	JP 1989-14958	19890124
ES 2055030	T3	19940816	ES 1989-300640	19890124
US 5019571	A	19910528	US 1989-428452	19891030

PRIORITY APPLN. INFO.: US 1988-147471 A 19880125

OTHER SOURCE(S): MARPAT 112:118541

GI For diagram(s), see printed CA Issue.

AB The title compds. I (A = H, amino-protecting group, etc.; R1 = neg. charge, H, biol. labile group, carboxy-protecting group; R2 = H, C1-4 alkoxy, alkylthio, formamido; Z = quaternary ammonium group that may be acyclic, cyclic, or a combination of the two, and may contain one or more addnl. hetero atoms selected from N, S, O) and solvates or pharmaceutically acceptable salts thereof, useful as antibiotics (no data), were prepared Bu3SnH was added to a cooled mixture of I.F3CSO3- (A = Q; Z = pyridinio; R = H2C:CHCH2OCO; R1 = allyl; R2 = H), Ph3P, and (AcO)2Pd in MeCN containing Et2O. After 15 min, the ice bath was removed and the reaction mixture allowed to warm to room temperature After 30 min, the ice bath was again applied and 1 N HCl added. After stirring for 10 min, the ice bath was removed and the reaction mixture was stirred on addnl. 20 min. Workup of the reaction mixture, followed by purification using a HP-20-SS

column packed with H2O, gave I (A = Q; Z = pyridinio; R = R2 = H; R1 = anion). 125710-97-6P

IT RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, in preparation of antibiotic)

RN 125710-97-6 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[7-[(methoxyimino)[2-[(2-propenyloxy)carbonyl]amino]-4-thiazolyl]acetyl]amino]-8-oxo-2-[(2-propenyloxy)carbonyl]-1-azabicyclo[4.2.0]oct-2-en-3-yl]-3-methyl-, trans-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 125710-96-5

CMF C28 H29 N8 O7 S

Relative stereochemistry.

Double bond geometry unknown.



CM 2

CRN 37181-39-8

CMF C F3 O3 S



IT 125712-54-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of, as antibiotic)

RN 125712-54-1 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-1-azabicyclo[4.2.0]oct-2-en-3-yl]-3-methyl-, inner salt, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.





L3 ANSWER 96 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1989:594449 CAPLUS  
 DOCUMENT NUMBER: 111:194449  
 ORIGINAL REFERENCE NO.: 111:32315a,32318a  
 TITLE: 1-Dethia-2-thiacephalosporanic acid derivatives, their  
 preparation and formulations containing them  
 INVENTOR(S): Aszodi, Jozsef; D'Ambrieres, Solange Gouin; Teutsch,  
 Jean Georges  
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.  
 SOURCE: Fr. Demande, 40 pp. Addn. to Fr. Demende Appl. No. 84  
 2,138.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2610629	A2	19880812	FR 1987-1456	19870206
FR 2610629	B2	19890526		
FR 2559486	A1	19850816	FR 1984-2138	19840213
FR 2559486	B1	19880212		
NO 8500024	A	19850814	NO 1985-24	19850103
ZA 8500866	A	19860326	ZA 1985-866	19850205
IL 74253	A	19920818	IL 1985-74253	19850205
DK 8500632	A	19850814	DK 1985-632	19850212
FI 8500583	A	19850814	FI 1985-583	19850212
FI 86067	B	19920331		
FI 86067	C	19920710		
JP 60184087	A	19850919	JP 1985-23705	19850212
JP 06062637	B	19940817		
HU 39747	A2	19861029	HU 1985-526	19850212
HU 203356	B	19910729		
CA 1251443	A1	19890321	CA 1985-474115	19850212
AU 8538671	A	19850822	AU 1985-38671	19850213
AU 589352	B2	19891012		
ES 2009877	A6	19891016	ES 1988-281	19880202
NO 8800495	A	19880808	NO 1988-495	19880204
FI 8800536	A	19880807	FI 1988-536	19880205
JP 63253088	A	19881020	JP 1988-24077	19880205
US 5385897	A	19950131	US 1992-855324	19920320
JP 06220064	A	19940809	JP 1993-304568	19931111
JP 07042293	B	19950510		
US 5683996	A	19971104	US 1994-335163	19941107
PRIORITY APPLN. INFO.:			FR 1984-2138	19840213
			FR 1985-12218	A 19850809
			US 1986-895175	B2 19860811
			FR 1987-1456	A 19870206
			US 1988-151698	B1 19880202
			US 1990-605982	B1 19901030
			US 1992-855324	A3 19920320
OTHER SOURCE(S):	MARPAT 111:194449			
GI				



AB The title compds. I [R = LCONH, R'NH, etc.; L = organic group; R' = (substituted) aryl; R1 = ZR2, Z1R3, etc.; R2 = (substituted) alkyl, alkenyl, alkynyl; Z = (oxidized) S, O, etc.; R3 = (substituted) aryl, quaternary ammonium; Z1 = methylene, S, O, NH, etc.; R4 = H, OMe; A = H, alkali metal, etc.; or CO2A = CO2-; n = 0-2], useful as antibiotics, were prepared Reaction of 7-[(2-tritylaminothiazol-4-yl) (methoxyimino)acetamido]-8-oxo-3-iodopropenyl-4-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1,1-dimethylethyl ester with 2-(trifluoromethyl)thiazolo[4,5-c]pyridine, followed by deprotection with CF3CO2H/PhOMe, gave (6S,7S,Z)-5-[3-[7-[(2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-2-carboxy-8-oxo-4-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-(E)-propenyl]-2-(trifluoromethyl)thiazolo[4,5-c]pyridinium-CF3CO2H (II). II in vitro exhibited a MIC of 1.2 µg/mL against Staphylococcus aureus SG511. An injection containing (6S,7S,Z)-5-[3-[7-[(2-aminothiazol-4-yl) (methoxyimino)acetyl]amino]-2-carboxy-8-oxo-4-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-(E)propenyl]thiazolo[4,5-c]pyridinium 500 mg and H2O q.s. to 5 mL was prepared

IT 121037-47-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of, as antibiotic)

RN 121037-47-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[3-[7-[(2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-2-carboxy-8-oxo-4-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-2-propenyl]-2-methyl-, inner salt, [6S-[3(E),6α,7β(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L3 ANSWER 97 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:594373 CAPLUS

DOCUMENT NUMBER: 111:194373

ORIGINAL REFERENCE NO.: 111:32299a,32302a

TITLE: 3-Quaternary ammonium 1-carba-1-dethiacephems

AUTHOR(S): Cook, Gwendolyn K.; McDonald, John H., III; Alborn, William, Jr.; Boyd, Donald B.; Eudaly, Judy A.; Indelicato, Joseph M.; Johnson, Rod; Kasher, Jeffrey S.; Pasini, Carol E.; et al.

CORPORATE SOURCE: Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA


SOURCE: Journal of Medicinal Chemistry (1989), 32(11), 2442-50  
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:194373

GI



AB 1-Carba-1-dethiacephems I (R = pyridine, 3-methyl-3H-imidazo[4,5-c]pyridine, 6,7-dihydro-5H-1-pyridine, 5,6,7,8-tetrahydroquinoline, 1-methylimidazole, 2,5-dimethylpyridine, 3,4-dimethylpyridine, 4-dimethylaminopyridine) were prepared from p-nitrobenzyl 7β-phenoxyacetamido-3-trifluoromethanesulfonyloxy-1-carba-1-dethia-3-cephem-4-carboxylate. I were extremely potent antibacterials against a broad range of Gram pos. and neg. bacteria including constitutive cephalosporinase producers, such as Enterobacter cloacae. The exhibit similar hydrolysis kinetics and pharmacokinetics to the cephalosporin analogs.

IT 123078-22-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and bactericidal activity of)


RN 123078-22-8 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[7-[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-1-azabicyclo[4.2.0]oct-2-en-3-yl]-3-methyl-, inner salt, (6R-trans)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.






IT 123078-05-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and deblocking of)  
 RN 123078-05-7 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridinium, 5-[7-[[[(methoxyimino)[2-[(2-  
 propenyloxy)carbonyl]amino]-4-thiazolyl]acetyl]amino]-8-oxo-2-[(2-  
 propenyloxy)carbonyl]-1-azabicyclo[4.2.0]oct-2-en-3-yl]-3-methyl-,  
 (6R-trans)-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA  
 INDEX NAME)

CM 1

CRN 123078-04-6

CMF C28 H29 N8 O7 S

Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2

CRN 37181-39-8

CMF C F3 O3 S



L3 ANSWER 98 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:172994 CAPLUS

DOCUMENT NUMBER: 110:172994

ORIGINAL REFERENCE NO.: 110:28689a,28692a

TITLE: Preparation and formulation of crystalline cephalosporin antibiotic salts and solvates as antibacterials

INVENTOR(S): Katner, Allen S.

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: U.S., 6 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4734408	A	19880329	US 1986-943108	19861217
EP 272061	A2	19880622	EP 1987-310907	19871211
EP 272061	A3	19900328		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
JP 63198690	A	19880817	JP 1987-322637	19871217
PRIORITY APPLN. INFO.:			US 1986-943108	A 19861217

AB Crystalline

syn-7-[2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-(3-methyl-3H-imidazolo[4,5-c]pyridinium-5-ylmethyl)-3-cephem-4-carboxylate (I).H<sub>2</sub>SO<sub>4</sub>.2H<sub>2</sub>O (II) suitable for pharmaceutical administration as an antibacterial, and crystalline I.MeCONMe<sub>2</sub>.H<sub>2</sub>O (III) and crystalline I.DMF.H<sub>2</sub>O (IV)

which are intermediates in the synthesis of I in a highly pure state, were prepared syn-7-[2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-acetoxymethyl-3-cephem-4-carboxylic acid in CH<sub>2</sub>Cl<sub>2</sub> containing F<sub>3</sub>CCON(Me<sub>3</sub>Si)Me was reacted with Me<sub>3</sub>SiI to produce 3-iodomethylcephalosporin which is reacted in situ with 3-methyl-3H-imidazolo[4,3-c]pyridine to give I. I was converted to III which was dissolved in H<sub>2</sub>O and 1N H<sub>2</sub>SO<sub>4</sub> to give II having a purity of 99%. A formulation for i.v. use contained II 1.0 g and 0.9% saline 10 mL.

IT 98401-29-7P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and conversion to crystalline sulfate dihydrate)

RN 98401-29-7 CAPLUS

CN 3H-imidazo[4,5-c]pyridinium, 5-[[7-[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 115608-28-1P 115608-30-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and conversion to sulfate dihydrate)

RN 115608-28-1 CAPLUS


CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt,  
[6R-[6 $\alpha$ ,7 $\beta$ (Z)]]-, compd. with N,N-dimethylacetamide (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 98401-29-7

CMF C21 H20 N8 O5 S2

Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 127-19-5

CMF C4 H9 N O




RN 115608-30-5 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]-, compd. with N,N-dimethylformamide (1:1) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 98401-29-7

CMF C21 H20 N8 O5 S2


Absolute stereochemistry.  
 Double bond geometry as shown.



CM 2

CRN 68-12-2

CMF C3 H7 N O



IT 115608-29-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of crystalline, as antibiotic)

RN 115608-29-2 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 115857-57-3

CMF C21 H21 N8 O5 S2

Absolute stereochemistry.  
 Double bond geometry as shown.



C

CRN

CME



L3 ANSWER 99 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:473432 CAPLUS

DOCUMENT NUMBER: 109:73432

ORIGINAL REFERENCE NO.: 109:12301a,12304a

TITLE: Preparation of  
4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-  
carboxylic acids and analogs as antihypertensives

PATENT ASSIGNEE(S): Warner-Lambert Co., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 58 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62240683	A	19871021	JP 1987-76534	19870331
JP 2506105	B2	19960612		
US 4812462	A	19890314	US 1986-847067	19860401
EP 245637	A1	19871119	EP 1987-104736	19870331
EP 245637	B1	19911016		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 68495	T	19911115	AT 1987-104736	19870331
ES 2038613	T3	19930801	ES 1987-104736	19870331
US 4816463	A	19890328	US 1987-35521	19870407
JP 08208652	A	19960813	JP 1995-313683	19951108
JP 2648793	B2	19970903		

PRIORITY APPLN. INFO.: US 1986-847067 A 19860401

EP 1987-104736 A 19870331

OTHER SOURCE(S): CASREACT 109:73432; MARPAT 109:73432

GI



AB The title compds. [I-III; R = (un)substituted alkyl, heteroaryl, Ph, PhCH<sub>2</sub>; 1 R<sub>1</sub> = C<sub>4</sub>-20 alkyl, R<sub>5</sub>R<sub>6</sub>CH(CH<sub>2</sub>)<sub>y</sub>, the other is absent; R<sub>2</sub> = H, halo, alkyl, R<sub>5</sub>(CH<sub>2</sub>)<sub>x</sub>, R<sub>5</sub>CO, R<sub>1</sub>CH(OH); R<sub>3</sub> = R<sub>5</sub>(CH<sub>2</sub>)<sub>x</sub>, R<sub>5</sub>R<sub>6</sub>CH(CH<sub>2</sub>)<sub>y</sub>O, R<sub>7</sub>CO, R<sub>7</sub>SO<sub>2</sub>; R<sub>4</sub> = CH<sub>2</sub>OR<sub>7</sub>, CH<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>, CHO, cyano, (un)substituted CO<sub>2</sub>H; R<sub>5</sub> = cycloalkyl, naphthyl, heteroaryl, (un)substituted Ph; R<sub>6</sub> = H, alkyl, cycloalkyl, naphthyl, (un)substituted Ph; R<sub>7</sub> = C<sub>1</sub>-15 alkyl, R<sub>5</sub>R<sub>6</sub>CH(CH<sub>2</sub>)<sub>y</sub>, substituted vinyl, substituted amino, R<sub>5</sub>(CH<sub>2</sub>)<sub>y</sub>O, R<sub>5</sub>R<sub>6</sub>CH(CH<sub>2</sub>)<sub>y</sub>O; n = 0-3; x = 1-5; y = 0-5; R<sub>8</sub> = H, alkyl, PhCH<sub>2</sub>; R<sub>9</sub> = C<sub>3</sub>-5 branched alkyl, MeO-substituted Ph; Z = O, S], useful as antihypertensives, were prepared A mixture of 10.0 spinacine-HCl and 5.00 g Et<sub>3</sub>N in dioxane was stirred 15 min., 8.155 g p-MeOC<sub>6</sub>H<sub>4</sub>NCs was added, and the mixture was refluxed 25 h to give 10.9 g 1,4,6,7,8a,9-hexahydro-7-(4-methoxyphenyl)-6-thioxo-8H-


diimidazo[1,5-a:4',5'-d]pyridin-8-one (IV). In spontaneously hypertensive rats 30 mg IV/kg i.p. reduced blood pressure 39%.

IT 114785-42-1P 114785-44-3P 114785-45-4P  
114785-58-9P 114785-61-4P 114785-62-5P  
114785-63-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as antihypertensive)


RN 114785-42-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid,  
4,5,6,7-tetrahydro-1-(phenylmethyl)-5-[2-(3-pyridinyl)acetyl]- (CA INDEX NAME)




RN 114785-44-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid,  
4,5,6,7-tetrahydro-1-(phenylmethyl)-5-(9H-xanthen-9-ylcarbonyl)- (CA INDEX NAME)



RN 114785-45-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid,  
4,5,6,7-tetrahydro-5-[2-(1H-indol-3-yl)acetyl]-1-(phenylmethyl)- (CA INDEX NAME)




RN 114785-58-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid,



4,5,6,7-tetrahydro-1-[(4-methoxy-3-methylphenyl)methyl]-5-(9H-xanthen-9-ylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 114785-61-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid,  
4,5,6,7-tetrahydro-1-[(4-methoxy-3-methylphenyl)methyl]-5-(2-thienylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 114785-62-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid,  
4,5,6,7-tetrahydro-1-[(4-methoxy-3-methylphenyl)methyl]-5-(3-thienylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 114785-63-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid,  
4,5,6,7-tetrahydro-1-[(4-methoxy-3-methylphenyl)methyl]-5-(oxo-2-thienylacetyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 100 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1988:466224 CAPLUS  
 DOCUMENT NUMBER: 109:66224  
 ORIGINAL REFERENCE NO.: 109:10925a,10928a  
 TITLE: Determination of LY217332, a new 3'-quaternary ammonium cephalosporin, in plasma by solid phase column extraction and HPLC  
 AUTHOR(S): Whitaker, G. W.; Lindstrom, T. D.  
 CORPORATE SOURCE: Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA  
 SOURCE: Journal of Liquid Chromatography (1988), 11(4), 901-12  
 CODEN: JLCHD8; ISSN: 0148-3919  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



I

AB A sensitive and rapid assay is described for the determination of LY217332  
 (I), a 3'-imidazo[4,5-c]pyridinium cephalosporin, in plasma. The method utilizes cyano solid phase column extraction and HPLC with UV detection. The lower limit of detection is 5 ng/mL plasma and the relative standard deviation for precision and accuracy is  $\leq 5\%$  from 50-500 ng/mL. The method is applicable to the simultaneous assay of ceftazidime, cephaloridine, cefpirome and BMY-28142 with minor modification of the mobile phase and the detection wavelength.  
 IT 115681-28-2  
 RL: ANT (Analyte); ANST (Analytical study)  
 (determination of, in blood plasma by HPLC)  
 RN 115681-28-2 CAPLUS  
 CN 3H-Imidazo[4,5-c]pyridinium, 5-[(6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-3-methyl-, sulfate (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 115681-27-1  
 CMF C20 H19 N8 O5 S2

Absolute stereochemistry.  
 Double bond geometry as shown.



CM 2

CRN 14996-02-2

CMF H O4 S



L3 ANSWER 101 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:406311 CAPLUS

DOCUMENT NUMBER: 109:6311

ORIGINAL REFERENCE NO.: 109:1188h,1189a

TITLE: Preparation of  
(chloromethylene)acetamidocephemcarboxylic acid  
derivatives as antibiotics

INVENTOR(S): Tsunemoto, Dalei; Kobori, Takeo; Nishide, Kyoji;  
Kondo, Sei; Yamazaki, Mayumi; Horikawa, Noriko;  
Mizutani, Akemi; Yamamura, Mariko; Toshioka, Kichi; et  
al.

PATENT ASSIGNEE(S): Sagami Chemical Research Center, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 49 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 62158291	A	19870714	JP 1986-245	19860107
PRIORITY APPLN. INFO.:			JP 1986-245	19860107

GI For diagram(s), see printed CA Issue.

AB The title compds. I [R1 = H, protecting group; R2 = quaternary ammonio, Q wherein A is a (substituted) ring forming moiety], useful as antibiotics, were prepared Quaternization of 4-dimethylaminopyridine with (Z)-7-[2-chloromethylene-2-(2-formylaminothiazol-4-yl)acetamido]-3-acetoxymethyl-3-cephem-4-carboxylic acid, followed by deprotection and purification of the product, gave 9% (Z)-I (R1 = H, R2 = 4-dimethylamino-1-pyridinium) (II). II in vitro exhibited a MIC of 0.78 µg/mL against Staphylococcus aureus Smith.

IT 114576-10-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of, as antibiotic)

RN 114576-10-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[2-(2-amino-4-thiazolyl)-3-chloro-1-oxo-2-propenyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.






L3 ANSWER 102 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1988:204418 CAPLUS  
 DOCUMENT NUMBER: 108:204418  
 ORIGINAL REFERENCE NO.: 108:33585a,33588a  
 TITLE: Preparation of 3-[(bicyclic pyridinio)methyl]cephalosporins as antibiotics  
 INVENTOR(S): Katner, Allen S.  
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA  
 SOURCE: U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 542,619, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4692443	A	19870908	US 1984-679717	19841210
GB 2148289	A	19850530	GB 1984-25453	19841009
GB 2148289	B	19870923		
ZA 8407926	A	19860528	ZA 1984-7926	19841009
FI 8404000	A	19850418	FI 1984-4000	19841011
CA 1225390	A1	19870811	CA 1984-465150	19841011
DK 8404891	A	19850418	DK 1984-4891	19841012
AU 8434189	A	19850426	AU 1984-34189	19841012
AU 574107	B2	19880630		
SU 1360587	A3	19871215	SU 1984-3798239	19841012
JP 60105685	A	19850611	JP 1984-219350	19841016
HU 35687	A2	19850729	HU 1984-3865	19841016
HU 195512	B	19880530		
GB 2181136	A	19870415	GB 1986-27171	19861113
GB 2181136	B	19880525		
US 4748172	A	19880531	US 1987-2091	19870112
PRIORITY APPLN. INFO.:			US 1983-542619	A2 19831017
			GB 1984-25453	A3 19841009
			US 1984-679717	A3 19841210
			US 1985-740153	A1 19850603

GI



AB Title compds. I [R = H, HCO, (protected)- $\alpha$ -amino adipoyl, R' = ONCR'CO; R' = 5-6-member aminoheterocyclyl; R'' = H, C1-4 alkyl, carboxy-substituted alkyl, -cycloalkyl, N-substituted carbamoyl; R1 = H, C1-4 alkyl, -alkoxy, -alkylthio, -alkanoylamino, -alkylamino, di-C1-4 alkylamino, H2N, thienyl, HOCO, Ph, etc; X = O, S; m, y = 0-3, provided m + y = 3] and their salts, were prepared  
 syn-7-[2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-acetoxymethyl-3-cephem-4-carboxylic acid in CH2Cl2 containing F3CONMeSiMe3 (II) was warmed to 40°, sonicated and reacted with Me3SiI to give an oil, which, in MeCN and THF, was reacted with 1H-imidazo[4,5-c]pyridine in MeCN containing II to give syn-7-[2-(2-aminothiazol-4-yl)-2-methyliminoacetamido]-3-(1H-imidazo[4,5-c]pyridinio-5-methyl)-3-cephemcarboxylate (III) which had

min. inhibitory concentration of 1 µg/mL against Staphylococcus aureus, compared to 8 µg/mL for ceftazidime . A formulation for i.v. use comprised 1.0 g III and 100 mL 0.9% saline .

IT 98382-97-9P 98382-98-0P 98383-00-7P  
98383-02-9P 98383-03-0P 98383-04-1P  
98383-05-2P 98401-29-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of, as antibiotic)

RN 98382-97-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[2-amino-4-thiazolyl][(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98382-98-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[2-amino-4-thiazolyl] (methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 98383-00-7 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[2-amino-4-thiazolyl] (methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-



azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-1-methyl-, inner salt,  
[6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-02-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-1,2-dimethyl-, inner salt,  
[6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-03-0 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2,3-dimethyl-, inner salt,  
[6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-04-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-(2-thienyl)-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-05-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-phenyl-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98401-29-7 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[2-amino-4-thiazolyl] (methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.

Double bond geometry as shown.



L3 ANSWER 103 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1985:541739 CAPLUS  
 DOCUMENT NUMBER: 103:141739  
 ORIGINAL REFERENCE NO.: 103:22691a, 22694a  
 TITLE: 3-[(Bicyclic pyridinio)methyl]cephalosporins  
 INVENTOR(S): Katner, Allen Samuel  
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA  
 SOURCE: Eur. Pat. Appl., '78 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 138552	A2	19850424	EP 1984-306866	19841009
EP 138552	A3	19860319		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
GB 2148289	A	19850530	GB 1984-25453	19841009
GB 2148289	B	19870923		
ZA 8407926	A	19860528	ZA 1984-7926	19841009
FI 8404000	A	19850418	FI 1984-4000	19841011
CA 1225390	A1	19870811	CA 1984-465150	19841011
DK 8404891	A	19850418	DK 1984-4891	19841012
AU 8434189	A	19850426	AU 1984-34189	19841012
AU 574107	B2	19880630		
SU 1360587	A3	19871215	SU 1984-3798239	19841012
JP 60105685	A	19850611	JP 1984-219350	19841016
HU 35687	A2	19850729	HU 1984-3865	19841016
HU 195512	B	19880530		
GB 2181136	A	19870415	GB 1986-27171	19861113
GB 2181136	B	19880525		
PRIORITY APPLN. INFO.:			US 1983-542619	A 19831017
			GB 1984-25453	A3 19841009
OTHER SOURCE(S):		MARPAT 103:141739		
GI				



AB Cephalosporins I (R = H, acyl; R1 = H, alkyl, Ph, thienyl, NH2, acylamino; X = O, S, NH, alkylimino; m, n = 0-3; m + n = 3) were prepared. Thus, cephem II (R2 = OAc) was iodinated and treated with the imidazopyridine to give III which had a min. inhibitory concentration against *Staphylococcus aureus*

X1.1

of 1 µg/mL.

IT 98382-97-9P 98382-98-0P 98383-00-7P

98383-01-8P 98383-02-9P 98383-03-0P

98383-04-1P 98383-05-2P 98401-29-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation and bactericidal activity of)

RN 98382-97-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)][(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98382-98-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, [6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-00-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-1-methyl-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-01-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-2-methyl-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-02-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-1,2-dimethyl-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-03-0 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2,3-dimethyl-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-04-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-(2-thienyl)-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98383-05-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-phenyl-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 98401-29-7 CAPLUS

CN 3H-Imidazo[4,5-c]pyridinium, 5-[[7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-2-phenyl-, inner salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.






L3 ANSWER 104 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1981:569075 CAPLUS  
 DOCUMENT NUMBER: 95:169075  
 ORIGINAL REFERENCE NO.: 95:28265a,28268a  
 TITLE: New synthesis of spinaceamine derivatives  
 AUTHOR(S): Yutilov, Yu. M.; Eilazyan, O. G.  
 CORPORATE SOURCE: Inst. Fiz.-Org. Khim. Uglekhim., Donetsk, 340048, USSR  
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1981), (7), 992  
 CODEN: KGSSAQ; ISSN: 0453-8234  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Russian  
 GI




AB Spinaceamine derivs. I (R = Et, CH<sub>2</sub>CH<sub>2</sub>OH), II (R = Me, benzyl, CH<sub>2</sub>CH<sub>2</sub>OH) and III were prepared in 69-98% yield by reduction of quaternary salts of 1- and 3-substituted imidazo[4,5-c]pyridine with NaBH<sub>4</sub> or KBH<sub>4</sub> in aqueous or alc. solution at room temperature  
 IT 79457-32-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 79457-32-2 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridine, 5,5'-(1,10-decanediyl)bis[4,5,6,7-tetrahydro-1-methyl-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)

CM 1  
 CRN 79457-31-1  
 CMF C24 H40 N6



CM 2  
 CRN 88-89-1  
 CMF C6 H3 N3 O7




IT 79457-38-8



RL: RCT (Reactant); RACT (Reactant or reagent)  
(reduction of)

RN 79457-38-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5,5'-(1,10-decanediyl)bis[1-methyl- (CA  
INDEX NAME)



L3 ANSWER 105 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1981:174980 CAPLUS  
 DOCUMENT NUMBER: 94:174980  
 ORIGINAL REFERENCE NO.: 94:28591a,28594a  
 TITLE: Quaternization of  
 4-amino-1,3-dimethylimidazo[4,5-c]pyridin-2-one  
 Yutilov, Yu. M.; Khabarov, K. M.; Svertilova, I. A.  
 CORPORATE SOURCE: USSR  
 SOURCE: Deposited Doc. (1979), VINITI 4182, 9 pp. Avail.:  
 VINITI  
 DOCUMENT TYPE: Report  
 LANGUAGE: Russian  
 OTHER SOURCE(S): CASREACT 94:174980  
 GI




AB Imidazopyridinium salts I (R = Me, Et, Bu, octyl, hexadecyl, PhCH<sub>2</sub>, CH<sub>2</sub>:CHCH<sub>2</sub>, X = I, Br) were obtained in 69-100% yields by treatment of the title compound with RX. Treatment of I (R = Me, Et) with 45% aqueous NaOH gave 90 and 82% II (Z = NH), resp., which were oxidized by NaNO<sub>2</sub>-AcOH to give 82 and 65% II (Z = O). Addnl. obtained were III (n = 2, 10).  
 IT 77246-06-1P 77259-53-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 77246-06-1 CAPLUS

CN 2H-Imidazo[4,5-c]pyridin-2-one, 5,5'-(1,10-decanediyl)bis[1,3,4,5-tetrahydro-4-imino-1,3-dimethyl-, dihydrobromide (9CI) (CA INDEX NAME)



RN 77259-53-1 CAPLUS

CN 2H-Imidazo[4,5-c]pyridin-2-one, 5,5'-(1,2-ethanediyl)bis[1,3,4,5-tetrahydro-4-imino-1,3-dimethyl-, dihydrobromide (9CI) (CA INDEX NAME)



● 2 HBr

L3 ANSWER 106 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1976:69638 CAPLUS

DOCUMENT NUMBER: 84:69638

ORIGINAL REFERENCE NO.: 84:11393a,11396a

TITLE: Antiluteinizing hormone (LH)-releasing activity of

several analogs of LH-releasing hormone

AUTHOR(S): Vilchez-Martinez, Jesus A.; Coy, David H.; Coy,

Esther; Schally, Andrew V.; Arimura, Akira

CORPORATE SOURCE: Endocrine Polypeptide Lab., VA Hosp., New Orleans, LA, USA

SOURCE: Fertility and Sterility (1975), 26(6), 554-9

CODEN: FESTAS; ISSN: 0015-0282

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In ovariectomized, estrogen-progesterone treated rats and in immature male rats, after synthetic LH-releasing hormone (LH-RH) [33515-09-2] injection, a 2 hr infusion of LH-releasing hormone analogs inhibited, but never completely, the increase in serum LH [9002-67-9]. Analogs tested were (Leu3)-LH-RH, (Leu3,desGly10)-LH-RH ethylamide [56867-47-1], (desHis2,Leu3,desGly10)-LH-RH ethylamide [56867-48-2], (Gly2,Leu3,desGly10)-LH-RH ethylamide [56867-49-3], (Leu1,desGly10)-LH-RH ethylamide [56867-50-6], (desHis2,Leu3,D-Ala6,desGly10)-LH-RH ethylamide [56867-51-7], (desHis2,D-Ala6,desGly10)-LH-RH ethylamide [56670-52-1], or (D-pGlu1,desHis2,desGly10)-LH-RH ethylamide [56867-52-8]. No significant differences were found among the analogs tested. The inhibitory potency was not improved with those peptides containing D-alanine in position 6 of the chain. None of the analogs tested, blocked the LH-RH induced FSH [9002-68-0] release in these systems.


IT 56867-45-9


RL: BIOL (Biological study)  
(LH secretion inhibition by)

RN 56867-45-9 CAPLUS

CN Luteinizing hormone-releasing factor (swine),  
2-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid)- (9CI)  
(CA INDEX NAME)

PAGE 1-A





```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          603.84      790.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                                ENTRY      SESSION
CA SUBSCRIBER PRICE          -86.92      -86.92
```

FILE 'REGISTRY' ENTERED AT 11:59:20 ON 28 JAN 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

```
STRUCTURE FILE UPDATES:  27 JAN 2009  HIGHEST RN 1096770-81-8
DICTIONARY FILE UPDATES: 27 JAN 2009  HIGHEST RN 1096770-81-8
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> s isoxazolylyl
L4      164649 ISOXAZOLYL

=> s isoxazolylyl/cn
L5      0 ISOXAZOLYL/CN
```

```
=>
Uploading C:\Program Files\Stnexp\Queries\10583814a.str
```



```
chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9 14 15 16 17 18
chain bonds :
1-10 10-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 14-15 14-18 15-16 16-17 17-18
```



```

exact/norm bonds :
1-2  1-6  1-10  2-3  3-4  4-5  4-7  5-6  5-9  7-8  8-9  10-14  14-15
exact bonds :
14-18  15-16  16-17  17-18
isolated ring systems :
containing 14 :

```

G1:O,S,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s 16 full

FULL SEARCH INITIATED 12:00:53 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS


0 ANSWERS

SEARCH TIME: 00.00.01

L7 0 SEA SSS FUL L6

=>

Uploading C:\Program Files\Stnexp\Queries\10583814b.str



```

chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9 14 15 16 17 18
chain bonds :
1-10 10-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 14-15 14-18 15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 1-10 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 16-17
exact bonds :
10-14 14-15 14-18 15-16 17-18
isolated ring systems :
containing 14 :

```

G1:O,S,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L8 STRUCTURE LOADED

=> d 18

L8 HAS NO ANSWERS

L8 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s 18 full  
FULL SEARCH INITIATED 12:06:19 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1227 TO ITERATE

100.0% PROCESSED 1227 ITERATIONS 81 ANSWERS  
SEARCH TIME: 00.00.01

L9 81 SEA SSS FUL L8

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	387.26	1177.68
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-86.92

FILE 'CAPLUS' ENTERED AT 12:06:25 ON 28 JAN 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Jan 2009 VOL 150 ISS 5  
FILE LAST UPDATED: 27 Jan 2009 (20090127/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19 full  
L10 3 L9

=> d ibib abs hitstr tot

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:117372 CAPLUS

DOCUMENT NUMBER: 146:202022

TITLE: Drug-resistant mutation in nonstructural proteins of hepatitis C virus

INVENTOR(S): Boddeker, Nina; Neyts, Johan; Shih, I-Hung; Vliegen, Inge; Zhong, Weidong

PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA; K.U. Leuven Research & Development; Puerstinger, Gerhard

SOURCE: PCT Int. Appl., 27pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014174	A2	20070201	WO 2006-US28727	20060724
WO 2007014174	A3	20070913		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20070128625	A1	20070607	US 2006-491756	20060724
----------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2005-702534P P 20050725


AB Provided are hepatitis C virus mutations in nonstructural proteins, which are associated with drug resistance, especially imidazopyridine compds. The mutations are (1) Q581E, A391V, M582L, and C432S within NS3 region, (2) V24A within NS4A region, (3) L4P, Q93R, and L78T within NS4B region, (4) M416T, E441G, and V362A within NS5A region, and (5) C316Y, C445F, Y448H, and Y452H within NS5N region. The mutations V24A, E441G, C316Y, C445F, Y448H, and Y452H were found to be sufficient resistance when introduced into wildtype replicons. The combination of two mutations was found to be resistance at a higher drug level than either single mutation. In addition, the present invention provides methods for screening for therapeutic compds. capable of inhibiting HCV as well as methods for inhibiting HCV, e. g., by targeting specific binding sites associated with HCV drug resistance.

IT 858935-18-9 858935-19-0 858935-21-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(resistant to; drug-resistant mutation in nonstructural proteins of hepatitis C virus)


RN 858935-18-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858935-19-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-bis(trifluoromethyl)phenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)



RN 858935-21-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:630269 CAPLUS

DOCUMENT NUMBER: 145:83341

TITLE: Preparation of the antiviral compound  
5-[[3-(2,4-bis(trifluoromethyl)phenyl)isoxazol-5-yl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and its use in the treatment of HCV viral infections

INVENTOR(S): Bondy, Steven S.; Oare, David A.; Tse, Winston C.

PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE				
WO 2006069193	A2	20060629	WO 2005-US46477	20051221				
WO 2006069193	A3	20060810						
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW								
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM								
AU 2005319167	A1	20060629	AU 2005-319167	20051221				
CA 2592388	A1	20060629	CA 2005-2592388	20051221				
US 20060252791	A1	20061109	US 2005-316050	20051221				
EP 1841765	A2	20071010	EP 2005-855097	20051221				
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR								
JP 2008524335	T	20080710	JP 2007-548448	20051221				
US 20080188516	A1	20080807	US 2008-22557	20080130				
PRIORITY APPLN. INFO.:								
			US 2004-638215P	P 20041221				
			US 2005-316050	B1 20051221				
			WO 2005-US46477	W 20051221				
AB	5-[[3-(2,4-Bis(trifluoromethyl)phenyl)isoxazol-5-yl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine is prepared and claimed for use in the treatment or prophylaxis of HCV viral infections.							
IT	858935-19-0P, 5-[[3-(2,4-Bis(Trifluoromethyl)phenyl)isoxazol-5-yl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine							
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)								
(preparation of the antiviral compound)								
5-[[3-(2,4-bis(trifluoromethyl)phenyl)isoxazol-5-yl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and its use in the treatment of HCV viral infections)								
RN	858935-19-0 CAPLUS							
CN	5H-imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)							



REFERENCE COUNT:



2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:612284 CAPLUS  
 DOCUMENT NUMBER: 143:133371  
 TITLE: Preparation of imidazo[4,5-c]pyridine derivatives as  
 antiviral agents  
 INVENTOR(S): Puerstinger, Gerhard; Bondy, Steven S.; Dowdy, Eric  
 Davis; Kim, Choung U.; Oare, David A.; Neyts, Johan;  
 Zia, Vahid  
 PATENT ASSIGNEE(S): K. U. Leuven Research & Development, Belg.; Gilead  
 Sciences, Inc.  
 SOURCE: PCT Int. Appl., 265 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063744	A2	20050714	WO 2004-US43112	20041221
WO 2005063744	A3	20050901		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004309390	A1	20050714	AU 2004-309390	20041221
CA 2549606	A1	20050714	CA 2004-2549606	20041221
US 20050222198	A1	20051006	US 2004-19830	20041221
EP 1706403	A2	20061004	EP 2004-815224	20041221
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1902198	A	20070124	CN 2004-80038144	20041221
JP 2007518720	T	20070712	JP 2006-547305	20041221
KR 2006132850	A	20061222	KR 2006-712554	20060622
US 20070244148	A1	20071018	US 2007-583814	20070604
PRIORITY APPLN. INFO.:			US 2003-532292P	P 20031222
			US 2004-533963P	P 20040102
			US 2004-590989P	P 20040726
			US 2004-590990P	P 20040726
			US 2004-591024P	P 20040726
			US 2004-591069P	P 20040726
			WO 2004-US43112	W 20041221
OTHER SOURCE(S):		CASREACT 143:133371; MARPAT 143:133371		
GI				






AB Title compds. I [dotted lines represent at least 3, optionally 4, double bonds; R1 = H, (un)substituted aryl, thioalkyl, etc.; Y = single bond, O, alkylene optionally containing 1-3 heteroatoms, etc.; R2 and R4 independently = H, alkyl, alkenyl, etc. with provisions; X = alkylene, alkenylene, alkynylene where each optionally may include one or more heteroatoms; R3 = (un)substituted aryl, aryloxy, arylthio, etc.; R5 = H, OH, CN, etc.; R6 and R7 are usually not present, but if they are then they are cyclopentyl or cyclohexyl] and their pharmaceutically acceptable salts, are prepared and disclosed as antiviral agents. Thus, e.g., II was prepared by coupling of 2-(2-fluorophenyl)-3H-imidazo[4,5-c]pyridine with 5-(chloromethyl)-3-(4-chlorophenyl)isoxazole. The activity of I was evaluated in an anti-HCV/Replicon assay system and it was revealed that substantially all of the compds. of the invention demonstrated activity of at least 1  $\mu$ M. I as antiviral agent should prove useful in the treatment of hepatitis C virus (HCV). Pharmaceutical compns. comprising I are disclosed.

IT 858935-21-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of imidazo[4,5-c]pyridine derivs. as antiviral agents)

RN 858935-21-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-[4-fluoro-2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)



IT 858935-18-9P 858935-19-0P 858935-20-3P  
858935-30-5P 858935-31-6P 858935-64-5P  
858936-58-0P 858936-59-1P 858936-64-8P  
858936-65-9P 858936-67-1P 858936-68-2P  
858936-69-3P 858936-70-6P 858936-71-7P


858936-72-8P 858936-73-9P 858936-74-0P  
 858936-75-1P 858936-76-2P 858936-77-3P  
 858936-78-4P 858936-79-5P 858936-80-8P  
 858936-81-9P 858936-82-0P 858936-83-1P  
 858936-84-2P 858936-85-3P 858936-86-4P  
 858936-87-5P 858936-88-6P 858936-89-7P  
 858936-90-0P 858936-91-1P 858937-43-6P  
 858937-44-7P 858937-45-8P 858938-53-1P  
 858938-56-4P 858938-57-5P 858938-58-6P  
 858938-59-7P 858938-60-0P 858938-61-1P  
 858938-62-2P 858938-63-3P 858938-64-4P  
 858938-65-5P 858938-66-6P 858938-67-7P  
 858938-68-8P 858938-69-9P 858938-70-2P  
 858938-71-3P 858938-72-4P 858938-73-5P  
 858938-74-6P 858938-75-7P 858938-76-8P  
 858938-77-9P 858938-78-0P 858938-81-5P  
 858938-82-6P 858938-83-7P 858938-84-8P  
 858938-85-9P 858938-94-0P 858938-95-1P  
 858939-15-8P 858939-16-9P 858939-17-0P  
 858939-18-1P 858939-19-2P 858939-20-5P  
 858939-21-6P 858939-22-7P 858939-23-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of imidazo[4,5-c]pyridine derivs. as antiviral agents)


RN 858935-18-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-  
 (2,3-difluorophenyl)- (CA INDEX NAME)




RN 858935-19-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858935-20-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858935-30-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858935-31-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858935-64-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 858936-58-0 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(3-thienyl)- (CA INDEX NAME)



RN 858936-59-1 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[(3-phenyl-5-isoxazolyl)methyl]-2-(3-thienyl)-

(CA INDEX NAME)




RN 858936-64-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-(trifluoromethyl)phenyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858936-65-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-(trifluoromethoxy)phenyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858936-67-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-dichlorophenyl)-5-isoxazolyl)methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858936-68-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-(trifluoromethoxy)phenyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858936-69-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]phenyl]-5-isoxazolyl)methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858936-70-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-fluoro-2-(trifluoromethyl)phenyl]-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858936-71-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2-(difluoromethoxy)phenyl]-5-isoxazolyl)methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858936-72-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 858936-73-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-bromo-2-fluorophenyl)-5-isoxazolyl)methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858936-74-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2,4,6-trifluorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-75-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-fluoro-4-methylphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-76-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2-fluoro-4-methylphenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-77-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2,4-dimethoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-78-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-79-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-dichlorophenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-80-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-[4-(trifluoromethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-81-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2-(difluoromethoxy)phenyl]-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-82-0 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-bromo-2-fluorophenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-83-1 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-dimethoxyphenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858936-84-2 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 858936-85-3 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-(2,4-dichlorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-86-4 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-[4-(trifluoromethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858936-87-5 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[2,4-bis(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-2-(3-chloro-2-fluorophenyl)- (CA INDEX NAME)






RN 858936-88-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-([3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-isoxazolyl]methyl)- (CA INDEX NAME)




RN 858936-89-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-([3-(2-(difluoromethoxy)phenyl)-5-isoxazolyl]methyl)- (CA INDEX NAME)




RN 858936-90-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-([3-(2-fluoro-4-(trifluoromethyl)phenyl)-5-isoxazolyl]methyl)- (CA INDEX NAME)




RN 858936-91-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-([3-(4-bromo-2-fluorophenyl)-5-isoxazolyl]methyl)-2-(3-chloro-2-fluorophenyl)- (CA INDEX NAME)




RN 858937-43-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858937-44-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 858937-45-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(3-chloro-2-fluorophenyl)-5-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-53-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-methoxy-2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-56-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-ethoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-57-5 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-58-6 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methylphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-59-7 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-furanyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-60-0 CAPLUS

CN 5H-imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-thienyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-61-1 CAPLUS

CN Benzenamine, 4-[5-[[2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]pyridin-5-yl]methyl]-3-isoxazolyl]-N,N-dimethyl- (CA INDEX NAME)




RN 858938-62-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[1,1'-biphenyl]-4-yl]-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-63-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-bromophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-64-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(phenylmethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-65-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(methylthio)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-66-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(2-fluoro-4-methoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-67-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chloro-2-fluorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-68-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-propoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-69-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-phenoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-70-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(1-methyl-1H-pyrrol-2-yl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-71-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(1-methylethoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-72-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(5-chloro-2-thienyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-73-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(5-bromo-2-thienyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-74-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-butoxyphenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858938-75-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-(4-propoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-76-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(2-propen-1-yloxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858938-77-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[4-chloro-3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)



RN 858938-78-0 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[[4-bromo-3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)



RN 858938-81-5 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-

(2,3-difluorophenyl)-4-methyl- (CA INDEX NAME)




RN 858938-82-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)-7-methyl- (CA INDEX NAME)




RN 858938-83-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 7-chloro-2-(2,3-difluorophenyl)-5-[[3-(4-ethoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 858938-84-8 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)-7-(trifluoromethyl)- (CA INDEX NAME)



RN 858938-85-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)-7-fluoro- (CA INDEX NAME)






RN 858938-94-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-[4-fluoro-2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-, methanesulfonate (1:?)  
(CA INDEX NAME)

CM 1

CRN 858935-21-4

CMF C23 H13 F5 N4 O



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 858938-95-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)-5-[[3-[4-fluoro-2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl


RN 858939-15-8 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(4-methoxy-2-methylphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858939-16-9 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-(4-chloro-3-fluorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858939-17-0 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(1,1-dimethylethoxy)-3-fluorophenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 858939-18-1 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(pentyloxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858939-19-2 CAPLUS  
 CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-(3-furanyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858939-20-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 5-[[3-[4-(cyclohexylmethoxy)phenyl]-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)- (CA INDEX NAME)




RN 858939-21-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-[(5-methyl-4-hexen-1-yl)oxy]phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 858939-22-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(hexyloxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 858939-23-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine, 2-(2,3-difluorophenyl)-5-[[3-[4-(2-ethylbutoxy)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)





=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

17.42

1195.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.46

-89.38

STN INTERNATIONAL LOGOFF AT 12:06:53 ON 28 JAN 2009